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A B S T R A C T
Background
Osteoarthritis (OA) is the most prevalent chronic joint disorder worldwide and is associated with significant pain and disability.
Objectives
To assess the effects of viscosupplementation in the treatment of OA of the knee. The products were hyaluronan and hylan derivatives
(Adant, ArthrumH, Artz (Artzal, Supartz), BioHy (Arthrease), Durolane, Fermathron, Go-On,Hyalgan, Hylan G-F 20 (Synvisc Hylan
G-F 20), NRD-101, Orthovisc, Ostenil, Replasyn, SLM-10, Suplasyn, Synject and Zeel compositum).
Search strategy
MEDLINE, EMBASE, PREMEDLINE, Current Contents up to July 2003, and the Cochrane Central Register of Controlled Trials
(CENTRAL) were searched. Specialised journals and reference lists of identified randomised controlled trials (RCTs) and pertinent
review articles up to April 2004 were handsearched.
Selection criteria
RCTs of viscosupplementation for the treatment of people with a diagnosis of OA of the knee were eligible. Single and double-blinded
studies, placebo-based and comparative studies were eligible. At least one of the four OMERACT III core set outcome measures had
to be reported (Bellamy 1997).
Data collection and analysis
Each trial was assessed independently by two reviewers (NB, JC) for its methodological quality using a validated tool. All data were
extracted by one reviewer (JC) and verified by a second reviewer (VR). Continuous outcome measures were analysed as weighted mean
differences (WMD) with 95% confidence intervals (CI). Dichotomous outcomes were analyzed by relative risk (RR).
Main results
Sixty-three trials with a median quality score of 3 (range 1 to 5) were identified. Follow-up periods varied between day of last injection
and one year. Thirty-seven trials included comparisons of hyaluronan/hylan and placebo, nine trials included comparisons of intra-
articular (IA) corticosteroids, and five trials included comparisons of nonsteroidal anti-inflammatory drugs (NSAIDs). The pooled
analyses of the effects of viscosupplements against ’placebo’ controls generally supported the efficacy of this class of intervention. In
these same analyses, differential efficacy effects were observed for different products on different variables and at different timepoints.
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Of note is the 5 to 13 week post injection period which showed a percent improvement from baseline of 11 to 54% for pain and 9
to 15% for function. In general, comparable efficacy was noted against NSAIDs and longer-term benefits were noted in comparisons
against IA corticosteroids. In general, few adverse events were reported in the hyaluronan/hylan trials included in these analyses.
Authors’ conclusions
Based on the aforementioned analyses, viscosupplementation is an effective treatment for OA of the knee with beneficial effects: on pain,
function and patient global assessment; and at different post injection periods but especially at the 5 to 13 week post injection period. It
is of note that based on non-randomised groups, the magnitude of the clinical effect, as expressed by theWMD and standardised mean
difference (SMD) from the RevMan 4.1 output, is different for different products, comparisons, timepoints, variables and trial designs.
However, there are few randomised head-to-head comparisons of different viscosupplements and readers should be cautious, therefore,
in drawing conclusions regarding the relative value of different products. The clinical effect for some products, against placebo, on
some variables at some timepoints is in the moderate to large effect-size range. Readers should refer to relevant tables to review specific
detail given the heterogeneity in effects across the product class and some discrepancies observed between the RevMan 4.1 analyses and
the original publications. Overall, the analyses performed are positive for the HA class and particularly positive for some products with
respect to certain variables and timepoints, such as pain on weight bearing at 5 to 13 weeks postinjection.
In general, sample-size restrictions preclude any definitive comment on the safety of the HA class of products; however, within the
constraints of the trial designs employed no major safety issues were detected. In some analyses viscosupplements were comparable in
efficacy to systemic forms of active intervention, with more local reactions but fewer systemic adverse events.
In other analyses HA products had more prolonged effects than IA corticosteroids. Overall, the aforementioned analyses support the
use of the HA class of products in the treatment of knee OA.
P L A I N L A N G U A G E S U M M A R Y
Osteoarthritis (OA) is themost common formof chronic arthritis worldwide.Hyaluronan and hylan (HA) products provide opportunity
to treat OA in individual knee joints. To evaluate the efficacy, effectiveness and safety of HA products, in knee OA, we have conducted
a systematic review using Cochrane methodology. The analyses support the contention that the HA class of products is superior to
placebo. There is considerable between-product, between-variable and time-dependent variability in the clinical response. The clinical
effect for some products against placebo on some variables at some time points is in the moderate to large effect size range. In general,
sample size restrictions preclude any definitive comment on the safety of the HA class of products, however, within the constraints of
the trial designs employed, no major safety issues were detected. The analyses suggest that viscosupplements are comparable in efficacy
to systemic forms of active intervention, with more local reactions but fewer systemic adverse events, and that HA products have more
prolonged effects than IA corticosteroids. Overall, the aforementioned analyses support the use of the HA class of products in the
treatment of knee OA.
B A C K G R O U N D
Of all of the specific joint diseases osteoarthritis (OA) is the most
frequent cause of rheumatic complaints. OA of the knee is a major
cause of pain and disability. Guidelines for the management of
kneeOAhave been reported in four publications (ACRGuidelines
2000; Jordan 2003; Pendleton 2000; Walker-Bone 2000).
Viscosupplementation is an intra-articular (IA) therapeutic
modality for the treatment of knee OA based on the physiologic
importance of hyaluronan in synovial joints. Its therapeutic goal is
to restore the viscoelasticity of synovial hyaluronan, decrease pain,
improve mobility and restore the natural protective functions of
hyaluronan in the joint. The short-term mode of action of visco-
supplementation is believed to be based on the pain-relieving ef-
fect of the elastoviscous fluid in the affected joint. In the long term,
the restoration of joint mobility due to relief of pain is thought
to trigger a sequence of events which restores the trans-synovial
flow and subsequently the metabolic and rheological homeostases
of the joint.
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The principle of viscosupplementation was pioneered by Balazs
and coworkers (Balazs 1982; Denlinger 1998; Peyron 1974;Weiss
1999). There are now several different formulations of viscosup-
plements (hyaluronan and hylan) produced by different manu-
facturers and of widely different molecular weights. This differ-
ence in molecular weight (MW) is thought to be of importance
with respect to the volume/amount and number of injections, the
residue time in the joint and biologic effects. Aviad and Houpt
found no correlation between MW and efficacy (Aviad 1994). Lo
et al. reported that at a higher MW HA may have greater effects,
but the heterogeneity of the trials used in this meta-analysis lim-
ited this conclusion (Lo 2003). Based on results observed in vitro,
Maneiro et al. concluded that HA products were different due to
differences in biological activity that resulted from the difference
in MW (Maneiro 2004).
Viscosupplementation as treatment for knee OA has been the
focus of several review publications (Aggarwal 2004; Altman
2003; Altman 2000; Ayral 2001; Brandt 2000; Collange 1999;
Dougados 2000; Espallargues 2003; Haraoui 2002; Hochberg
2000; Kelly 2003; Khanuja 2003; Kirwan 1997; Kirwan 2001;
Lussier 1996; Maheu 1994; Maheu 1995; Maheu 2003; Marshall
2000; MSAC 2003; Moreland 2003; Moskowitz 2000; Peyron
1993; Uebelhart 1999; Watterson 2000). Two meta-analyses have
been reported (Lo 2003; Wang 2004). A third meta-analysis has
been reported only as an abstract (Choi 1999). These publications
employ different methodologies and have shown conflicting re-
sults. The review by Espallargues and Pons concluded that a hy-
lan (Hylan G-F 20) was a safe and well-tolerated therapy in the
short term, but they recommended further work on the effect of
multiple courses of hylan (Espallargues 2003). The Medical Ser-
vices Advisory Committee (Australia) recommended that public
funding should not support viscosupplementation for the treat-
ment of knee OA, in March 2003 (MSAC 2003). Choi et al. con-
cluded from their meta-analysis of seven placebo-controlled trials
that viscosupplementation significantly reduced pain in patients
with knee OA, for a period of 5 to 10 weeks after the last injection
(Choi 1999). Lo et al.’s meta-analysis of 18 trials of HA against
IA placebo indicated that HA had a small effect when compared
to placebo (Lo 2003; Bernstein 2004; Hou 2004).
Given this diversity of opinion there is, therefore, a rational basis
for performing aCochrane reviewof viscosupplementation in knee
OA.
O B J E C T I V E S
To assess the effects of viscosupplementation in the treatment
of OA of the knee. The products were hyaluronan and hylan
derivatives of widely different molecular weights and formulation
(Adant, Arthrum H, Artz (Artzal, Supartz), BioHy (Arthrease),
Durolane, Fermathron, Go-On, Hyalgan, Hylan G-F 20 (Synvisc
Hylan G-F 20), NRD-101, Orthovisc, Ostenil, Replasyn, SLM-
10, Suplasyn, Synject and Zeel compositum).
The systematic review of the literature was based on TheCochrane
Collaboration methodology and RevMan 4.1. Data were sum-
marised, when possible, using meta-analytic techniques following
the Cochrane methodology.
R E S U L T S
Results are presented by product. An independent evaluation by
product is recommended rather than a by-class meta-analysis since
these products differ in theirMW, concentration, treatment sched-
ules, and mode of production (Altman 2003; Blue Cross 1998).
At the end of the product-by-product evaluation there is a section
based on the by-class (pooled) results. Readers are cautioned to
note themany differences in study design while reading the results
of this analysis. The Discussion section addresses some of these
issues.
Product - Adant
Description of studies
One RCT was included: a comparison of Adant and another
hyaluronan (Roman 2000).
Roman et al. reported a six-month, parallel-group, blind RCT
performed at a single centre comparing five weekly injections of
Adant (Treatment: MW 900,000 D biotechnically obtained) to
five weekly injections of Hyalgan (Control: MW 800,000 D ob-
tained from rooster crest) in 49 patients with OA of the knee
(Roman 2000). The authors concluded that the efficacy of Adant
was greater than with Hyalgan at three months after treatment.
They reported that maximum improvement was seen at five weeks
with response decreasing over time resulting in almost 75% of pa-
tients reporting only ’fair’ or ’no’ clinical response at six months
postinjection. Pain at the injection site was almost twice as great
with Adant. The Jadad score for this study was 3 out of a max-
imum of 5; specific details of blinding and randomisation were
not reported in the publication. The randomisation allocation was
1.6:1 (e.g. n = 30:19) in favour of the Adant group. Allocation
concealment was unclear (i.e. not reported).
In this RCT several design issues were noted: 1) one and a half
times as many patients were randomised to the Adant group com-
pared to the Hyalgan group; 2) eighty-four percent of the patients
were female; 3) no exclusion criteria were reported in the Mate-
rials and Methods section of the publication; 4) details regarding
presence or absence of effusion, uni- or bilateral disease, OA di-
agnosis criteria and disease duration were not published; 5) effi-
cacy was assessed only by the patient subjective assessment, the
details of which were not published. However, injection technique
was standardised and the effect of concomitant analgesic and/or
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anti-inflammatory drugs was considered. Although the authors at-
tributed the ’greater efficacy’ with Adant at three months and the
higher incidence of pain at the injection site to its greater viscos-
ity and volume, there were no statistically significant differences
between the products in either the efficacy or safety profiles.
Three trials were excluded: Couceiro 2003; Guerrero 1999;
Guerrero 1999a. One trial is awaiting assessment: Blanco Garcia
2004.
Adant versus placebo: no trials included.
Adant versus corticosteroid: no trials included.
Adant versus NSAID: no trials included.
Adant versus other hyaluronan
Efficacy
The only efficacy outcome measure extracted from this trial
(Roman 2000) was patient global assessment (e.g. number of pa-
tients excellent or good). At each of the three timepoints there were
no statistically significant differences between the two groups. At
1 to 4 weeks postinjection, 43% of the Adant patients and 37%
of the Hyalgan patients were excellent or good (RR 1.18; 95%
CI 0.57 to 2.41, P value 0.7). At 5 to 13 weeks post injection,
50% of the Adant patients and 21% of the Hyalgan patients were
excellent or good (RR 2.38; 95% CI 0.93 to 6.09, P value 0.07).
At 14 to 26 weeks postinjection, 33% of the Adant patients and
16% of the Hyalgan patients were excellent or good (RR 2.11;
95% CI 0.66 to 6.70, P value 0.2).
The RevMan analysis differed from the publication analysis. The
publication reported a significant difference in favour of Adant
compared to Hyalgan at three months in the number of patients
rating the improvement as excellent or good (P value < 0.05).
Safety
The number of patients reporting painful injections was almost
twice as high in the Adant group (6/30, 20%) versus Hyalgan (2/
19, 11%). This difference was not statistically significant. The RR
of having a painful injection was 1.90 (95% CI 0.43 to 8.46, P
value 0.4) at 1 to 4 weeks postinjection.
The RevMan analysis differed from the publication analysis. The
publication reported a significant difference in favour of Hyalgan
compared to Adant in the number of patients with painful infil-
trations (P value < 0.001).
Product - Arthrum H
Description of studies
One trial was excluded: Bardin 2004.
Product - Artz (Artzal,Supartz)
Description of studies
Nine trials of Artz (Seikagaku Corporation) have been included.
Seven included comparisons of Artz against placebo (Day 2004;
Karlsson 2002; Lohmander 1996; Puhl 1993; Shichikawa 1983a;
Shichikawa 1983b; Wu 1997) and three included comparisons
of Artz against three other hyaluronan/hylan products: Hylan G-
F 20 (Karlsson 2002), NRD-101 (Tsukamoto 1995 (abstract);
Yamamoto 1994) and SLM-10 (Kawabata 1993). Readers are di-
rected to the Hylan G-F 20, NRD-101 and SLM-10 sections for
results based on these products. With respect to methodological
quality, the average Jadad score was 4.3 out of 5 with three tri-
als scoring 5 (Day 2004; Karlsson 2002; Puhl 1993), three tri-
als scoring 4 (Lohmander 1996; Shichikawa 1983a; Shichikawa
1983b) and one trial scoring 3 (Wu 1997). Allocation conceal-
ment was adequate in three trials (Puhl 1993; Shichikawa 1983a;
Shichikawa 1983b) and unclear (not reported) in four trials (Day
2004; Karlsson 2002; Lohmander 1996; Wu 1997). Two ran-
domised, double-blind, placebo-controlled,multicentre trials have
been completed: one in France (Bourgeois (Artz)) and one in the
United Kingdom (Byrd (Artz)) but have only been published as
part of the Food and Drug Administration Pre-Market Approval
Package (Number P980044, Docket #01M-0342). Fifteen stud-
ies, reported between 1982 and 1999, were excluded (Arizono
1997;Dahlberg 1994; Fuji 1994;Hashimoto 1992;Honma 1989;
Igarashi 1983; Iseki 1983; Iwasaki 1993; Kawakami 1993;Namiki
1982; Oshima 1983; Shibata 1993; Suzu 1990; Takeuchi 1993;
Yoh 1989).
Day et al. reported an 18-week, placebo-controlled, double-blind
RCT performed at 17 centres in Australia comparing five weekly
injections of Artz to five weekly injections of saline in 240 pa-
tients with OA of the knee (Day 2001; Day 2004). A significant
difference between the two comparison groups for each outcome
measure evaluated was reported. A total of 482 adverse events were
reported but only 81 were possibly, probably or definitely related
to study medication (Artz n = 50, saline n = 31). Tolerability was
reported as being excellent since approximately 95% of patients
completed the full treatment schedule. Injection site pain and in-
flammation, that was mild and of short duration, was the most
frequent adverse event and occurred in approximately 10% of pa-
tients.
In the Discussion of the Day RCT (Day 2004) the authors sug-
gested that their positive result, in comparison to the Lohmander
RCT (Lohmander 1996), may have been due to the inclusion cri-
teria. Specifically, only patients with unilateral, mild-to-moderate
disease, with no patellofemoral OA or clinically large effusions,
and who were not morbidly obese were entered into the trial. Both
lateral andmedial approaches were utilised for IA injections in this
trial. However, the same approach was used for all injections in
one patient.
Karlsson et al. reported a one-year, placebo-controlled, parallel-
group, double-blindRCTperformed at 19 centres in Sweden com-
paring three weekly injections of Artzal (Astra Lakemedel) to three
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weekly injections of Hylan G-F 20 (Roche) and three weekly in-
jections of placebo (phosphate-buffered saline solution) in 210 pa-
tients with OA of the knee (Karlsson 2002). All patients, regard-
less of treatment, showed clinical improvement during the first 26
weeks of the treatment. Neither hyaluronan/hylan product pro-
duced a longer duration of clinical benefit than placebo. How-
ever, a significantly longer duration of clinical benefit was achieved
when data from the two hyaluronan products were pooled. No
serious adverse events due to the treatments were reported. Treat-
ment was discontinued due to adverse events in similar numbers of
patients in each of the treatment groups. In this review the Karls-
son 2002a reference refers to the Artzal versus placebo comparison
(Karlsson 2002a (AvP), the Karlsson 2002b reference refers to the
Hylan G-F 20 versus placebo comparison (Karlsson 2002b (SvP))
and the Karlsson 2002c reference refers to the Artzal versus Hylan
G-F 20 comparison (Karlsson 2002c (AvS)).
The Karlsson RCT (Karlsson 2002) inclusion criteria were based
on the Lohmander RCT (Lohmander 1996): patients aged 60
years or above, with a baseline Lequesne Index above 10, and ra-
diographically verifiedOA as Ahlback grade I-II. A Lequesne score
of 8 to 10 points represents severe handicap. Surgery is indicated
for scores of 10 to 12 points and higher. An Ahlback Stage I is
classified as narrowing of the joint space (with or without sub-
chondral sclerosis); joint space narrowing is defined by a space
inferior to 3 mm or inferior to the half of the space in the other
compartment (or in the homologous compartment of the other
knee). An Ahlback Stage II is classified as “obliteration of the joint
space” (Karlsson 2003d, Magilavy 2003).
Lohmander et al. reported a 20-week, placebo-controlled, dou-
ble-blind RCT performed at eight centres in Denmark, Finland,
Norway and Sweden comparing five weekly injections of Artzal
to five weekly injections of saline in 240 patients with OA of the
knee (Lohmander 1996). Prior to code break, patient data were
stratified by age (40 to 60 y, 61 to 75 y) and Lequesne algofunc-
tional index score (4 to 10, greater than 10). Although both groups
improved from baseline at the end of the study there was no dif-
ference between the two groups. However, when the two stratifi-
cation variables were utilised in the analyses Artzal was found to
be more effective than saline in older (greater than 60 y) patients
with more severe symptoms (Lequesne greater or equal to 10).
Although no serious adverse events were reported seven patients
(Artz n = 2, saline n = 5) withdrew from the trial due to adverse
events. Severity of injection-site swelling was significantly greater
in the Artz group. Dr. S. Lohmander kindly provided unpublished
data from the trial for this review.
The well-designed Lohmander RCT (Lohmander 1996) had a
pretrial meeting to standardize the injection procedure and assess-
ment procedures. The discussion of this report summarises some
of the difficulties in interpreting trials of HA. This is one of the few
trials which stratified patients based on baseline age and Lequesne
Index scores.
Puhl et al. reported an 18-week, parallel-group, double-blindRCT
performed at 25 centres in Germany comparing five weekly injec-
tions of Artz to five weekly injections of suspending vehicle (0.25
mg of sodium hyaluronate per 2.5 ml) in 209 patients with OA
of the knee (Puhl 1993). A statistically significant difference was
reported in the Lequesne Index (the primary outcome measure) in
favour of the Artz group from the third injection to the end of the
trial. In a subsequent publication (Puhl 1997) a subgroup analysis
confirmed the findings of the Lohmander et al. trial (Lohmander
1996) in that patients older than 60 ywith a Lequesne score greater
than 10 were the most likely to benefit from treatment. Local reac-
tions at the injection site were reported in similar numbers in both
groups (Artz n = 4, vehicle n = 5) and all were of short duration
and minor severity.
This well-designed trial excluded patients with excessive (greater
than 100 ml) joint effusion (Puhl 1993).
Shichikawa et al. reported a five-week, parallel-group, double-
blindRCTperformed at 38 centres in Japan comparing five weekly
injections of Artz (1.0% sodium hyaluronate) plus one placebo
tablet (lactose coated) administered three times daily after ev-
ery meal to five weekly injections of suspending vehicle (0.25
mg, 0.01% sodium hyaluronate) plus one placebo tablet (lactose
coated) administered three times daily after every meal in 228 pa-
tients with OA of the knee (Shichikawa 1983a). Statistically sig-
nificant differences in favour of Artz compared to control were
reported for final effectiveness and usefulness. No systemic adverse
events were reported. Local reactions were reported by four pa-
tients in the control group and one patient in the Artz group. One
patient in the control group had treatment discontinued due to
side effects.
The following design issues were noted: 1) follow-up was lim-
ited to one week after final injection; 2) patients with severe joint
space narrowing and marked retention of synovial effusion were
excluded; 3) patients recorded in symptom diaries at 10:00 daily;
4) authors attributed some of the local pain to injection procedure
(Shichikawa 1983a).
Shichikawa et al. reported a five-week, parallel-group, double-
blind RCT performed at 16 centres in Japan comparing five
weekly injections of Artz (0.5% sodium hyaluronate) plus two
placebo tablets (sugar coated lactose) administered three times
daily to five weekly injections of suspending vehicle (0.01%
sodium hyaluronate solution) plus two placebo tablets (sugar
coated lactose) administered three times daily in 107 patients with
OA of the knee (Shichikawa 1983b). Statistically significant dif-
ferences in favour of Artz compared to control were reported for
final effectiveness, pain in motion and usefulness. Treatment was
discontinued in three patients (Artz n = 1, control n = 2) due to
adverse events.
The following design issues were noted: 1) follow-up was limited
to one week after final injection; 2) patients with moderate-to-
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severe joint space narrowing and synovial effusion were excluded
(Shichikawa 1983b).
Wu et al. reported a 26-week, placebo-controlled, double-blind
RCT performed at a single centre in China comparing five weekly
injections of Artz to five weekly injections of the solvent for Artz
in 90 patients with OA of the knee (Wu 1997). Statistically signifi-
cant efficacy was reported for Artz compared to placebo beginning
one week after the fifth injection and lasting up to three months.
During the six-month trial no adverse events were reported.
The following design issue was noted: 1) patients with marked
joint space narrowing and large amounts of synovial effusion were
excluded (Wu 1997).
Artz versus placebo
Efficacy
With respect to the placebo comparisons at 1 to 4 weeks postin-
jection, there were no statistically significant differences between
Artz and placebo for the following outcome measures: pain (0
to 3 scale) (WMD -0.07; 95% CI -0.26 to 0.12, P value 0.5)
(Shichikawa 1983b); pain (0 to 100 mmVAS) (WMD 0.22; 95%
CI -3.89 to 4.34, P value 0.9) (Karlsson 2002a (AvP); Lohmander
1996; Puhl 1993); Lequesne Index (0 to 24) (WMD0.19; 95%CI
-0.77 to 1.15, P value 0.7) (Puhl 1993); range of motion (degrees)
(WMD 3.05; 95% CI -2.49 to 8.59, P value 0.3) (Shichikawa
1983b). There was a statistically significant difference in favour of
Artz for patient global assessment (RR 1.17; 95%CI 1.04 to 1.32,
P value 0.008) (Lohmander 1996; Shichikawa 1983a; Shichikawa
1983b). With the exception of the Lohmander trial (Lohmander
1996), the NNT for patient global assessment was between 5 and
11 patients.
The RevMan analysis differed from the Puhl et al. publication
analysis (Puhl 1993). The publication reported a statistically sig-
nificant difference in favour of Artz compared to placebo for the
Lequesne Index at 1 to 4 weeks postinjection (P value 0.043) com-
pared to the RevMan analysis (P value 0.7).
At 5 to 13 weeks postinjection, there were no statistically signifi-
cant differences between Artz and placebo for: WOMAC Pain (0
to 20) (WMD -0.77; 95% CI -1.61 to 0.07, P value 0.07) (Day
2004); WOMAC Function (0 to 68) (WMD -2.44; 95% CI -
5.33 to 0.45, P value 0.10) (Day 2004); Lequesne Index (WMD -
0.36; 95%CI -1.30 to 0.58, P value 0.5) (Puhl 1993); and patient
global assessment (RR 1.07; 95% CI 0.95 to 1.21; P value 0.3)
(Lohmander 1996; Puhl 1993). However, Artz was significantly
better thanplacebo for pain (100mmVAS) (WMD-5.00; 95%CI
-9.18 to -0.83, P value 0.02) (Karlsson 2002a (AvP); Lohmander
1996; Puhl 1993). Artz was between 5 and 20% more effective
than saline in relieving pain at 5 to 13 weeks postinjection.
TheRevMan analysis differed from theDay et al. publication anal-
ysis (Day 2004). The publication reported statistically significant
between-group differences in WOMAC pain (P value 0.045) and
WOMAC stiffness (P value 0.024) in favour of the Artz group
compared to the placebo group, whereas the RevMan analysis did
not detect a significant difference. The RevMan analysis differed
from the Puhl et al. publication analysis (Puhl 1993). The pub-
lication reported a statistically significant difference in favour of
Artz compared to placebo for the Lequesne Index at 5 to 13 weeks
post injection (P value 0.0053) compared to the RevMan analysis
(P value 0.5).
At 14 to 26 weeks postinjection, no statistically significant dif-
ferences were found between Artz and placebo for: the Lequesne
Index (WMD 0.51; 95% CI -0.43 to 1.45, P value 0.3) (Karlsson
2002a (AvP); Lohmander 1996); pain (100 mm VAS) (WMD -
0.42; 95% CI -6.90 to 6.06, P value 0.9) (Karlsson 2002a (AvP);
Lohmander 1996). However, more patients improved in the Artz
than placebo group for patient global assessment (RR 1.31; 95%
CI 1.00 to 1.72, P value 0.05) (Lohmander 1996). The number of
clinical failures was higher in the saline group (11%) versus Artzal
(2%) (RR 0.21; 95% CI 0.04 to 0.98; P value 0.0)5 (Karlsson
2002a (AvP)).
At 45 to 52weeks postinjection therewas no statistically significant
difference in the number of clinical failures (RR 0.73; 95% CI
0.49 to 1.08; P value 0.12) or in the number of survivors (i.e.
patients not requiring additional treatment for study knee) (RR
1.30; 95% CI 0.86 to 1.97, P value 0.2) (Karlsson 2002a (AvP)).
Safety
There was no statistically significant difference in the number of
withdrawals, overall, at 1 to 4 weeks postinjection (RR 1.03; 95%
CI 0.47 to 2.22, P value 0.9) (Shichikawa 1983a; Shichikawa
1983b); at 5 to 13 weeks postinjection (RR 1.06; 95% CI 0.64
to 1.76, P value 0.8) (Day 2004; Puhl 1993); and at 14 to 26
weeks postinjection (RR 0.60; 95% CI 0.15 to 2.45, P value 0.5)
(Lohmander 1996). There was no statistically significant differ-
ence in the number of withdrawals due to adverse events at 1 to 4
weeks postinjection (RR 0.26; 95% CI 0.03 to 2.28, P value 0.2)
(Shichikawa 1983a; Shichikawa 1983b); at 5 to 13 weeks postin-
jection (RR 1.06; 95% CI 0.07 to 16.81, P value 1) (Day 2004);
at 14 to 26 weeks postinjection (RR 0.40; 95% CI 0.08 to 2.02, P
value 0.3) (Lohmander 1996); and at 45 to 52 weeks postinjection
(RR 0.73; 95% CI 0.11 to 5.07, P value 0.8) (Karlsson 2002a
(AvP)). There were no statistically significant differences in the
number of participants withdrawn overall at 5 to 13 weeks postin-
jection (RR 0.40; 95% CI 0.16 to 0.98, P value 0.05) or at 14 to
26 weeks postinjection (RR 0.93; 95% CI 0.65 to 1.34, P value
0.7). The number of adverse events probably or possibly related to
treatment was statistically greater in the Artz group compared to
the saline group at 5 to 13 weeks postinjection (RR 1.59; 95% CI
1.12 to 2.26, P value 0.009) (Day 2004; Puhl 1993) but there was
no difference at 45 to 52 weeks postinjection (RR 0.53; 95% CI
0.08 to 3.72, P value 0.5) (Karlsson 2002a (AvP)). There was no
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statistically significant difference in the number of patients with
local adverse events in whom the study treatment was continued
at 1 to 4 weeks postinjection (RR 0.25; 95% CI 0.03 to 2.18, P
value 0.2) (Shichikawa 1983a). In Karlsson’s trial (Karlsson 2002a
(AvP)) at 45 to 52 weeks postinjection there was no statistically
significant difference in the number of patients reporting adverse
events (RR 1.22; 95% CI 0.91 to 1.64; P value 0.18) or in the
number of serious adverse events (RR 0.58; 95% CI 0.27 to 1.26,
P value 0.17). In Wu’s study (Wu 1997) no side effects developed
over a six-month period.
Artz versus corticosteroid: No trials included.
Artz versus NSAID: No trials included.
Artz versus other hyaluronan
One RCT included was a comparison of Artzal and Hylan G-F
20 (Karlsson 2002c (AvS)). Readers are directed to the NRD-101
and SLM-10 sections for results based on comparisons of Artz and
these products.
Efficacy
With respect to the Artzal comparison against Hylan G-F 20
(Karlsson 2002c (AvS)), there were no statistically significant dif-
ferences between the two products in pain on weight bearing (0 to
100 mm VAS) at the three assessment times: 1 to 4 weeks postin-
jection (WMD -1.00; 95% CI -8.41 to 6.41, P value 0.8); 5 to 13
weeks postinjection (WMD 1.00; 95% CI -7.83 to 9.83, P value
0.8); 14 to 26 weeks postinjection (WMD 5.00; 95% CI -4.98 to
14.98, P value 0.3). There was no statistically significant differ-
ence between the two products in the Lequesne Index at 14 to 26
weeks postinjection (WMD 1.00; 95% CI -0.37 to 2.37, P value
0.15). There were no statistically significant differences between
the two products in the number of clinical failures at both 14 to
26 weeks postinjection (RR 0.32; 95% CI 0.07 to 1.54, P value
0.15) and 45 to 52 weeks postinjection (RR 0.86; 95% CI 0.58 to
1.28, P value 0.5) or in the number of survivors (i.e. patients not
requiring additional treatment to study knee) at 45 to 52 weeks
postinjection (RR 0.98; 95% CI 0.70 to 1.37, P value 0.9).
Safety
There were no statistically significant differences between Artzal
and Hylan G-F 20 at 45 to 52 weeks postinjection in the number
of patients withdrawn due to adverse events (RR 1.91; 95% CI
0.18 to 20.70, P value =0.6), the number of adverse events related
to treatment (RR 1.23; 95% CI 0.11 to 13.40, P value 0.9), or
the number of patients reporting adverse events (RR 1.19; 95%
CI 0.92 to 1.56, P value 0.19).
Product - Biohy (Arthrease)
Description of studies
Two trials of BioHy have been included. One trial included a com-
parison against placebo (Tamir 2001) and the other trial included
a comparison against Hylan G-F 20 (Thompson 2002).
Tamir et al. reported a 20-week, placebo-controlled, single-blind,
open-label RCTperformed at a single orthopaedic clinic in Turkey
comparing three weekly injections of BioHy (Bio-Technology
General, manufactured by bacterial fermentation of the non-
hemolytic strain of Streptococcus zooepidemicus) to three weekly
injections of phosphate-buffered saline in 49 patients with OA of
the knee (Tamir 2001). The authors reported that this feasibility
study was not sufficiently powered to detect between-group dif-
ferences. However, they found a ’favourable trend’ for BioHy in
decreasing pain. With respect to safety, they reported that BioHy
was well tolerated and no HA-related adverse events were found.
With respect to methodological quality, it scored 3 out of 5 on the
Jadad scale; specific details of randomisation were not reported in
the publication. Allocation concealment was unclear.
In this RCT, several design issues were noted: 1) patients with
more than 15 ml of aspirated synovial fluid (SF) were excluded;
2) concurrent and escape medication such as paracetamol and
NSAIDs were permitted throughout the trial; 3) although the
AAOSMODEMS arthritic module was utilised for assessing pain,
stiffness and physical function, all the pain variables were assessed
and scored by the investigator and not by the patient; 4) in re-
porting the results the authors did not provide baseline means,
rather they reported change in mean categorical scores without
any measure of dispersion excluding this trial from the analysis; 5)
the trial was found to be under powered.
The Thompson et al. trial has been published as an abstract (
Thompson 2002). Thompson et al. reported a 12-week, parallel-
group, double-blind, multicentre RCT performed in Germany
comparing three weekly injections of Arthrease to three weekly
injections of Hylan G-F 20 in 321 patients with OA of the knee.
The authors reported that both groups had a statistically significant
reduction in pain compared to baseline but there was no between-
group difference. With respect to safety, statistically significantly
more cases of joint effusion were reported in the Hylan G-F 20
group (n = 13) compared to the Arthrease group (n = 1). With
respect to methodological quality, it scored 2 out of 5 on the
Jadad scale; specific details of randomisation and blinding were
not reported in the abstract. Allocation concealment was unclear.
Biotechnology General (Israel) Ltd. kindly provided the poster of
this trial that was presented at the OARSI 2002 Congress as well
as an Excel file of the WOMAC pain data.
BioHy versus placebo
Efficacy
No efficacy results have been extracted from this trial (Tamir
2001). Pain and stiffness results were reported as change but nei-
ther baseline values nor measures of dispersion were reported.
7Viscosupplementation for the treatment of osteoarthritis of the knee (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Safety
There were no statistically significant differences in the safety pro-
file of BioHy and placebo. There were a similar number of with-
drawals overall in both groups: BioHy 12% and placebo 17% (RR
0.72; 95% CI 0.18 to 2.89, P value 0.6). The difference in the
percentage of patients in the BioHy group (72%) who reported
knee pain immediately after the injection, which was related to
the injection procedure, was not significantly different from that
in the placebo group (46%) (RR 1.57; 95% CI 0.95 to 2.59, P
value 0.08). No systemic adverse events were reported in either
group.
BioHy versus corticosteroid: no trials included.
BioHy versus NSAID: no trials included.
BioHy versus other hyaluronan
One RCT was included comparing BioHy and Hylan G-F 20
(Thompson 2002).
Efficacy
There were no statistically significant differences in theWOMAC
pain subscale either at 1 to 4 weeks postinjection (WMD -3.70;
95% CI -8.13 to 0.73, P value 0.10) or at 5 to 13 weeks postin-
jection (WMD -3.80; 95% CI -8.10 to 0.50, P value 0.08). There
was no statistically significant difference in the number of patients
that assessed the treatment as ’very satisfied or satisfied’ (Arthrease
80%, Hylan G-F 20 77%) (RR 1.04; 95% CI 0.93 to 1.16, P
value 0.5) (Thompson 2002).
The RevMan analysis differed from the publication analysis. The
publication reported a statistically significant difference in favour
of BioHy compared to Hylan G-F 20 for the number of patients
that assessed the treatment as ’very satisfied or satisfied’ (P value
0.03) whereas RevMan detected no difference.
Safety
There was no statistically significant difference in the number of
patients reporting adverse events (Arthrease 34%, Hylan G-F 20
40%) (RR 0.84; 95% CI 0.63 to 1.11, P value 0.2). There was a
statistically significant difference in the number of patients with
joint effusion (Arthrease 0.6%,Hylan G-F 20 8%) (RR 0.08; 95%
CI 0.01 to 0.58, P value 0.01). The RevMan P value for this last
comparison differed from the publication P value of 0.0015.
Product - Durolane (NASHA - non-animal stabilized
hyaluronic acid)
Description of studies
One trial is awaiting assessment: Sinha 2003.
One trial was excluded: Akermark 2004.
Product - Fermathron
Description of studies
One RCT was included comparing Fermathron to another
hyaluronan (McDonald 2000).
McDonald et al. reported a six-month, parallel-group, double-
blind RCT performed at 12 centres in Germany comparing five
weekly injections of Fermathron (FermentechMedical Ltd., man-
ufactured by bacterial fermentation) to five weekly injections of
Hyalart (Fidia SpA, obtained from rooster combs) in 256 patients
with OA of the knee (McDonald 2000). The authors reported
that the products were similar in efficacy and that both were well
tolerated. With respect to methodological quality, the trial scored
5 out of 5 on the Jadad scale achieving points for both randomisa-
tion and blinding details. Allocation concealment was adequate.
This was a well-designed and reported ’non-inferiority’ study of
two HA products. The importance of escape medication was ad-
dressed in the study design. Patients kept a daily diary which was
declared as the secondary performance variable. Moreover, the au-
thors investigated the correlation between the route of injection
(knee straight or bent, medial or lateral approach) with the local
adverse event incident rate. They found that the lowest risk was
associated with a lateral approach to a straight knee (Jones 1993).
Source of HA (i.e. bacterial fermentation versus rooster combs)
did not affect the results.
One trial is awaiting assessment: Sinha 2003.
Fermathron versus placebo: no trials included.
Fermathron versus corticosteroid: no trials included.
Fermathron versus NSAID: no trials included.
Fermathron versus other hyaluronan
Efficacy
The three efficacy outcome measures extracted from this trial were
pain (0 to 100 mm VAS), the Lequesne Index (0 to 24), and
patient global assessment (very good, good, average, poor, very
poor). No statistically significant differences were found between
the two products: for pain (WMD 2.30; 95% CI -2.84 to 7.44, P
value 0.4) at 1 to 4 weeks postinjection and (WMD 0.80; 95% CI
-4.51 to 6.11, P value 0.8) at 5 to 13 weeks postinjection. Results
for the Lequesne Index showed a similar pattern (WMD 0.46;
95% CI -0.59 to 1.51, P value 0.4) at 1 to 4 weeks postinjection
and (WMD 0.55; 95% CI -0.48 to 1.58, P value 0.3) at 5 to
13 weeks postinjection. No statistically significant difference was
found in the number of responders (RR 0.96; 95% CI 0.82 to
1.13, P value 0.6) at 5 to 13 weeks postinjection with 72.4% in the
Hyalart group and 69.6% in the Fermathron group that reported
feeling better or much better.
Safety
There was no statistically significant difference in the number of
related adverse events (Fermathron 21% versus Hyalart 14%) (RR
1.47; 95% CI 0.84 to 2.59, P value 0.18).
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These results confirmed the results of the publication indicating
that the two products were similar in performance and well toler-
ated.
Product - Go-On
There were no RCTs of Go-On available (correspondence from
Rotta Research Laboratorium July 1, 2004).
Product - Hyalgan
Description of studies
Twenty-eight randomised controlled trials have been included
with Hyalgan (marketed also as Hyalart and Polyreumin)
(Fidia Pharmaceutical Corporation, Italy, derived from rooster
combs): 14 included comparisons against placebo (Altman 1998;
Bragantini 1987; Bunyaratavej 2001; Carrabba 1995; Corrado
1995; Creamer 1994; Dougados 1993; Formiguera Sala 1995;
Grecomoro 1987; Henderson 1994; Huskisson 1999; Jubb 2003;
St. J. Dixon 1988; Tsai 2003), one was a comparison against no
treatment (Miltner 2002; Schneider 1997), one was a comparison
against arthroscopic washout (Forster 2003), three were compar-
isons against other hyaluronanproducts (McDonald 2000;Roman
2000; Brown 2003), five were comparisons against corticosteroids
(Frizziero 2002; Leardini 1987; Leardini 1991; Pietrogrande 1991,
against methylprednisolone acetate; Jones 1995, against triamci-
nolone acetate), one was a comparison against NSAID (Altman
1998), one was a comparison against a homeopathic preparation
(Zeel Compositum) (Nahler 1998) (readers are directed to the
Zeel product section), one was a comparison against mucopolysac-
caride polysulfuric acid ester (Graf 1993), one was a comparison
against conventional therapy (Listrat 1997) and one was a com-
parison of treatment regimens (Karras 2001). Except for three tri-
als (Brown 2003; Karras 2001; Tsai 2003) which have been pub-
lished as abstracts the remaining trials have been published as jour-
nal articles. In three trials, Hyalgan was the control intervention
(McDonald 2000; Nahler 1998; Roman 2000). The frequency of
injection varied between studies (3, 4 and 5 weekly injections).
Considering only the 25 trials in which Hyalgan was designated
the experimental intervention (i.e. excluding McDonald 2000;
Nahler 1998; Roman 2000), with respect to methodological qual-
ity the average Jadad score was 2.7 out of 5 with one trial scoring 5
(Henderson 1994), 7 trials scoring 4 (Altman 1998; Bunyaratavej
2001; Frizziero 2002; Huskisson 1999; Jones 1995; Jubb 2003;
St. J. Dixon 1988), 5 trials scoring 3 (Carrabba 1995; Corrado
1995; Formiguera Sala 1995; Forster 2003; Grecomoro 1987),
10 trials scoring 2 (Bragantini 1987; Creamer 1994; Dougados
1993; Graf 1993; Karras 2001; Leardini 1987; Leardini 1991;
Listrat 1997; Pietrogrande 1991; Tsai 2003) and 2 trials scoring 1
(Brown 2003;Miltner 2002). Again, considering only the 25 trials
in which Hyalgan was designated the experimental intervention
allocation concealment was adequate in two trials (Forster 2003;
Frizziero 2002) and unclear (not reported) in 23 trials.
Twenty studies were excluded (Aglas 1997; Carrabba 1992;
D’Agnolo 1988; Dahlberg 1994; Frizziero 1993; Frizziero
1997; Frizziero 1998; Grecomoro 1992; Hamburger 2004; Kotz
1999; Mazzocato 1987; Mensitieri 1995; Milini 1989; Pasquali
Ronchetti 2001; Pavelka 2002; Pipino 1990; Punzi 1988; Rao
2001; Scali 1995; Sieliwonczyk 1997). Two trials are
awaiting assessment (Garcia 2004; Stitik 2004).
Altman et al. reported a 26-week, placebo- and naproxen-con-
trolled, double-blind, double-dummy, stratified, parallel-group
RCT performed at 15 centres in the United States comparing five
weekly injections of Hyalgan plus oral placebo twice daily to five
weekly injection of saline plus oral placebo or naproxen 500 mg
twice daily in 495 patients with OA of the knee (Altman 1998).
Only 67% of the patients completed the trial. Hyalgan was more
efficacious (pain relief and improved function) than placebo and
as effective as naproxen with fewer side effects. Injection site pain
was more common in the Hyalgan group while gastrointestinal
adverse events were more common in the naproxen group.
Several design issues are noted: 1) the placebo group received active
treatment in the form of 4 g of acetaminophen and arthrocentesis
with synovial fluid aspiration if necessary; 2) the naproxen group
did not receive arthrocentesis, they received a subcutaneous injec-
tion; 3) a training video was provided to all sites; 4) one criterion
of success was defined as an effect size of 0.25 of the standard de-
viation or 6 mm; 5) the data for all secondary outcome measures
was analysed only for those patients who completed the 26 weeks
of follow-up since the intent-to-treat analysis detected only a 1.5
mm difference between the Hyalgan and placebo groups in the
primary outcomemeasure (pain during the 50-foot walk test); and
6) escape analgesia, as 500 mg acetaminophen up to 4000 mg/day,
was permitted. Analyses showed no statistically significant differ-
ences between the three arms of the trial.
Bragantini et al. reported a 60-day, placebo-controlled, single-
blind, parallel-group RCT performed at a single centre in Italy
comparing three weekly injections of Hyalgan (both 20 mg and
40 mg) to three weekly injections of saline in 55 patients with OA
of the knee (Bragantini 1987). Both dosage levels of Hyalgan were
significantly superior to placebo. Four patients experienced local
pain and burning after injection with Hyalgan but these reactions
resolved within a short time. In this review, we have only used the
Hyalgan 20 mg arm for comparison against saline.
Brown and Beinat reported a six-week, parallel-group, RCT per-
formed at a single centre in England comparing five weekly in-
jections of Hyalgan to three weekly injections of Hylan G-F 20
in 54 patients with OA of the knee (Brown 2003). This trial was
discontinued, with about 50% of enrolment completed, due to
a high frequency of acute inflammatory reactions with Hylan G-
F 20. The protocol called for a sample size of 100 patients with
50 to be randomised to each group. The trial was designed to last
six months. The number of patients that developed an acutely in-
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flamed painful knee was 6 out of 29 in the Hylan G-F 20 group
compared to 0 of 25 in the Hyalgan group. Statistically signifi-
cant improvement in WOMAC pain and function was found for
Hyalgan while a trend of improvement was found for Hylan G-F
20.
Two study design points were noted: 1) this RCT was conducted
in a clinical practice setting; 2) randomisation was based on the
consultant to whom the patient was referred.
Bunyaratavej et al. reported a six-month, placebo-controlled,
double-blind RCT performed at three centres in Asia (China,
Malaysia, Thailand) comparing four weekly injections of Hyalgan
to four weekly injections of saline in 49 patents with OA of the
knee (Bunyaratavej 2001). Statistically significant differences in
favour of Hyalgan were reported one month after treatment as
reflected by decreased pain and increased joint mobility. No local
or systemic adverse events related to treatment were observed. No
measure of dispersion was reported for the saline group for pain
on active movement nor for either treatment group for day pain at
baseline. Consequently, this review includes safety but not efficacy
data.
This was one of two RCT where a four-injection schedule of
Hyalgan was followed. In addition, acetaminophen (paracetamol)
up to 3000 mg daily was permitted.
Carrabba et al. reported a six-month, placebo- and arthrocente-
sis-controlled, double-blind, parallel-group RCT performed at a
single centre in Italy comparing three dose schedules of Hyalgan
(one, three and five weekly injections) to five weekly arthrocen-
tesis or five weekly injections of saline in 100 patients with OA
of the knee (Carrabba 1995). All five groups received arthrocen-
tesis at the baseline visit. A significantly superior effect of five
and three injections of Hyalgan was shown in comparison with
placebo, arthrocentesis and one injection of Hyalgan. Four pa-
tients reported minor local reactions after injection (one patient
each in the arthrocentesis group, the one, three and five injection
Hyalgan groups). This review does not report results based on the
one injection Hyalgan arm. The 1995 reference refers to the five
injection Hyalgan versus saline comparison (Carrabba 1995); the
1995a reference refers to the three injection Hyalgan versus saline
comparison (Carrabba 1995a); the 1995b reference refers to the
five injection Hyalgan versus arthrocentesis comparison
(Carrabba 1995b); and the 1995c reference refers to the three
injection Hyalgan versus arthrocentesis comparison (Carrabba
1995c).
In this RCT paracetamol (acetaminophen) was permitted. How-
ever, only 15% of the patients used it at baseline, and there was
no change in usage over the duration of the trial.
Corrado et al. reported a two-month, placebo-controlled, double-
blind RCT performed at a single centre in Italy comparing five
weekly injections of Hyalgan to five weekly injections of placebo
(water, sodium chloride, sodium phosphate) in 40 patients with
OA of the knee (Corrado 1995). A significant difference in favour
of Hyalgan was reported for pain and range
of motion. Two patients experienced ’accidental trauma’ to the
knee during treatment.
In order to study the possible anti-inflammatory activity of
Hyalgan, Corrado et al. completed a biochemical assessment of
synovial fluid and plasma.
Creamer et al. reported a nine-week, placebo-controlled, single-
blind, blind-observer RCT performed at a single centre in Eng-
land comparing five weekly injections of Hyalgan to five weekly
injections of saline in 12 patients with bilateral OA of the knee
(Creamer 1994). This study investigated the mode of action of
HA. It was not designed to assess clinical efficacy. No beneficial
clinical effect was found for Hyalgan as compared to placebo.
Twelve adverse events were reported by seven patients. Five local
reactions (pain and swelling), graded as severe, occurred in three
Hyalgan-treated knees and two placebo-treated knees.
Several design issues were noted: 1) each patient acted as his/her
own control; 2) paracetamol up to 4 g daily was permitted; 3)
imaging assessments, both MRI and 99m Tc scintigraphic bone
scans, were performed; and 4) four of the treated knees and six of
the placebo knees had only patellofemoral disease.
Dougados et al. reported a one-year, placebo-controlled, single-
blind RCT performed at a single centre in France comparing four
weekly injections of Hyalectin to four weekly injections of the
vehicle in 110 patients with OA of the knee (Dougados 1993).
Greater improvement was found in theHyalectin group compared
to the placebo group for pain and function (Lequesne) in the
early assessment and for physician’s overall assessment of efficacy
and the Lequesne Index in the long term. Nine patients did not
receive all four injections: four in the Hyalectin group (two due
to painful injection, one lack of efficacy, and one improved) and
five in the placebo group (one due to painful injection, one lack
of efficacy, three due to reasons unrelated to treatment (traumatic
hemarthrosis in one, refusal to continue in two).
Several design issues were noted: 1) this RCT followed a four
injection schedule of Hyalgan; 2) one-sided tests were used in
the statistical analysis; and 3) the physician that administered the
injection also completed the clinical assessment.
Formiguera Sala and Esteve de Miguel reported a 90-day, placebo-
controlled, double-blind RCT performed at a single centre in
Spain comparing five weekly injections of Hyalgan to five weekly
injections of saline in 36 patients withOAof the knee (Formiguera
Sala 1995). There were no significant differences between the
groups at day 35. However, at day 90, statistically significant dif-
ferences in favour of Hyalgan were reported for pain outcome
measures. Three patients in each group reported pain that “could
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be attributed to the route of administration and the individual
idiosyncrasies of the patients”.
Several design issues were noted: 1) the supero-external approach
with the patient in a supine position was followed for injections;
2) study population consisted of 36 patients, but 40 joints; 3)
four patients were recruited twice: two receiving placebo in one
knee and Hyalgan in the other, one patient receiving Hyalgan in
separate knees at both times, one patient receiving placebo in the
same knee on two occasions; and 4) the treatment in the second
knee took place some time after the first knee was treated.
Forster and Straw reported a one-year, parallel-group RCT per-
formed at a single centre in England comparing five weekly injec-
tions of Hyalgan to arthroscopic washout (two litres 0.9% saline
at least) with either general or spinal anaesthesia in 38 patients
with OA of the knee (Forster 2003; Forster 2003a). No signifi-
cant differences between the two groups were found in any of the
clinical outcome measures at any assessment point. Two patients
in the Hyalgan group reported pain at the injection site following
one injection.
Dr. Forster kindly provided an Excel data file from which we cal-
culated means and standard deviations.
Frizziero and Pasquali Ronchetti reported a six-month, parallel-
group, single-blind RCT performed at a single centre in Italy com-
paring five weekly injections of Hyalgan to three weekly injections
of methylprednisolone acetate in 99 patients with primary or sec-
ondary OA of the knee (Frizziero 2002). The authors found an
initial statistically significant difference in favour of methylpred-
nisolone acetate at day 35 but not at day 180. The clinical effect
with Hyalgan appeared more gradually but lasted longer than that
of methylprednisolone acetate. Arthroscopic evaluations showed
thatHyalgan was superior tomethylprednisolone acetate in reduc-
ing the extent and grade of cartilage damage. No adverse events
were reported in the Hyalgan group compared to two patients in
themethylprednisolone acetate group, one resulting in withdrawal
from the trial.
This RCT was one of the trials which examined the structural
effects of Hyalgan using both arthroscopic and microarthroscopic
examinations.
Graf et al. reported a six-month, verum-controlled, single-blind
RCT performed at a single centre inGermany comparing Hyalgan
once per week (seven injections) to mucopolysaccharide polysul-
furic acid (MPA) ester twice per week (13 injections) in 60 pa-
tients with OA of the knee (Graf 1993). At the end of the treat-
ment phase the improvement in the modified total Larson rating
score was significantly better in the Hyalgan group. The authors
reported a more rapid onset of pain relief with Hyalgan. At the
end of the trial significantly more patients in the Hyalgan group
were symptom free or markedly improved. There was a causal re-
lationship with study medication for six adverse events in the
Hyalgan group and for two adverse events in the MPA group.
This RCT was the only trial where a seven injection schedule of
Hyalgan was followed.
Grecomoro et al. reported a 60-day, placebo-controlled, double-
blind RCT performed at a single centre in Italy comparing three
weekly injections of Hyalgan to three weekly injections of phos-
phate buffer in 34 patients with OA of the knee (Grecomoro
1987). A significant difference between treatments was reported
for all the clinical variables assessed. In theHyalgan group, pain re-
lief was both rapid and long lasting. No ’untoward signs or symp-
toms’ were reported. Two patients withdrew early in the placebo
group for reasons unrelated to treatment.
In this RCT results were based on 40 joints of 34 patients.
Henderson et al. reported a five-month, placebo-controlled, dou-
ble-blind RCT performed at a single centre in England compar-
ing five weekly injections of Hyalgan to five weekly injections of
vehicle in 91 patients with OA of the knee (Henderson 1994). Pa-
tients were stratified into two groups based on radiological sever-
ity. In this review, the reference to Henderson 1994 refers to
the milder severity group; while Henderson 1994a refers to the
more severe group. No significant differences were found between
the two groups. The rate of return to previously prescribed or
other NSAIDs or analgesia was significantly slower in the Hyalgan
treated group in the subgroup of patients with mild disease. Local
reactions (pain and swelling) were observed in 47% of the patients
in the Hyalgan group compared to 22% in the placebo group.
Several design issues were noted: 1) all but one patient had bilateral
disease; 2) a clinical metrologist was used; 3) injections were into
the patello-femoral space with a medial approach; and 4) there
was a high percentage of withdrawals (38%).
Huskisson and Donnelly reported a six-month, placebo-con-
trolled, blind-observer, parallel-group RCT performed at a single
centre in England comparing five weekly injections of Hyalgan
to five weekly injections of saline in 100 patients with OA of the
knee (Huskisson 1999). Superiority of Hyalgan over placebo was
demonstrated. Local reactions occurred in similar numbers in each
group: seven patients in each group reported flare at the joint while
effusion was present in three patients in the placebo group and
one patient in the Hyalgan group.
This trial was conducted in England to readdress the efficacy of
Hyalgan over placebo (see: Henderson 1994).
Jones et al. reported a six-month, double-blind, parallel-group
RCT performed at a single centre in England comparing five
weekly injections of Hyalgan to one injection of triamcinolone
hexacetonide followed by four injections of saline in 63 patients
with bilateral OA of the knee (Jones 1995). Active treatment,
which was randomised, was always given to the worst knee. The
placebo therapy was not randomised, and, therefore, no data were
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extracted for comparisons between Hyalgan and saline. No sta-
tistically significant differences were found between the groups in
the intention-to-treat analysis. However, in the completer analysis
significantly less pain was seen in the Hyalgan group with other
parameters showing a similar trend in favour of Hyalgan. Sixty-
eight percent of the patients dropped out of the study, themajority
due to lack of efficacy. By week 29 only 26% of the triamcinolone
hexacetonide patients and 38% of the Hyalgan patients remained
in the trial.
Jubb et al. reported a one-year, placebo-controlled, double-blind
RCT performed at 17 centres in the United Kingdom comparing
three weekly injections of Hyalgan to three weekly injections of
saline (vehicle placebo) in 408 patients with OA of the knee (Jubb
2001a; Jubb 2001b; Jubb 2001c; Jubb 2001d; Jubb 2003). The
treatment schedule was repeated twice more at four-monthly in-
tervals. The aim of the study was to investigate structural changes
as measured by joint space narrowing (the primary outcome). Sta-
tistically significant differences in favour of Hyalgan were found
for the pain outcome measures. Since the primary analysis did
not show any differences between the two groups with respect to
joint space narrowing, the authors performed a subgroup analysis
based on baseline joint space width. Those patients with radio-
logically milder disease (less than 4.6 mm) had less progression of
joint space narrowing when treated with Hyalgan. A total of 7.2%
of the Hyalgan patients and 3% of the saline patients withdrew
prematurely due to adverse events; 2.4% and 1.5%, respectively,
due to local adverse events. Local effects were reported by 36.1%
of the Hyalgan patients and 27.5% of the saline patients. Serious
adverse events, all due to concomitant disease, were reported by
13% of the Hyalgan patients and 7% of the saline patients.
In the Tables of Comparisons and data Jubb 2003 entries refer to
the full journal publication; Jubb 2001a entries refer to the primary
analysis population; Jubb 2001b entries refer to the subgroup with
joint space width equal or greater than 4.6mm; Jubb 2001c entries
refer to the subgroup with joint space width less than 4.6 mm.
Since reduction of joint space width was the primary efficacy
outcome measure in this trial evaluation was based on comput-
erised digital image analysis of anteroposterior weight-bearing ra-
diographs. The trial also addressed the safety of repeated cycles of
Hyalgan.
Karras et al. reported a one-year, parallel-group RCT performed at
a single centre in Greece comparing five weekly injections every six
months of Hyalgan to three weekly injections every three months
ofHyalgan in 200patientswithOAof the knee (Karras 2001). The
objective was to compare the effectiveness of the two regimens.
The authors reported that the three-injection regimen was more
effective than the five-injection regimen. Except for three cases of
local pain there were no side effects reported.
Leardini et al. reported a one-year, single-blind, parallel-group
RCT performed at a single centre in Italy comparing three weekly
injections of Hyalgan to three weekly injections of methylpred-
nisolone acetate (MPA) in 36 patients with OA of the knee
(Leardini 1987). No statistically significant differences were found
between the two groups in the clinical assessments. Local reactions
were reported in three patients in the MPA group compared to
four patients in the Hyalgan group.
This trial reported results on 40 joints of 36 patients (four with
bilateral disease).
Leardini et al. reported a 60-day, open, parallel-group RCT per-
formed at a single centre in Italy comparing three weekly injections
of Hyalgan to three weekly injections of 6-methylprednisolone
acetate (6-MPA) in 40 patients with OA of the knee (Leardini
1991). Assessments, completed one week after the end of treat-
ment, showed that Hyalgan was comparable to 6-MPA. In the
longer term significant differenceswere found in favour ofHyalgan
for the pain outcomes. All patients completed the treatment sched-
ule. No local or systemic reactions were reported.
In this trial, all patients were kept ’at rest’ for two days after injec-
tion.
Listrat et al. reported a one-year, open, parallel-group RCT per-
formed at a single centre in France comparing three weekly injec-
tions of Hyalgan every three months for a total of nine injections
to conventional therapy in 39 patients withOAof the knee (Listrat
1997). All patients underwent knee arthroscopy before randomi-
sation. A statistically significant difference in favour of Hyalgan
was found for the quality of life index. A statistically significant
difference for two of three structural parameters was found in
favour of Hyalgan. Forty percent of the Hyalgan patients reported
transient local reactions (pain) associated with the injection.
This study evaluated the potential structure-modifying effects
of Hyalgan. The arthroscopy was videotaped and assessed by a
blinded assessor. The primary efficacy outcomes were the arthro-
scopic parameters.
Miltner et al. reported a seven-week, right to left comparison RCT
performed at a single centre in Germany comparing five weekly
injections of Hyalart in the impaired knee to no treatment in the
contralateral, untreated knee in 43 patients with OA of the knee
(Miltner 2002; Schneider 1997). The objective of this trial was
to assess the effect of Hyalart on total work and isokinetic muscle
strength. This pilot study showed that Hyalart was effective with
regard to both clinical outcomes (e.g. relieving pain and improving
function) as well as to functional outcomes (e.g. peak torque and
total work). Schneider et al. published a preliminary evaluation of
this trial in German based on 18 patients (Schneider 1997).
Several design issues were noted: 1) all patients had bilateral dis-
ease; 2) the control group received no treatment; and 3) follow-
up was limited to one week after the final injection.
Pietrogrande et al. reported a 60-day, open, parallel-group RCT
performed at three centres in Italy comparingfiveweekly injections
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of Hyalgan to three weekly injections of 6-methylprednisolone
acetate in 90 patients with OA of the knee (Pietrogrande 1991).
Although both treatments reduced the disease symptoms 6-MPA
had amore rapid action that did not last as long as that of Hyalgan.
At the final assessment significant differences were found between
the treatments for most outcome measures. One patient in the
Hyalgan group had a local reaction which resolved spontaneously
but the patient was withdrawn due to lack of efficacy. No systemic
adverse reactions were reported in either group.
St. J. Dixon et al. reported a 48-week, placebo-controlled, double-
blind, parallel-group RCT performed at three centres in England
comparing Hyalgan (up to eleven injections over 23 weeks) to ve-
hicle (0.2 mg sodium hyaluronate) in 63 patients with OA of the
knee (St. J. Dixon 1988). Knee pain was significantly reduced in
the Hyalgan group compared to the placebo group. No between-
group difference was found for function as measured by activities
of daily living. Possible treatment-related (Hyalgan) adverse events
occurred in three patients: hemarthrosis developed in one patient,
effusion volume increased in one patient, and phlebitis developed
in one patient. Ten patients did not complete the trial. Five pa-
tients in the placebo group withdrew early because of increased
pain; while five patients withdrew early in the Hyalgan group: one
because of a torn meniscus, one because knee was painless, one
had increased pain, one defaulted and one had a hemarthrosis. No
measure of dispersion was reported for pain on movement, pain
at rest, or activities of daily living and, consequently, efficacy data
are not included in this review. Only safety data are included in
this review.
This is the only RCT where up to 11 injections of Hyalgan were
used.
Tsai et al. reported a 25-week, placebo-controlled, multicentre,
double-blind RCT performed in Taiwan comparing five weekly
injections of Hyalgan to five weekly injections of saline in 200
patients with OA of the knee (Tsai 2003). Statistically significant
differences were found in favour of Hyalgan for pain on 50-foot
walk, WOMACOA Index pain and physical function. No differ-
ences between treatments were reported in adverse event occur-
rence.
Fidia Spa kindly provided an in-house report (Lin 2004) as only
an abstract, based on this trial, had been published in 2003 (Tsai
2003).
Hyalgan versus placebo
Efficacy
Based on14 comparisons, therewas a statistically significant differ-
ence in pain on weight bearing, measured on a 0 to 100 mm VAS,
in favour of Hyalgan compared to placebo at 1 to 4 weeks postin-
jection (WMD (random-effects model) -6.20; 95% CI -11.02 to
-1.38, P value 0.009). Hyalgan was 2 to 31% more effective than
placebo in improving pain. Based on 10 comparisons there was a
statistically significant difference in favour of Hyalgan compared
to placebo at 5 to 13 weeks postinjection (WMD (random-ef-
fects model) -9.04; 95% CI -14.10 to -3.98; P value 0.0005).
Hyalgan was 18 to 44% more effective than placebo in improv-
ing pain. There was a statistically significant difference in favour
of Hyalgan compared to placebo at 14 to 26 weeks postinjection
(WMD -4.12; 95% CI -6.97 to -1.27, P value 0.005) (Altman
1998; Huskisson 1999; Jubb 2003; Tsai 2003). Hyalgan was 3 to
26%more effective than placebo in improving pain. There was no
statistically significant difference at 45 to 52 weeks postinjection
(WMD -2.60; 95% CI -7.40 to 2.19, P value 0.3) (Dougados
1993; Jubb 2003; St. J. Dixon 1988).
There was a statistically significant difference in spontaneous pain,
measured on a 100 mm VAS, in favour of Hyalgan compared
to placebo at 1 to 4 weeks postinjection (WMD -23.88; 95%
CI -33.50 to -14.25, P value < 0.00001) and at 5 to 13 weeks
postinjection (WMD (random-effects model) -22.28; 95% CI
-38.88 to -5.68, P value 0.009) (Bragantini 1987; Grecomoro
1987). Hyalgan was 38 to 67% more effective than placebo in
improving pain.
There was a statistically significant difference in pain at rest, mea-
sured on a 0 to 100 mm VAS, in favour of Hyalgan compared
to placebo at 1 to 4 weeks postinjection (WMD (random-effects
model) -6.37; 95% CI -11.57 to -1.18, P value 0.02) (Carrabba
1995; Carrabba 1995a; Carrabba 1995b; Carrabba 1995c;
Corrado 1995; Dougados 1993; Henderson 1994; Henderson
1994a; St. J. Dixon 1988) and at 5 to 13 weeks postinjec-
tion (WMD -9.65; 95% CI -14.18 to -5.13, P value 0.00003)
(Carrabba 1995; Carrabba 1995a; Carrabba 1995b; Carrabba
1995c; Corrado 1995). Hyalgan was 13 to 116% more effective
than placebo in improving pain. There was no difference at 45
to 52 weeks postinjection (WMD 1.61; 95% CI -5.28 to 8.51, P
value 0.6) (Dougados 1993; St. J. Dixon 1988).
There was no statistically significant difference in pain at night,
measured on a 0 to 100 mm VAS, between Hyalgan and placebo
at 5 to 13 weeks post injection (WMD (random-effects model)
-4.55; 95% CI -12.49 to 3.39, P value 0.3) (Henderson 1994;
Henderson 1994a).
There were no statistically significant differences in WOMAC
pain, measured on a 0 to 100 mm VAS, between Hyalgan and
placebo at 1 to 4 weeks postinjection (WMD -2.67; 95%CI -6.84
to 1.50, P value 0.2) or at 5 to 13 weeks postinjection (WMD -
1.49; 95% CI -5.75 to 2.77, P value 0.5). There was a statistically
significant difference in favour of Hyalgan compared to saline at
14 to 26 weeks postinjection (WMD -5.66; 95% CI -10.06 to
-1.26, P value 0.01) (Lin 2004, Tsai 2003) with Hyalgan being
14% more effective than saline.
Pain was measured using several dichotomous outcome measures.
There were statistically significant differences in favour of Hyalgan
compared to placebo for the number of joints improved for walk-
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ing pain at the end of treatment (RR 1.68; 95% CI 1.02 to 2.78, P
value 0.04) (Bragantini 1987); at 1 week postinjection (RR 3.60;
95% CI 1.48 to 8.78, P value 0.005) (Grecomoro 1987); and
at 5 to 13 weeks postinjection (RR 2.30; 95% CI 1.26 to 4.19,
P value 0.006) (Bragantini 1987). The NNT for walking pain
was 2 to 3. Similarly, statistically significant differences in favour
of Hyalgan compared to placebo were found for the number of
joints improved for pain under load at the end of treatment (RR
0.37; 95% CI 0.19 to 0.73, P value 0.004) (Bragantini 1987);
at 1 week postinjection (RR 3.60; 95% CI 1.48 to 8.78, P value
0.005) (Grecomoro 1987); and at 5 to 13 weeks postinjection (RR
0.25; 95%CI 0.10 to 0.60, P value 0.002) (Bragantini 1987). The
NNT for pain under load was 2.
There was no statistically significant difference in pain expressed
as the number of patients improved at 5 to 13 weeks postinjection
(RR 1.19; 95% CI 0.93 to 1.52, P value 0.16). The RevMan
analysis differed from the publication analysis where P value was
0.04 (chi square test). A significant difference in favour of Hyalgan
compared to placebo was found at 32
weeks postinjection (RR 1.36; 95%CI 1.06 to 1.75, P value 0.02)
(Jubb 2003). The NNT for patient global assessment was 9.
There was no statistically significant difference in the number of
patients who had moderate to marked pain (RR 0.74; 95% CI
0.53 to 1.04, P value 0.08) or in those who had none to slight to
mild pain at 14 to 26 weeks postinjection (RR 1.22; 95% CI 0.98
to 1.52, P value 0.08) (Altman 1998).
There were no statistically significant differences in the number of
knee joints without night pain at 1 to 4 weeks postinjection (RR
1.40; 95%CI 0.61 to 3.19, P value 0.4) or at 5 to 13 weeks postin-
jection (RR 1.40; 95% CI 0.61 to 3.19, P value 0.4) (Creamer
1994). There were no statistically significant differences in the
number of participants without rest pain at 1 to 4 weeks postin-
jection (RR 1.20; 95% CI 0.50 to 2.88, P value 0.7)or at 5 to 13
weeks postinjection (RR 2.50; 95%CI 0.60 to 10.46, P value 0.2)
(Creamer 1994).
There was a statistically significant difference in the number of
joints with improvement in pain on touch in favour of Hyalgan
compared to placebo (RR 2.25; 95% CI 1.12 to 4.53, P
value 0.02) (Grecomoro 1987). The NNT for pain on touch was
2.
There were no statistically significant differences in theWOMAC
function, measured on a 0 to 100 mm VAS, between Hyalgan
and saline at 1 to 4 weeks postinjection (WMD -1.30; 95% CI -
5.52 to 2.92, P value 0.5); 5 to 13 weeks postinjection (WMD -
1.06; 95% CI -5.37 to 3.25, P value 0.6); or at 14 to 26 weeks
postinjection (WMD -4.05; 95% CI -8.38 to 0.28, P value 0.07)
(Lin 2004; Tsai 2003). The RevMan analysis differed from the
publication analysis where a statistically significant difference was
found in favour of Hyalgan in WOMAC function from baseline
to week 25 (P value 0.0038 (ANOVA)).
Statistically significant differences in the Lequesne Index, mea-
sured on a 0 to 24 scale, in favour of Hyalgan compared to placebo
were found at 1 to 4 weeks postinjection (WMD -1.50; 95% CI -
2.36 to -0.65, P value 0.0006) (Carrabba 1995; Carrabba 1995a;
Carrabba 1995b; Carrabba 1995c; Dougados 1993; Huskisson
1999) and at 5 to 13 weeks postinjection (WMD -2.34; 95% CI -
3.41 to -1.27, P value 0.00002) (Carrabba 1995; Carrabba 1995a;
Carrabba 1995b; Carrabba 1995c; Huskisson 1999). Hyalgan was
11 to 25%more effective than placebo. Nodifference was found at
14 to 26 weeks postinjection (WMD -1.40; 95%CI -3.40 to 0.60,
P value 0.17) (Huskisson 1999) or at 45 to 52 weeks postinjection
(WMD -1.11; 95% CI -2.70 to 0.48, P value 0.17) (Dougados
1993). The RevMan analysis differed from the Dougados publi-
cation (Dougados 1993) which reported a statistically significant
difference (P value 0.046) in the Lequesne Index at week 52.
Although not recommended as core-set outcome measures, data
were extracted on range of motion, synovial fluid volume, and
joint space width. There was no statistically significant difference
in flexion, measured in degrees, between Hyalgan and placebo at
1 to 4 weeks postinjection (WMD 3.50; 95% CI -4.11 to 11.11,
P value 0.4) but Hyalgan was significantly better than placebo at
5 to 13 weeks postinjection (WMD 7.60; 95% CI 0.46 to 14.74,
P value 0.04) (Corrado 1995). Hyalgan was 6% more effective in
improving flexion than placebo. There were no statistically signifi-
cant differences in synovial fluid volume, measured inml, between
Hyalgan and placebo at 1 to 4 weeks postinjection (WMD -0.76;
95%CI -3.49 to 1.98, P value 0.6) (Corrado 1995; Creamer 1994;
Dougados 1993) or at 5 to 13 weeks postinjection (WMD (ran-
dom-effects model) -3.96; 95% CI -11.10 to 3.19, P value 0.3)
(Corrado 1995; Creamer 1994). There was a statistically signifi-
cant difference in joint space width, measured in mm, in favour
of Hyalgan compared to placebo at 45 to 52 weeks postinjection
(WMD 0.40; 95% CI 0.03 to 0.77, P value 0.03) (Jubb 2003).
However, when the treatment groups were stratified by baseline
joint space width there was no difference (WMD (random-effects
model) 0.15; 95% CI -0.34 to 0.64, P value 0.6) (Jubb 2003).
These RevMan analyses differed from the Jubb publication (Jubb
2003) analysis where no difference was found in the total popu-
lation but a difference in favour of the subgroup with joint space
width equal to or greater than 4.6 mm at baseline was reported.
There was no statistically significant difference between Hyalgan
and placebo in patient global assessment, measured as number of
patients improved, at 1 to 4 weeks postinjection (RR 1.45; 95%
CI 0.97 to 2.15, P value 0.07) (Corrado 1995; Creamer 1994;
Formiguera Sala 1995). A statistically significant difference was
found in favour of Hyalgan compared to placebo at 5 to 13 weeks
postinjection (RR 2.44; 95% CI 1.43 to 4.16, P value 0.0010)
(Corrado 1995; Formiguera Sala 1995). The NNT for patient
global assessment was 10. A statistically significant difference was
14Viscosupplementation for the treatment of osteoarthritis of the knee (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
found in favour of Hyalgan compared to placebo at 14 to 26
weeks postinjection (RR 1.24; 95%CI 1.03 to 1.50, P value 0.02)
(Henderson 1994; Huskisson 1999; Lin 2004). No difference was
found at 45 to 52 weeks postinjection in the number of patients
rating treatment effective (RR 1.17; 95% CI 0.85 to 1.62, P value
0.3) (Dougados 1993). When patient global assessment was mea-
sured by the number of joints that were fairly good to very good, a
statistically significant difference in favour of Hyalgan compared
to placebo was found at 5 to 13 weeks postinjection (RR 2.12;
95% CI 1.22 to 3.70, P value 0.008) (Bragantini 1987; Creamer
1994). The NNT for patient global assessment was 11.
Safety
There were no statistically significant differences in the total num-
ber of withdrawals overall at 5 to 13 weeks postinjection (RR
0.60; 95% CI 0.11 to 3.23, P value 0.6) (Carrabba 1995; Corrado
1995); at 14 to 26 weeks postinjection (RR 1.11; 95% CI 0.87
to 1.41, P value 0.4) (Altman 1998; Henderson 1994; Huskisson
1999; Lin 2004); or at 45 at 52 weeks postinjection (RR 1.13;
95% CI 0.81 to 1.56, P value 0.5) (Dougados 1993; Jubb 2003;
St. J. Dixon 1988). There were no statistically significant differ-
ences in the number of withdrawals due to lack of efficacy during
the treatment phase (RR 1.00; 95% CI 0.06 to 15.59, P value 1)
(Dougados 1993) or 14 to 26 weeks postinjection (RR 0.80; 95%
CI 0.47 to 1.36, P value 0.4) (Altman 1998; Huskisson 1999; Lin
2004). A statistically significant difference in favour of placebo
compared to Hyalgan was found in the number of patients with
local adverse events that caused discontinuation of study drug (RR
3.34; 95%CI1.31 to 8.56, P value 0.01) (Altman 1998;Dougados
1993; Henderson 1994; Jubb 2003). Similarly, there was a sta-
tistically significant difference in favour of placebo compared to
Hyalgan found in the number of patients with local adverse events
but the study drug was continued (RR 1.42; 95%CI 1.10 to 1.84,
P value 0.007). There was no difference in the number of pa-
tients with serious adverse events at 14 to 26 weeks postinjection
(RR 1.67; 95% CI 0.41 to 6.85, P value 0.5) (Huskisson 1999;
Lin 2004). There was a trend of more serious adverse events in
the Hyalgan group compared to the placebo group at 45 to 52
weeks postinjection (RR 1.85; 95%CI 1.00 to 34.3, P value 0.05)
(Dougados 1993, Jubb 2003). There was a trend of more patients
withdrawing due to adverse events in theHyalgan group compared
to the placebo group (RR 2.35; 95% CI 0.99 to 5.56, P value
0.05) (Huskisson 1999, Jubb 2003). There was no difference in
the number of knee joints with local adverse events (RR 2.16; 95%
CI 0.54 to 8.69, P value 0.3) (Bragantini 1987; Creamer 1994).
There was no statistically significant difference in the number of
patients with injection site pain (RR 1.39; 95% CI 0.98 to 1.97,
P value 0.06) (Altman 1998; Dougados 1993; Formiguera Sala
1995). There was no difference in the number of patients with
treatment related adverse events at 5 to 13 weeks postinjection,
0% in both the Hyalgan and control groups (Formiguera Sala
1995). There was a statistically significant difference in the num-
ber of patients with treatment-related adverse events at 14 to 26
weeks postinjection (RR 2.19; 95%CI 1.18 to 4.07, P value 0.01)
(Bunyaratavej 2001; Henderson 1994; Huskisson 1999) but not
at 45 to 52 weeks postinjection (RR 7.68; 95%CI 0.41 to 142.78,
P value 0.17). In the Altman trial (Altman 1998) at 14 to 26 week
postinjection there was a statistically significant difference in the
number of patients with gastrointestinal complaints in favour of
placebo compared to Hyalgan (RR 1.89; 95% CI 1.24 to 2.90, P
value 0.003). There was no difference in the number of patients
with local skin rash at 14 to 26 weeks postinjection (RR 0.91;
95% CI 0.54 to 1.52, P value 0.7) (Altman 1998).
Hyalgan versus arthroscopy
One trial was included which was a comparison of Hyalgan and
arthroscopy (Forster 2003; Forster 2003a).
Efficacy
In the comparison against arthroscopy, there was no statistically
significant difference between Hyalgan and arthroscopy in pain (0
to 10 cm VAS) at any of the four assessments: 1 to 4 weeks post
injection (WMD 1.20; 95% CI -0.88 to 3.28, P value 0.3); 5 to
13 weeks postinjection (WMD 0; 95% CI -2.51 to 2.51, P value
1); 14 to 26 weeks postinjection (WMD -0.90; 95% CI -3.46 to
1.66, P value 0.5); and 45 to 52 weeks postinjection (WMD 0;
95%CI -2.47 to 2.47, P value 1). There was no statistically signifi-
cant difference between Hyalgan and arthroscopy in the Lequesne
Index (0-24) at any of the four assessments: 1 to 4 weeks postin-
jection (WMD 0.60; 95% CI -3.72 to 4.92, P value 0.8); 5 to 13
weeks postinjection (WMD -0.60; 95% CI -5.00 to 3.80, P value
0.8), 14 to 26 weeks postinjection (WMD -3.00; 95% CI -7.58
to 1.58, P value 0.2); and 45 to 52 weeks postinjection (WMD
-2.90; 95% CI -8.10 to 2.30, P value 0.3). Although there was
a statistically significant difference between groups pre-trial for
the Knee Society Function scale score (i.e. Hyalgan group better
score), except for the 14 to 26 week assessment, there was no sta-
tistically significant difference between Hyalgan and arthroscopy:
at 1 to 4 weeks postinjection (WMD 16.90; 95% CI -6.32 to
40.12, P value 0.15); at 5 to 13 weeks postinjection (WMD16.20;
95% CI -6.50 to 38.90, P value 0.16); at 14 to 26 weeks postin-
jection (WMD 23.50; 95% CI 1.68 to 45.32, P value 0.03) (i.e.
Hyalgan was 2% more effective than arthroscopy); and 45 to 52
weeks postinjection; (WMD 23.90; 95% CI -1.45 to 49.25, P
value 0.06). There was no difference between the number of pa-
tients requiring further intervention (RR 2.06; 95% CI 0.64 to
6.57, P value 0.2).
The RevMan analysis differed from the Forster publication
(Forster 2003) analysis. The publication reported no difference in
theKnee Society Function scale at sixmonthswhereas the RevMan
analysis detected a statistically significant difference (P value 0.03)
in favour of Hyalgan over arthroscopy.
Safety
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There was no difference in the number of withdrawals overall:
Hyalgan 2 out of 19 versus arthroscopy 4 of 19 (RR 0.50; 95% CI
0.10 to 2.41, P value 0.4). There was no difference in the number
of patients with pain at the injection site: Hyalgan 2 out of 19
versus arthroscopy 0 out of 19 (RR 5.00; 95% CI 0.26 to 97.70,
P value 0.3).
Hyalgan versus corticosteroid
Five RCTs that were included were comparisons of Hyalgan and
IA corticosteroid.
Four RCT were comparisons of Hyalgan and methylprednisolone
acetate (Depomedrol, MPA) (Frizziero 2002; Leardini 1987;
Leardini 1991; Pietrogrande 1991) and one RCT was a compari-
son of Hyalgan and triamcinolone hexacetonide (Jones 1995).
Efficacy
There was no statistically significant difference in spontaneous
pain intensity (0 to 100 mm VAS) at 1 to 4 weeks postinjection
(WMD -4.90; 95% CI -9.91 to 0.10, P value 0.05) (Leardini
1987; Leardini 1991; Pietrogrande 1991). There was a statistically
significant difference in favour of Hyalgan at 5 to 13 weeks postin-
jection (WMD -7.73; 95% CI -12.81 to -2.64, P value 0.003)
(Leardini 1987; Leardini 1991; Pietrogrande 1991). Hyalgan was
11 to 41% more effective than MPA. At 45 to 52 weeks postin-
jection, there was no difference (WMD 2.50; 95% CI -14.98 to
19.98, P value0.8) (Leardini 1987). For pain expressed as the num-
ber of joints with moderate or severe pain under load (Leardini
1987), there was no statistically significant difference at 1 to 4
weeks postinjection (RR 1.00; 95% CI 0.47 to 2.14, P value 1);
at 5 to 13 weeks postinjection (RR 0.86; 95% CI 0.35 to 2.10,
P value 0.7); or at 45 to 52 weeks postinjection (RR 0.82; 95%
CI 0.46 to 1.49, P value 0.5). For pain expressed as the num-
ber of patients with moderate or severe pain under load (Leardini
1991; Pietrogrande 1991), there was no difference at 1 to 4 weeks
postinjection (RR (random-effects model) 0.90; 95% CI 0.54 to
1.50, P value 0.7). There was a statistically significant difference in
favour of Hyalgan at 5 to 13 weeks postinjection (RR 0.61; 95%
CI 0.44 to 0.84, P value 0.003). The NNT for moderate to severe
pain under load was 10. For the number of joints with moderate
or severe walking pain, no statistically significant differences were
detected at the three timepoints: at 1 to 4 weeks postinjection
(RR 1.22; 95% CI 0.65 to 2.29, P value 0.5), at 5 to 13 weeks
postinjection (RR 0.80; 95% CI 0.40 to 1.60, P value 0.5), and
at 45 to 52 weeks postinjection (RR 1.04; 95% CI 0.67 to 1.60,
P value 0.9) (Leardini 1987). For the number of patients with
moderate or greater night pain, there was no statistically signifi-
cant difference at 1 to 4 weeks postinjection (RR (random-effects
model) 1.12 (95% CI 0.06 to 21.12) P value 0.9) or at 5 to 13
weeks postinjection (RR 0.14; 95%CI 0.02 to 1.13, P value 0.07)
(Leardini 1991; Pietrogrande 1991). For the number of patients
with moderate or greater rest pain, there was no statistically signif-
icant difference at 1 to 4 weeks postinjection (RR 0.68; 95% CI
0.38 to 1.24, P value 0.2), but a significant difference in favour of
Hyalgan at 5 to 13 weeks postinjection (RR 0.39; 95% CI 0.19
to 0.78, P value 0.008) (Leardini 1991; Pietrogrande 1991). The
NNT for rest pain was 20.
Statistically significant differences in range of motion (flexion)
in favour of Hyalgan were found at 1 to 4 weeks postinjection
(WMD 5.93; 95% CI 0.71 to 11.14, P value 0.03) and at 5 to 13
weeks post injection (WMD 5.41; 95% CI 0.54 to 10.28, P value
0.03) (Leardini 1987; Pietrogrande 1991) (i.e. Hyalgan was 2%
more effective than MPA) but no difference was detected at 45 to
52 weeks postinjection (WMD 1.50; 95% CI -12.92 to 15.92, P
value 0.8) (Leardini 1987).
The global assessment, expressed by number of patients good
or very good, was not significantly different between groups at
1 to 4 weeks postinjection (RR (random-effects model) 0.98;
95% CI 0.47 to 2.06, P value 1) (Frizziero 2002; Leardini 1991;
Pietrogrande 1991). There was a statistically significant difference
in favour of Hyalgan at 5 to 13 weeks postinjection (WMD 1.86;
95%CI 1.26 to 2.75, P value 0.002) (Leardini 1991; Pietrogrande
1991). The NNT for patient global assessment was 7. At 45 to 52
weeks postinjection, there was no difference (WMD 1.05; 95%
CI 0.81 to 1.36, P value 0.7) (Frizziero 2002).
One RCT was a comparison of Hyalgan and triamcinolone hex-
acetonide (Jones 1995). Except for pain at night at the latter as-
sessment time, there were no statistically significant differences
between treatment detected by the three pain measures (100 mm
VAS): pain on nominated activity (WMD -0.20; 95% CI -17.39
to 16.99, P value 1) at end of treatment; and (WMD -10.00; 95%
CI -31.83 to 11.83, P value 0.4) at 14 to 26 weeks postinjection;
pain at rest (WMD -0.70; 95%CI -18.17 to 16.77, P value 0.9) at
end of treatment; and (WMD -20.40; 95% CI -43.92 to 3.12, P
value 0.09) at 14 to 26 weeks postinjection; pain at night (WMD
-7.10; 95% CI -24.30 to 10.10, P value 0.4) at end of treatment;
and (WMD-20.70; 95%CI -37.74 to -3.66, P value 0.02) at 14 to
26 weeks postinjection. That is, Hyalgan was 26% more effective
than triamcinolone hexacetonide in relieving pain at night at 14
to 26 weeks postinjection. The RevMan analysis differed from the
Jones publication (Jones 1995) analysis. The publication reported
significant differences in favour of Hyalgan in pain on nominated
activity and pain at rest at 14 to 26 weeks postinjection.
Safety
There were no statistically significant differences in any of the ex-
tracted safety outcomes. There was no difference in the total num-
ber of withdrawals overall at 1 to 4 weeks postinjection (RR 0.54;
95% CI 0.21 to 1.38, P value 0.2) (Frizziero 2002); at 5 to 13
weeks postinjection (RR 3.00; 95%CI 0.13 to 71.74, P value 0.5)
(Leardini 1991; Pietrogrande 1991); at 14 to 26 weeks postin-
jection (RR 1.81; 95% CI 0.67 to 4.91, P value 0.2) (Frizziero
2002); or at 45 to 52 weeks postinjection (RR 1.67; 95% CI 0.46
to 6.06, P value 0.4) (Leardini 1987). There was no difference in
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the number of patients withdrawn due to lack of efficacy at 5 to
13 weeks postinjection (RR 3.00; 95% CI 0.13 to 71.74, P value
0.5) (Pietrogrande 1991). There was no difference in the number
of joints with local reactions at 1 to 4 weeks postinjection (RR
1.33; 95% CI 0.34 to 5.21, P value 0.7) (Leardini 1987). There
was no difference in the number of patients with local or systemic
reactions at 5 to 13 weeks postinjection (RR 3.00; 95% CI 0.13
to 71.74, P value 0.5) (Leardini 1991, Pietrogrande 1991). There
was no difference in the number of patients withdrawn due to ad-
verse events after the first injection in the Frizziero trial (Frizziero
2002) (RR 0.30; 95% CI 0.01 to 7.24, P value 0.5).
There were no statistically significant differences betweenHyalgan
and triamcinolone hexacetonide (Jones 1995) in the total number
of withdrawals overall at the end of treatment (RR 0.73; 95% CI
0.18 to 2.99, P value 0.7) or at 14 to 26 weeks postinjection (RR
0.80; 95%CI 0.56 to 1.14, P value 0.2). There were no statistically
significant differences in the number of withdrawals due to lack of
efficacy at the end of treatment (RR 4.85; 95% CI 0.24 to 97.11,
P value 0.3) or at 14 to 26 weeks postinjection (RR 0.89; 95% CI
0.49 to 1.65, P value 0.7). There were no statistically significant
differences in the number of withdrawals due to adverse events at
the end of treatment (RR 0.97; 95% CI 0.06 to 14.82, P value 1)
or
at 14 to 26 weeks postinjection (RR 0.78; 95% CI 0.23 to 2.62,
P value 0.7).
Hyalgan versus other IA therapy
One RCT included was a comparison of Hyalgan and mu-
copolysaccharide polysulfuric acid ester (Graf 1993).
Efficacy
The results were presented as change scores. The six-month data
reported in the publication were not used since it was presented as
the change from end of treatment not the change from baseline.
For the Larson rating scale, a higher score indicated improvement.
At the endof treatment (week 6), therewas a statistically significant
difference in favour of Hyalgan compared to mucopolysaccharide
polysulfuric acid ester for pain (0 to 30) (WMD4.00; 95%CI 0.98
to 7.02, P value 0.009) and for the total Larson rating score (0 to
77) (WMD5.90; 95%CI1.31 to 10.49, P value 0.01). Thismeans
that Hyalgan was 25% more effective than mucopolysaccharide
polysulfuric acid ester in relieving pain and 13% more effective in
improving ’overall’ function. There was no statistically significant
difference for function (0-30) (WMD0.60; 95%CI -1.95 to 3.15,
P value 0.6) or for range of motion (0 to 10) (WMD 0.30; 95%
CI -0.06 to 0.66, P value 0.10). The global assessment, expressed
by the number of patients symptom free or markedly improved,
was significantly better in the Hyalgan group (76%) compared
to the mucopolysaccharide polysulfuric acid ester group (46%)
(RR 1.65; 95% CI 1.03 to 2.66, P value 0.04) at 14 to 26 weeks
postinjection. The NNT for patient global assessment was 3.
Safety
There were no statistically significant differences betweenHyalgan
and mucopolysaccharide polysulfuric acid ester at 14 to 26 weeks
postinjection either in the total number of withdrawals overall
(RR 0.41; 95% CI 0.04 to 4.27, P value 0.5) or in the number of
adverse events due to study medication (RR 2.45; 95% CI 0.54
to 11.19, P value 0.2).
Hyalgan versus NSAID
One RCT included was a comparison of Hyalgan and naproxen
(Altman 1998).
Efficacy
No statistically significant difference was found between Hyalgan
and naproxen for pain after a 50 foot walk measured on a 100 mm
VAS at any of the three assessment times: 1 to 4 weeks postinjec-
tion (WMD 0; 95% CI -5.99 to 5.99, P value 1); 5 to 13 weeks
postinjection (WMD 2.00; 95% CI -4.33 to 8.33, P value 0.5);
and 14 to 26 weeks postinjection (WMD -3.00; 95% CI -9.15 to
3.15, P value 0.3). There was no statistically significant difference
in the number of patients with moderate to marked pain at 14 to
26 weeks postinjection (RR 0.90; 95% CI 0.63 to 1.28, P value
0.6) or in those with none to slight to mild pain (RR 1.06; 95%
CI 0.87 to 1.30, P value 0.6).
Safety
There was a statistically significant difference in the number of
patients with gastrointestinal complaints reported in the Hyalgan
group (29%) compared to the naproxen group (42%) (RR 0.70;
95%CI 0.52 to 0.95, P value 0.02). There was a statistically signif-
icant difference in the number of adverse events for injection site
pain reported in the naproxen group (9%) compared to Hyalgan
(23%) (RR 2.70; 95% CI 1.52 to 4.79, P value 0.0007). There
were more adverse events due to local joint pain and swelling re-
ported in theHyalgan group (13%) than the naproxen group (6%)
(RR 2.09; 95% CI 1.01 to 4.29, P value 0.05).
There were no statistically significant differences for the other
safety outcomemeasures: total withdrawals overall (RR 1.17; 95%
CI 0.86 to 1.60, P value 0.3), withdrawals due to lack of efficacy
(RR 1.69; 95% CI 0.80 to 3.58, P value 0.17), number of adverse
events of local skin rash (RR 0.79; 95% CI 0.48 to 1.30, P value
0.4), or pruritis (RR 1.70; 95% CI 0.69 to 4.22, P value 0.2).
Hyalgan versus conventional therapy
One RCT included was a comparison of Hyalgan and conven-
tional therapy (Listrat 1997).
Efficacy
There were no statistically significant differences betweenHyalgan
and conventional care at 45 to 52 weeks postinjection in overall
pain (measured on 0 to 100 mm VAS) (WMD -14.40; 95% CI
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-31.86 to 3.06, P value 0.11) or in function (measured by the
Lequesne Index) (WMD -0.90; 95% CI -3.81 to 2.01, P value
0.5). Since the arthroscopic outcomemeasureswere chosen a priori
as the primary efficacy variables in this trial, their results are also
reported. Joint space width, measured in mm, was greater at 45 to
52 weeks postinjection, in the Hyalgan group (WMD 1.10; 95%
CI -0.01 to 2.21, P value 0.05). A statistically significant difference
in favour of Hyalgan, at 45 to 52 weeks postinjection, was found
for both the arthroscopy overall assessment (0 to 100 mm VAS)
(WMD -22.30; 95% CI -40.52 to -4.08, P value 0.02) and the
SFA system score (0 to 100 mm VAS) (WMD -18.20; 95% CI
-31.27 to -5.13, P value 0.006). Therefore, Hyalgan was 14 to
22% more effective than conventional therapy in improving these
arthroscopy parameters at 45 to 52 weeks postinjection. This trial
also utilised a quality of life outcomemeasure, the Arthritis Impact
Measurement Scales (AIMS), based on the total of 12 items. There
was no statistically significant difference between groups (WMD
-0.20; 95% CI -0.98 to 0.58, P value 0.6).
The RevMan analysis differed from the Listrat publication (Listrat
1997) analysis. The publication reported a statistically significant
difference in favour of Hyalgan for AIMS (P value 0.047) at 45 to
52 weeks postinjection whereas the RevMan analysis detected no
difference.
Safety
Safety, as assessed by total withdrawals overall, was similar in the
two groups (RR 0.48; 95% CI 0.05 to 4.82, P value 0.5). One
patient in the Hyalgan group withdrew because of lack of pain
while two patients in the conventional therapy group withdrew:
one because of osteotomy performed on the study knee and one
because of relocation.
Hyalgan versus homeopathic treatment
Readers are directed to the Zeel section for results based on a
comparison of Zeel compositum and Hyalart (Nahler 1998).
Hyalgan versus Hyalgan
OneRCT included was a schedule comparison ofHyalgan (Karras
2001).
Efficacy
There was no statistically significant difference in the number of
patients assessing the response as satisfactory between the five in-
jection Hyalgan schedule (67%) and the three injection Hyalgan
schedule (79%) (RR 0.85; 95% CI 0.70 to 1.03, P value 0.10).
Safety
From the abstract it was not possible to ascertain to which group
the patients belonged that experienced three cases of local pain.
Hyalgan versus other hyaluronans
Readers are directed to the Adant and Fermathron product results
for comparisons of Hyalgan against these two HA products, re-
spectively.
One RCT included was a comparison of Hyalgan and Hylan G-F
20 (Brown 2003). This trial was discontinued on ethical grounds
due to the frequency of acute inflammatory reactions with Hylan
G-F 20 (21%) compared to Hyalgan (0%) (RR 0.09; 95% CI
0.01 to 1.50, P value 0.09). No efficacy data were extracted from
the abstract.
Product - Hylan G-F 20 (Synvisc)
Description of studies
Eighteen RCTs were included (Adams 1995; Ardic 2001;
Auerbach 2002; Bayramoglu 2003; Brown 2003; Caborn 2004;
Dickson 2001; Groppa 2001; Kahan 2003a; Karlsson 2002;
Leopold 2003; Moreland 1993; Raynauld 2002; Scale 1994a (2
inj); Scale 1994b (3 inj); Thompson 2002; Wobig 1998; Wobig
1999). Considering only the 14 trials in which Hylan G-F 20 was
designated the experimental intervention, the Jadad score ranged
from 1 to 5 with an average quality of 3.1. One trial scored 5
(Moreland 1993), five scored 4 (Dickson 2001; Scale 1994a (2
inj); Scale 1994b (3 inj); Wobig 1998;Wobig 1999), four scored 3
(Adams 1995; Kahan 2003a; Leopold 2003; Raynauld 2002), two
scored 2 (Auerbach 2002; Caborn 2004), and two scored 1 (Ardic
2001; Groppa 2001). When considering all 18 trials, the aver-
age Jadad score was 2.9. Allocation concealment was adequate in
nine trials and inadequate (not reported) in five trials (Ardic 2001;
Auerbach 2002; Caborn 2004; Dickson 2001; Groppa 2001).
Hylan G-F 20 has been compared against IA control treat-
ment (Ardic 2001; Dickson 2001; Groppa 2001; Karlsson 2002b
(SvP); Moreland 1993; Scale 1994a (2 inj); Scale 1994b (3
inj); Wobig 1998; Wobig 1999c (NEhyl)), IA corticosteroid
(Caborn 2004; Leopold 2003), nonsteroidal anti-inflammatory
drug (Adams 1995; Dickson 2001), IA gaseous oxygen (Auerbach
2002), physiotherapy (Bayramoglu 2003), appropriate care (
Kahan 2003a; Raynauld 2002), and hyaluronan (Bayramoglu
2003 [Orthovisc]; Brown 2003 [Hyalgan]; Karlsson 2002c (AvS)
[Artzal]; Thompson 2002 [BioHy(Arthrease)];Wobig 1999 [Artz,
Healon]). The draft manuscript for the abstract presented by
Moreland et al. (Moreland 1993) was kindly provided by Bioma-
trix, Inc. as were the Pre-Market Approval (PMA) data for the stud-
ies by Adams et al. (Adams 1995), Scale et al. (Scale 1994a (2 inj);
Scale 1994b (3 inj)), andWobig et al. (Wobig 1998;Wobig 1999).
The trials were completed in eight countries: Canada (Adams
1995; Raynauld 2002), England (Dickson 2001), France (Kahan
2003a), Germany (Auerbach 2002; Scale 1994a (2 inj); Scale
1994b (3 inj); Wobig 1998; Wobig 1999), Republic of Moldova
(Groppa 2001), Scotland (Dickson 2001), Turkey (Ardic 2001),
and the United States (Caborn 2004; Leopold 2003; Moreland
1993). They were published over an eleven-year period: 1993
through 2004. Sample size per group varied from 15 (Scale 1994b
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(3 inj)) to 253 (Kahan 2003a) while sample size per trial varied
from 30 to 518. One trial was eight weeks in duration (Ardic
2001), two trials were twelve weeks in duration (Dickson 2001;
Wobig 1999), four trials were 12 weeks in duration with a tele-
phone interview at 26 weeks (Adams 1995; Scale 1994a (2 inj);
Scale 1994b (3 inj); Wobig 1998), one trial was 24 weeks in dura-
tion (Leopold 2003), one trial was 26 weeks in duration (Caborn
2004), one trial was 34 weeks in duration (Moreland 1993), one
trial was 36weeks in duration (Kahan 2003a), and three trials were
52 weeks in duration (Auerbach 2002; Groppa 2001; Raynauld
2002).
For the six trials that were included in the PMA P940015 (Adams
1995; Moreland 1993; Scale 1994a (2 inj); Scale 1994b (3 inj);
Wobig 1998; Wobig 1999), control and Hylan G-F 20 treatments
were prepared in syringes that had identical appearances andwhich
were coded only by random numbers. All subjects participating
in these trials received arthrocentesis with removal of effusion if
present. All IA procedures were performed in an identical manner
for treatment and control study groups in these trials. A screen,
blinding the patient from the procedure, was utilised in four trials
(Adams 1995; Dickson 2001; Moreland 1993; Wobig 1998).
Twenty-four studies were excluded (Bell 1999; Bruce 2004;
Chhabra 2000; Clarke 2001; Evanich 2001; Goorman 2000; Ines
2002; Koyuncu 2003; Legre 2001; Lussier 1996; Magobotha
2001; Mathieu 2001; Miller 1999; Myburgh 2001; Olszynski
2002; Sripada 1999; Stambuk 2001; Torrance 2002; Vad 2000;
Waddell 2001a; Waddell 2001b; Weiss 1999; Wobig 1999d;
Wulwik 2001). Four trials are awaiting assessment (Atamaz 2004;
Kotevoglu 2002; Russell 2003; Shariati 2001). These trials have
been published only as abstracts
with no extractable data, and at the closure of the database for this
review no full length manuscripts have been published.
Adams et al. reported a 26-week, parallel-group RCT performed
at six centres in Canada comparing three weekly injections of
Hylan G-F 20 to either NSAID continuation plus three weekly
control arthrocenteses or NSAID continuation plus three weekly
injections of Hylan G-F 20 in 102 patients with OA of the knee
(Adams 1995). All groups showed significant improvement from
baseline at 12 weeks but did not differ from each other. The two
groups receiving Hylan G-F 20 were significantly better than the
NSAID alone group at Week 26.
Several design issues are noted for the Adams et al. RCT (Adams
1995). This trial was designed to evaluate viscosupplementation
with Hylan G-F 20 as a replacement for continuous NSAID ther-
apy. There was no washout period. The concomitant use of ac-
etaminophen for analgesia was permitted and recorded by pill
counts. However, usage was not reported since it was documented
in different formats by the treating physicians and could not be
standardised into a single format for purposes of uniform anal-
ysis. The resumption of NSAID between weeks 12 and 26 was
reported. 55.6% of patients in the Hylan G-F 20 group only re-
sumed taking NSAID compared to 84.4% in the NSAID plus
Hylan G-F 20 group and 96.8% in the NSAID group. Fifteen per
cent of the included patients presented with effusion at the first
visit. The Hylan G-F 20 only group may not have been blinded
since they were instructed to discontinue their NSAID. The au-
thors addressed this concern in the publication by commenting
that, “if incomplete blinding introduced a bias, it would be against
theHylan G-F 20-only group in that patients recognized that they
were discontinuing an active medication, and consequently may
have expected their condition to worsen”. The method of assess-
ment at 26 weeks was by telephone follow-up which differed from
that of baseline (i.e. office visit). A subsequent study showed that
there was no significant difference in results obtained by telephone
compared to office visits for the WOMAC 3.0 Osteoarthritis In-
dex (Bellamy 2002).
Ardic et al. reported an eight-week, placebo-controlled RCT per-
formed at one centre in Turkey comparing three weekly injections
of Hylan G-F 20 to three weekly injections of saline in 17 patients
with OA of the knee (Ardic 2001). The authors reported promi-
nent clinical improvement in the Hylan G-F 20 group after eight
weeks. No patients reported adverse events. Only safety data are
used in the review since only p-values are reported for the clinical
outcome measures.
The Ardic et al. trial reported results for only 17 patients (Ardic
2001). No explanation was given in the abstract for the unequal
group allocation (i.e. 2.4:1 patients or 3:1 knees). Details regard-
ing blinding and withdrawals/drop outs were not reported in the
abstract. The ’need of drug’ was an outcome measure in this trial.
Auerbach et al. reported a one-year, parallel-groupRCTperformed
at a single centre in Germany comparing three weekly injections
of Hylan G-F 20 plus an exercise programme to five weekly IA
injections of gaseous oxygen (three days per week) plus an exercise
programme in 111 patients with OA of the knee (Auerbach 2002;
Auerbach 2002a). Both treatments were effective in relieving pain
and improving joint function. Pain relief by Hylan G-F 20 and
improvement in function by oxygen treatment were shown for
more severe levels of cartilage damage.
The Auerbach trial was one of the few trials not published in En-
glish. Both the thesis (Auerbach 2002a) and the journal article
(Auerbach 2002) were published in German. An English abstract
was provided in the journal article. It was the only trial in which
HA was compared to IA injection of gaseous oxygen. The authors
studied the relation between treatment effect and severity of car-
tilage damage.
Caborn et al. reported a 26-week, parallel group, single-blindRCT
performed at 14 centres in the United States comparing three
weekly injections of Hylan G-F 20 to one IA injection of triam-
cinolone hexacetonide (Aristospan) in 218 patients with OA of
the knee (Caborn 2003; Caborn 2004; Lanzer 2002). Treatment
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with Hylan G-F 20 resulted in a longer duration of effect than
triamcinolone hexacetonide. Both treatments were well tolerated
with 10% of patients in each group reporting an adverse event
that resulted in withdrawal from the trial.
The Caborn et al. trial was single-blind and details regarding the
method of randomisation were not published (Caborn 2004).
The triamcinolone hexacetonide group received only one injec-
tion compared to the three injections administered to the Hy-
lan G-F 20 group. Analgesic and NSAID usage were monitored
throughout this trial. Patients with effusion of greater than 10 ml
were excluded. Almost 30% of each treatment group had severe
radiological ratings while approximately 60% in each group had
moderate ratings.
Dickson et al. reported a 12-week, parallel-group, double-blind
RCT performed at 18 centres in England and Scotland comparing
three weekly injections of Hylan G-F 20 and dummy capsules
taken once daily to either Diclofenac retard 100 mg taken once
daily and three weekly arthrocenteses or dummy capsules taken
once daily and three weekly arthrocenteses in 165 patients with
OA of the knee (Dickson 2001). Patients, completing the 12-
week study, could enter an open-label study in which they received
treatment with up to four additional courses of Hylan G-F 20
over a one-year period. Hylan G-F 20 was significantly better than
either diclofenac or arthrocentesis in reducingWOMACpain.The
diclofenac group had significantly more total and gastrointestinal
adverse events than the Hylan G-F 20 or control groups.
The Dickson et al. trial was one of the few trials conducted in gen-
eral practice (Dickson 2001). To ensure blinding, all three arms
of the trial received arthrocentesis. The diclofenac sodium dosage
of 100 mg daily may be considered by some as subtherapeutic but
the Diclomax Retard 1993 product label indicated this to be the
recommended adult dosage. The mean number of paracetamol
tablets taken for analgesic rescue medication (3000 mg daily per-
mitted) was published.
Groppa and Moshneaga reported a one-year, blind CT performed
at a single centre in The Republic of Moldova comparing three
weekly injections of Hylan G-F 20 to three weekly injections of
placebo in 25 patients with OA of knee (Groppa 2001). Courses
were repeated at six and 12 months. After the first course, one-
third of the patients treated withHylan G-F 20 had decreased pain
and improved joint function compared to none in the placebo
group. After three courses, 87% of the Hylan G-F 20 patients
had moderate or very good effect compared to only 20% of the
patients in the control group who had moderate effect. No safety
data were reported in the abstract.
The Groppa trial randomised a sample size of 25 patients (Groppa
2001). However, the control group was matched by gender, dis-
ease duration and x-ray date. The study was designed to address
the important issue of repeat treatment with a second and third
course repeated at six and 12 months, respectively. Radiography,
ultrasonography and scintigraphy with Te 99m were all utilised in
evaluation.
Kahan et al. reported a nine-month, open-label, parallel-group,
RCT performed with 81 rheumatologists (21 hospital based, 60
office based) in France comparing threeweekly injections of Hylan
G-F 20 to conventional treatment in 518 patients with OA of the
knee (Kahan 2003 [article published in French]; Kahan 2003a).
The authors reported that Hylan G-F 20 viscosupplementation
was more effective than conventional treatment at no additional
cost.
The Kahan et al. trial provided medicoeconomic data on visco-
supplementation forOA (Kahan 2003a; Kahan 2003). The design
was very similar to the Raynauld et al. trial (Raynauld 2002). The
study was completed under conditions of actual practice.
Leopold et al. reported a six-month, single-blind, parallel-group,
RCT performed at a single centre in the United States compar-
ing three weekly injections of Hylan G-F 20 to one injection of
betamethasone sodium phosphate-betamethasone acetate (Cele-
stone Soluspan), which could be repeated during the study, in 100
patients with OA of the knee (Leopold 2003; Redd 2003). No
differences in pain or function were found between the two groups
at the six months follow-up. Neither treatment worked well in fe-
males. One patient in the Hylan G-F 20 group withdrew because
of an acute local reaction. One-fifth of the study population with-
drew because of a lack of treatment efficacy. Only safety data have
been extracted from this trial. Since the outcome variables had
results that were not normally distributed, nonparametric statisti-
cal methods were used to analyze the data (e.g. change in median
outcomes scores).
The Leopold et al. trial was an independent trial not funded by
the manufacturer of the hyaluronate-based product under study
(Leopold 2003). The injection procedure was standardised by:
1) patient was in the supine position, 2) the injection was made
superolaterally into the suprapatellar notch, and 3) patients were
encouraged to refrain from strenuous activity for a day. However,
effusions were aspirated in the HA group whereas they were not in
the corticosteroid group. In addition, patients in the corticosteroid
group were permitted to have one more injection any time during
the study. The authors chose not to use the Ahlback radiographic
grading system, “because three of the four stages include knees
with a completely obliterated joint space”. This was the only trial
to find a gender difference in treatment response.
Moreland et al. reported a 34-week, parallel-group, double-blind
RCT performed at five centres in the United States comparing
three weekly injections of Hylan G-F 20 to three weekly arthro-
centeses in 94 patients with OA of the knee (Moreland 1993).
This trial had two phases. Phase I lasted 10 weeks, after which
patients could enter Phase II in which all patients received treat-
ment with Hylan G-F 20. For this analysis, the Phase II data were
not included because, although patient blinding was maintained
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during this Phase, treatment was not randomised. Analyses were
based on the week eight evaluation endpoint which was two weeks
after the third injection in Phase I. A statistically significant dif-
ference, in favour of Hylan G-F 20, was detected in overall pain
only in a predefined ’flare’ population but not in the ’intent-to-
treat’ population. During the two phases approximately 7% of
patients receiving Hylan G-F 20 discontinued treatment due to
local adverse reactions (pain or swelling) in the injected knee.
The Moreland et al. trial was only published as an abstract but an
in-house unpublished manuscript allowed this trial to be included
in the review (Moreland 1993). This trial examined the “clinimet-
ric utility” of identifying a flare population. Despite a four-week
washout of all anti-inflammatory medication, only 30% of pa-
tients demonstrated a flare in pain symptoms. However, patients
were randomised regardless of flare criteria. The authors noted that
the final evaluation for Phase I of the trial was only two weeks after
completing treatment. This may have minimised any between-
group differences, and could havemaximised the short-term effect
of arthrocentesis. Acetaminophen usage was permitted through-
out the entire trial duration but there was no significant difference
between the groups in daily usage.
Raynauld et al. reported a one-year, open-label, parallel-group,
RCT performed at 14 centres in Canada comparing appropriate
care with Hylan G-F 20 (AC + H) to appropriate care without
HylanG-F20 (AC) in 255patients withOAof the knee (Raynauld
2002). For all the primary and secondary effectiveness outcome
measures the AC + H group was superior to the AC group. Safety
differences favoured the AC + H group.
The Raynauld et al. trial was an effectiveness study that also in-
cluded an economic evaluation (Torrance 2002). The study was
strengthened by the expertise of an independent, academic Steer-
ing Committee. This ’pragmatic’ study operated under ’a real
world scenario’. The trial highlighted the difference between radi-
ologic grading completed by a central reader and that done by site
investigators. Although Kellgren and Lawrence Grade 4 was an
entry exclusion criteria, 20% of the appropriate care plus Hylan
G-F 20 group and 33% of the appropriate care without Hylan G-
F 20 group were rated as Grade 4 by the central reader. However,
when Grade 4 was used as a covariate there was no significant dif-
ference in the analysis results. Repeat treatment was permitted to
either or both knees as required during the trial.
The publication by Scale et al. reported two separate trials (Scale
1994a (2 inj); Scale 1994b (3 inj)). One was a comparison of two
biweekly injections ofHylanG-F20 versus twobiweekly injections
of saline in 50 patients with OA of the knee (Scale 1994a (2 inj)),
and the other was a comparison of three weekly injections ofHylan
G-F 20 versus three weekly injections of saline in 30 patients with
OA of the knee (Scale 1994b (3 inj)). Both studies were 26-week,
parallel-group, double-blind RCTs performed at a single centre
in Germany. Patients were excluded if effusion was present in the
joint. For most outcome measures, the Hylan G-F 20 treatment
showed statistically significant superiority over saline treatment for
both treatment regimens. The three-injection treatment regimen
was statistically more effective than the two-injection treatment
regimen. One local, treatment-related, adverse event represented
1% of all the Hylan G-F 20 injections or 2.5% of all the knees
treated with Hylan G-F 20 in this study.
Scale et al. published the first RCTs of Hylan G-F 20. Continu-
ous outcome measures were transformed into categorical scores.
’“Successful treatment’ (i.e. responder) was defined as a score of 0
to 20 mm on the VAS for the pain and activity reduction outcome
measures, and a score of 80 to 100 mm for the improvement of the
most painful knee movement. Although the journal publication
reported results based on a combined control group, the PMA
report provided results based on the separate randomised control
groups which were used in this review. The three-injection trial
randomised 30 patients in total.
Wobig et al. reported a 26-week, parallel-group, double-blind
RCT performed at four centres in Germany comparing three
weekly injections of Hylan G-F 20 to three weekly injections of
saline in 110 patients with OA of the knee (Wobig 1998). Statisti-
cally significant differences betweenHylanG-F20 and saline treat-
ment were reported for all outcome measures. No adverse events
were observed in the injected joint after Hylan G-F 20 treatment.
In the Wobig et al. RCT, patients with effusion were excluded
(Wobig 1998). Again a categorical analysis was completed based
on the same responder criteria as Scale et al. above. 98% of the
randomised patients completed all follow-up visits. Only one Hy-
lan G-F 20 patient did not participate in the telephone interview
and one saline patient, who missed the visits at weeks eight and
12, did participate in the telephone interview at week 26.
The 1999Wobig publication reported the results of two arms (Hy-
lan G-F 20 versus Artz) of a four-arm trial (Artz, Healon, Hylan
G-F 20, nonelastoviscous hylan) (Wobig 1999). This was a 12-
week, parallel-group, double-blind RCT performed at six centres
inGermany comparing three weekly injections ofHylanG-F 20 to
either three weekly injections of Artz (Wobig 1999b (Artz)), three
weekly injections of Healon (Wobig 1999a (Healon)), or three
weekly injections of nonelastoviscous (denatured) hylan (Wobig
1999c (NEhyl)) in 109 knees. Considering only the published
Hylan G-F 20 versus Artz comparison, significantly greater pain-
relieving effects were detected in favour of Hylan G-F 20. No sta-
tistically significant differences in the incidence of adverse events
between these two groups were detected.
In an attempt to explain the mechanism of action of viscosupple-
mentation, the objective of the Wobig et al. trial (Wobig 1999b
(Artz)) was to determine if a correlation existed between clini-
cal effectiveness and elastoviscosity. Patients were once again cat-
egorised as ’symptom-free’ based on the Scale et al. criteria above.
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Descriptions of the four RCT in which Hylan G-F 20 was
the control treatment are found in the other product results
sections: BioHy (Arthrease) (Thompson 2002), Artz (Artzal,
Supartz) (Karlsson 2002), Hyalgan (Brown 2003), and Orthovisc
(Bayramoglu 2003).
Hylan G-F 20 (Synvisc) versus placebo
Nine RCTs included were comparisons of Hylan G-F 20 and
placebos (Ardic 2001; Dickson 2001; Groppa 2001; Karlsson
2002b (SvP); Moreland 1993; Scale 1994a (2 inj); Scale 1994b
(3 inj); Wobig 1998, Wobig 1999c (NEhyl)). Control treatments
included IA saline, arthrocentesis, arthrocentesis and placebo cap-
sules taken once daily, and nonelastoviscous (NE) denatured hylan
fluid. The current product monograph for Synvisc (Synvisc Hylan
G-F 20) indicates administration by IA injection once a week (one
week apart) for a total of three injections.
Efficacy
Statistically significant differences in favour of Hylan G-F 20 com-
pared to placebo were found in pain on weight bearing (mea-
sured on 0 to 100 mmVAS) at 1 to 4 weeks postinjection (WMD
(random-effects model) -12.54; 95% CI -20.39 to -4.69, P value
0.002) (Karlsson 2002b (SvP); Moreland 1993; Scale 1994a (2
inj); Scale 1994b (3 inj); Wobig 1998; Wobig 1999c (NEhyl)).
With the exception of the Karlsson RCT (Karlsson 2002b (SvP)),
Hylan G-F 20 was 4 to 24% more effective than placebo. With
five trials, a statistically significant difference in favour of Hylan
G-F 20 compared to placebo was found at 5 to 13 weeks postin-
jection (WMD (random-effects model) -22.46; 95% CI -35.24
to -9.68, P value 0.0006) (Karlsson 2002b (SvP); Scale 1994a (2
inj); Scale 1994b (3 inj); Wobig 1998; Wobig 1999c (NEhyl)).
Hylan G-F 20 was 1 to 43% more effective than placebo. At 14
to 26 weeks postinjection, there was a statistically significant dif-
ference in favour of Hylan G-F 20 compared to placebo (WMD
(random-effects model) -20.70; 95% CI -35.56 to -5.83, P value
0.006) (Karlsson 2002b (SvP); Scale 1994a (2 inj); Scale 1994b
(3 inj); Wobig 1998). Hylan G-F 20 was 1 to 49% more effective
than placebo.
Statistically significant differences in favour of Hylan G-F 20 com-
pared to placebo were found in pain at night (measured on 0 to
100 mm VAS) at 1 to 4 weeks postinjection (WMD -7.22; 95%
CI -12.01 to -2.42, P value 0.003) (Moreland 1993; Scale 1994a
(2 inj); Scale 1994b (3 inj); Wobig 1998; Wobig 1999c (NEhyl)).
Hylan G-F 20 was 13 to 31% more effective than placebo. With
four trials, a statistically significant difference in favour of Hylan
G-F 20 compared to placebo was found at 5 to 13 weeks postin-
jection (WMD (random-effects model) -10.64; 95% CI -18.55
to -2.73, P value 0.008) (Scale 1994a (2 inj); Scale 1994b (3 inj);
Wobig 1998; Wobig 1999c (NEhyl)). Hylan G-F 20 was 28 to
50%more effective than placebo. At 14 to 26 weeks postinjection,
based on three trials, there was a statistically significant difference
in favour of Hylan G-F 20 compared to placebo (WMD -17.12;
95% CI -23.22 to -11.02, P < 0.00001) (Scale 1994a (2 inj); Scale
1994b (3 inj); Wobig 1998). Hylan G-F 20 was 28 to 96% more
effective than placebo.
No statistically significant difference was detected at 1 to 4 weeks
postinjection in pain walking (0 to 100 mm VAS) (WMD -3.00;
95% CI -15.55 to 9.55, P value 0.6), pain at rest (0 to 100 mm
VAS) (WMD -5.00; 95% CI -18.86 to 8.86, P value 0.5), pain
overall (0 to 100 mmVAS) (WMD -2.00; 95%CI -13.09 to 9.09,
P value 0.7) (Moreland 1993), or at 5 to 13 weeks postinjection
in WOMAC pain (WMD -8.00; 95% CI -17.80 to 1.80, P value
0.11) (Dickson 2001).
The RevMan analysis differed from the publication analysis
(Dickson 2001). The publication reported a statistically signifi-
cant difference in favour of Hylan G-F 20 compared to the double
dummy placebo at 5-13 weeks postinjection forWOMACpain (P
value 0.04) whereas RevMan detected no statistically significant
difference (P value 0.11).
A statistically significant difference in favour of Hylan G-F 20 was
detected in the WOMAC physical function subscale at 5 to 13
weeks postinjection, (WMD -9.00; 95% CI -16.07 to -1.93, P
value 0.01) and in the Lequesne Index (WMD -1.60; 95% CI -
2.99 to -0.21, P value 0.02) (Dickson 2001). Hylan G-F 20 was 7
to 13% more effective than placebo. No significant difference was
detected in the Lequesne Index at 14 to 26 weeks postinjection
(WMD 0.10; 95%CI -1.38 to 1.58, P value 0.9) (Karlsson 2002b
(SvP)).
The RevMan analysis differed from the publication analysis
(Dickson 2001). The publication reported no difference in the
Lequesne Index at 5 to 13 weeks (P value 0.17) whereas RevMan
detected a statistically significant difference in favour of Hylan G-
F 20. The publication reported no difference in WOMAC phys-
ical function at 5 to 13 weeks (P value 0.05) whereas RevMan
detected a statistically significant difference in favour of Hylan G-
F 20.
A statistically significant difference in favour of Hylan G-F 20
compared to placebo was detected in improvement in the most
painful knee movement (0 to 100 mm VAS) both at 1 to 4 weeks
postinjection (WMD19.29; 95%CI12.16 to 26.31, P <0.00001)
and at 5 to 13weeks postinjection (WMD (random-effectsmodel)
33.87; 95% CI 21.19 to 46.55, P < 0.00001) (Scale 1994a (2 inj);
Scale 1994b (3 inj); Wobig 1998; Wobig 1999c (NEhyl)).
When patient global assessment data were dichotomised into im-
proved or not improved by classifying responses of ’very poor’,
’poor’ and ’fair’ as ’not improved’ and ’good’ and ’very good’ as
’improved’, more patients in the Hylan G-F 20 group were ei-
ther ’very good’ or ’good’ (69%) than in the double control group
(48%) at 5 to 13 weeks postinjection (RR 1.44; 95% CI 1.01 to
2.06, P value 0.05) (Dickson 2001).
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A statistically significant difference in favour of Hylan G-F 20
compared to placebo was detected for patient global assessment
of treatment efficacy (0 to 100 mm VAS) both at 1 to 4 weeks
postinjection (WMD21.94; 95%CI14.94 to 28.94, P <0.00001)
and at 5 to 13 weeks postinjection (WMD (random effects) 34.66;
95% CI 21.27 to 48.06, P < 0.00001) (Scale 1994a (2 inj); Scale
1994b (3 inj); Wobig 1998; Wobig 1999c (NEhyl)).
No statistically significant difference was noted in the number of
clinical failures at 14 to 26weeks postinjection: HylanG-F 20, 7%
and Saline 11% (RR 0.66; 95% CI 0.23 to 1.87, P value 0.4) or at
45 to 52 weeks postinjection: Hylan G-F 20 46% and saline 54%
(RR 0.84; 95% CI 0.59 to 1.22, P value 0.4) (Karlsson 2002b
(SvP)), or in the number of survivors (i.e. patients not requiring
additional treatment to study knee):HylanG-F 20 44%and saline
33% (RR1.33; 95%CI 0.87 to 2.0, P value 0.18) (Karlsson 2002b
(SvP)).
Considering only the twomost homogeneous trials, i.e., the three-
injection trial of Scale (Scale 1994b (3 inj)) and the Wobig trial
(Wobig 1998), a statistically significant difference in favour of Hy-
lan G-F 20 compared to saline was detected in pain on weight
bearing (0 to 100 mm VAS) at 1 to 4 weeks postinjection (WMD
-22.00; 95% CI -29.13 to -14.87, P < 0.00001), at 5 to 13
weeks postinjection (WMD -35.68; 95% CI -42.81 to -28.55, P
< 0.00001) and at 14 to 26 weeks postinjection (WMD -21.62;
95% CI -30.84 to -12.39, P < 0.00001). A statistically signifi-
cant difference in favour of Hylan G-F 20 compared to saline was
detected in pain at night (0 to 100 mm VAS) at 1 to 4 weeks
postinjection (WMD -10.64; 95% CI -17.29 to -3.99, P value
0.002), at 5 to 13 weeks postinjection (WMD -15.50; 95% CI -
21.38 to -9.62, P < 0.00001), and at 14 to 26 weeks postinjection
(WMD -16.20; 95% CI -22.85 to -9.55, P < 0.00001). A statis-
tically significant difference in favour of Hylan G-F 20 compared
to saline was detected in improvement in the most painful knee
movement (0 to 100 mm VAS) both at 1 to 4 weeks postinjec-
tion (WMD 23.97; 95% CI 14.34 to 33.60, P < 0.00001) and
at 5 to 13 weeks postinjection (WMD 40.56; 95% CI 31.11 to
50.01, P < 0.00001). A statistically significant difference in favour
of Hylan G-F 20 compared to saline was detected for the variable
treatment efficacy (improvement on 0 to 100 mm VAS) both at 1
to 4 weeks postinjection (WMD 26.62; 95% CI 17.39 to 35.84,
P < 0.00001) and at 5 to 13 weeks postinjection (WMD 43.85;
95% CI 34.62 to 53.07, P < 0.00001).
Safety
No statistically significant differences were detected in the total
number of withdrawals overall at 1 to 4 weeks postinjection (RR
0.70; 95% CI 0.12 to 3.97, P value 0.7) (Moreland 1993) or at 5
to 13 weeks (RR 1.40; 95%CI 0.64 to 3.06, P value 0.4) (Dickson
2001; Wobig 1998; Wobig 1999c (NEhyl)). No significant differ-
ences were detected in the number of withdrawals due to adverse
events (RR 13.55; 95% CI 0.79 to 233.96, P value 0.07). The
number of local reactions was significantly higher in the Hylan
G-F 20 plus arthrocentesis group compared to arthrocentesis (RR
30.23; 95% CI 1.86 to 492.59, P value 0.02).
No significant differences were detected in the number of patients
with local reactions (RR 1.17; 95% CI 0.48 to 2.83, P value 0.7)
(Dickson 2001; Wobig 1998; Wobig 1999c (NEhyl)), number of
patients with local adverse reaction at 1 to 4 weeks postinjection
but study drug continued (RR 3.00; 95% CI 0.13 to 68.26, P
value 0.5) (Scale 1994b (3 inj)), number of patients with adverse
events at 5 to 13 weeks postinjection (P value 1) (Ardic 2001),
number of patients with one or more probable or possible related
systemic adverse events at 5 to 13 weeks postinjection (RR 1.98;
95% CI 0.79 to 4.96, P value 0.14) (Dickson 2001) or number
of patients reporting systemic adverse reactions at 5 to 13 weeks
postinjection (RR 7.60; 95% CI 0.39 to 139.45, P value 0.18)
(Wobig 1998; Wobig 1999c (NEhyl)).
Hylan G-F 20 (Synvisc) versus corticosteroid
Two RCTs included were comparisons of Hylan G-F 20 and IA
corticosteroid.
One RCT was a comparison of Hylan G-F 20 and betamethasone
sodium phosphate - betamethasone acetate (Leopold 2003). One
RCT was a comparison of Hylan G-F 20 and triamcinolone hex-
acetonide (Caborn 2004).
Efficacy
The efficacy outcomemeasure results in the Leopold trial (Leopold
2003) were presented as changes in median scores because the data
were not normally distributed. Therefore, only safety data for this
RCT are reported.
A statistically significant difference in favour of Hylan G-F 20
compared to triamcinolone hexacetonide was found forWOMAC
pain walking on a flat surface (scored 0 to 4) in the Caborn trial
(Caborn 2004) (WMD -0.40; 95% CI -0.65 to -0.15, P value
0.002) at 5 to 13 weeks postinjection and (WMD -0.40; 95% CI
-0.68 to -0.12, P value 0.005) at 14 to 26 weeks postinjection.
Hylan G-F 20 was 17% more effective than triamcinolone hexac-
etonide. A statistically significant difference in favour of Hylan G-
F 20 compared to triamcinolone hexacetonide was found for the
WOMAC physical function subscale (scored 0 to 68) (WMD -
5.00; 95%CI -8.86 to -1.14, P value 0.01) at 5 to 13weeks postin-
jection and (WMD -5.20; 95% CI -9.10 to -1.30, P value 0.009)
at 14 to 26 weeks postinjection. Hylan G-F 20 was, on average,
17% more effective than triamcinolone hexacetonide. A statisti-
cally significant difference in favour of Hylan G-F 20 compared to
triamcinolone hexacetonide was found for WOMAC total score
(scored 0-96) (WMD -7.40; 95% CI -12.74 to -2.06, P value
0.007) at 5 to 13 weeks postinjection and (WMD -7.30; 95% CI
-12.76 to -1.84, P value 0.009) at 14 to 26 weeks postinjection.
Hylan G-F 20 was 15% more effective than triamcinolone hex-
acetonide. A statistically significant difference in favour of Hylan
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G-F 20 compared to triamcinolone hexacetonide was found for
for patient global assessment (scored 0 to 100 mm VAS) (WMD
-13.40; 95% CI -20.03 to -6.77, P value 0.00007) at 5 to 13
weeks postinjection and (WMD -15.10; 95% CI -22.17 to -8.03,
P value 0.00003) at 14 to 26 week postinjection. Hylan G-F 20
was approximately 23% more effective than triamcinolone hexac-
etonide.
In the Caborn trial (Caborn 2004) there was no statistically sig-
nificant difference in the number of responders defined as at least
a one-point improvement in the WOMAC pain walking on a flat
surface at 1 to 4 weeks postinjection (RR 1.21; 95% CI 0.96 to
1.53, P value 0.11). However, there was a statistically significant
difference in favour ofHylanG-F 20 at 5 to 13weeks postinjection
(RR 1.44; 95% CI 1.09 to 1.90, P value 0.01). The NNT for the
number of responders was 5. At 14 to 26 weeks postinjection, the
RR was 1.44 (95% CI 1.00 to 2.09) P value 0.05. There was no
statistically significant difference in analgesic usage between week
0 and prior to week 12 (RR 1.01; 95% CI 0.97 to 1.06, P value
0.6) or between week 12 and prior to week 26 (RR 0.84; 95% CI
0.64 to 1.11, P value 0.2).
Safety
With respect to the Leopold trial (Leopold 2003), there were no
statistically significant differences in the safety outcomes: total
withdrawals overall (RR 1.56; 95% CI 0.74 to 3.26, P value 0.2),
withdrawals due to lack of efficacy (RR 1.50; 95% CI 0.67 to
3.35, P value 0.3) and withdrawals due to acute local reactions
(RR 3.31; 95% CI 0.14 to 78.84, P value 0.5).
With respect to the Caborn trial (Caborn 2004), there was a statis-
tically significant difference in favour of Hylan G-F 20 compared
to triamcinolone hexacetonide in the number of withdrawals due
to lack of efficacy (RR 0.03; 95% CI 0.00 to 0.48, P value 0.01).
There were no statistically significant differences in the total num-
ber of withdrawals overall (RR 0.78; 95% CI 0.52 to 1.17, P value
0.2) or the number of withdrawals due to adverse events (RR 1.00;
95% CI 0.44 to 2.26, P value 1).
Hylan G-F 20 (Synvisc) versus NSAID
Two trials included were comparisons of Hylan G-F 20 and
NSAID (Adams 1995; Dickson 2001). In the Adams trial (Adams
1995), the early 5 to 13 weeks postinjection follow-up assessment
was reported as change (improvement) scores, while the 14 to 26
week follow-up was based on difference scores. The Dickson trial
(Dickson 2001) results were reported as change (improvement)
scores.
Efficacy
There were no statistically significant differences in any of the
efficacy measures at either 5 to 13 or 14 to 26 weeks postinjection
(Adams 1995): pain on motion (0 to 100 mm VAS) (WMD -
6.00; 95% CI -17.09 to 5.09, P value 0.3) at 5 to 13 weeks and
(WMD -12.00; 95% CI -24.55 to 0.55, P value 0.06) at 14 to
26 weeks postinjection; pain at rest (0 to 100 mm VAS) (WMD
-3.00; 95% CI -14.09 to 8.09, P value 0.6) at 5 to 13 weeks and
(WMD -3.00, 95% CI -12.80 to 6.80, P value 0.5) at 14 to 26
weeks postinjection; pain at night (0 to 100 mm VAS) (WMD -
7.00; 95% CI -19.55 to 5.55, P value 0.3) at 5 to 13 weeks and
(WMD -3.00; 95% CI -15.55 to 9.55, P value 0.6) at 14 to 26
weeks postinjection; pain overall (0 to 100 mm VAS) (WMD -
5.00; 95% CI -18.86 to 8.86, P value 0.5) at 5 to 13 weeks and
(WMD -5.00; 95% CI -16.09 to 6.09, P value 0.4) at 14 to 26
weeks postinjection.
TheRevMan analysis differed from theAdamspublication (Adams
1995) analysis. The publication reported a statistically significant
difference (P value 0.05) in favour ofHylanG-F 20 overNSAID in
pain at rest at 5 to 13 weeks whereas the RevMan analysis detected
no difference.
There was a statistically significant difference in favour of Hylan
G-F 20 compared to NSAID in the WOMAC pain subscale (0
to 100 mm VAS) (WMD -12.00; 95% CI -23.09 to -0.91, P
value 0.03) at 5 to 13 weeks postinjection (Dickson 2001). Hylan
G-F 20 was 16% more effective than NSAID. There were no
statistically significant differences in physical function measured
either on the WOMAC physical function subscale (0 to 100 mm
VAS) (WMD -4.00; 95% CI -11.07 to 3.07, P value 0.3) or on
the Lequesne Index (0 to 24) (WMD -1.00; 95%
CI -2.39 to 0.39, P value 0.16) at 5 to 13 weeks postinjection
(Dickson 2001).
There were no statistically significant differences in the patient
global assessment, measured as the number of patients assessing
the treatment as excellent, very good or good, either at 5 to 13
weeks postinjection (RR 0.83; 95%CI 0.65 to 1.06, P value 0.13)
(Dickson 2001) or at 14 to 26 weeks postinjection (RR 1.63; 95%
CI 0.96 to 2.76, P value 0.07) (Adams 1995).
Safety
There were no statistically significant differences in the follow-
ing safety outcome measures: total withdrawals overall (RR 0.80;
95% CI 0.38 to 1.66, P value 0.5) at 5 to 13 weeks postinjection
(Dickson 2001) and (RR 1.46; 95% CI 0.36 to 6.02, P value 0.6)
at 14 to 26 weeks postinjection (Adams 1995); withdrawals due
to adverse events (RR 3.28; 95% CI 0.14 to 77.69, P value 0.5)
at 14 to 26 weeks postinjection (Adams 1995); or the number of
patients with local reactions (RR 1.82; 95% CI 0.57 to 5.84, P
value 0.3) at 5 to 13 weeks postinjection (Dickson 2001). There
was a statistically significant difference in favour of Hylan G-F 20
compared to NSAID for the number of patients with possible or
probable related systemic adverse events at 5 to 13 weeks postin-
jection (RR 0.46; 95% CI 0.25 to 0.83, P value 0.01) (Dickson
2001). The NNT was 4.
Hylan G-F 20 (Synvisc) + NSAID versus NSAID alone
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The second comparison that was made from the Adams trial (
Adams 1995) was Hylan G-F 20 plus NSAID and arthrocentesis
versus NSAID and arthrocentesis alone.
Efficacy
There were no statistically significant differences between the two
groups at 5 to 13 weeks postinjection for: pain on motion (0 to
100 mm VAS) (WMD -10.00; 95% CI -21.09 to 1.09, P value
0.08); pain at rest (0 to 100 mm VAS) (WMD -6.00; 95% CI -
17.09 to 5.09, P value 0.3); pain at night (0 to 100 mm VAS)
(WMD -11.00; 95% CI -22.09 to 0.09, P value 0.05); and pain
overall (0 to 100 mm VAS) (WMD -12.00; 95% CI -24.55 to
0.55, P value 0.06). There were statistically significant differences
in favour of Hylan G-F 20+NSAID+arthrocentesis compared to
NSAID+arthrocentesis at 14 to 26weeks postinjection for pain on
motion (WMD -15.00; 95% CI -26.09 to -3.91, P value 0.008);
pain at rest (WMD -11.00; 95%CI -19.31 to -2.69, P value 0.01);
pain at night (WMD -19.00; 95% CI -30.09 to -7.91, P value
0.0008); and pain overall (WMD -15.00; 95% CI -26.09 to -
3.91, P value 0.008). Hylan G-F 20+NSAID+arthrocentesis was
approximately 10% more effective than NSAID + arthrocentesis.
There was no statistically significant difference in the number of
patients reporting that they were ’excellent, very good, or good’
(RR 1.12; 95% CI 0.73 to 1.70, P value 0.6).
Safety
There was no statistically significant difference in the total with-
drawals overall (RR 1.53; 95% CI 0.40 to 5.93, P value 0.5).
Hylan G-F 20 (Synvisc) + physiotherapy versus physiotherapy
alone
One RCT included a comparison of Hylan G-F 20 plus physio-
therapy to physiotherapy alone (Bayramoglu 2003).
Efficacy
There was no statistically significant difference in the Lequesne
Index (scored 0 to 24) either at the end of treatment (WMD -
0.70; 95% CI -3.25 to 1.85, P value 0.6) or at 5 to 13 weeks post
injection (WMD -0.80; 95% CI -3.95 to 2.35, P value 0.6).
Safety
There was no statistically significant difference in the number of
total withdrawals overall at 5 to 13 weeks postinjection (RR 0.50;
95% CI 0.15 to 1.64, P value 0.3).
Hylan G-F 20 (Synvisc) versus IA gaseous oxygen
One RCT was a comparison of Hylan G-F 20 plus an exercise
programme to IA gaseous oxygen plus an exercise programme
(Auerbach 2002; Auerbach 2002a).
Efficacy
A between-group difference was found for pain under load (0 to
100 mm VAS) at 5 to 13 weeks postinjection in favour of the oxy-
gen group (WMD12.83; 95%CI 1.96 to 23.70, P value 0.02) but
no statistically significant differences were found at the other as-
sessments: end of treatment (WMD 9.14; 95%CI -2.23 to 20.51,
P value 0.12); 14 to 26 weeks postinjection (WMD 8.02; 95% CI
-2.91 to 18.95, P value 0.15); and 45 to 52 weeks postinjection
(WMD 6.52; 95% CI -3.76 to 16.80, P value 0.2). There were
no statistically significant differences between the groups for pain
at rest (0 to 100 mm VAS) at any of the assessments: end of treat-
ment (WMD 1.41; 95% CI -7.83 to 10.65, P value 0.8); 5 to 13
weeks postinjection (WMD 6.90; 95% CI -3.10 to 16.90, P value
0.18); 14 to 26 weeks postinjection (WMD 2.94; 95% CI -8.08
to 13.96, P value 0.6); and 45 to 52 weeks postinjection (WMD
0.09; 95% CI -9.04 to 9.22, P value 1). There were no statistically
significant differences between the groups for WOMAC pain (0
to 20) at any of the assessments: end of treatment (WMD 1.30;
95% CI -0.15 to 2.75, P value 0.08); 5 to 13 weeks postinjec-
tion (WMD 1.40; 95% CI -0.10 to 2.90, P value 0.07); 14 to 26
weeks postinjection (WMD 0.60; 95% CI -1.04 to 2.24, P value
0.5); and 45 to 52 weeks postinjection (WMD 0.80; 95% CI -
0.72 to 2.32, P value 0.3). There were no statistically significant
differences between the groups for WOMAC physical function (0
to 68) at any of the assessments: end of treatment (WMD 3.30;
95% CI -1.83 to 8.43, P value 0.2); 5 to 13 weeks postinjection
(WMD 2.80; 95% CI -2.29 to 7.89, P value 0.3); 14 to 26 weeks
postinjection (WMD 4.10; 95% CI -1.51 to 9.71, P value 0.15);
and 45 to 52 weeks postinjection (WMD 4.00; 95% CI -1.63 to
9.63, P value 0.16).
The RevMan analysis differed from the Auerbach publication
(Auerbach 2002) analysis. In the publication, statistically signif-
icant differences were found at 45 to 52 weeks postinjection in
favour of Hylan G-F 20 compared to IA gaseous oxygen for pain
under load (P value 0.001), WOMAC pain (P value 0.003), and
WOMAC function (P value 0.001) whereas the RevMan analysis
did not detect any significant differences.
Safety
There was no statistically significant difference in the total number
of withdrawals overall (RR 1.42; 95% CI 0.25 to 8.16, P value
0.7) or in the number of patients having total knee replacements
(RR 2.84; 95% CI 0.30 to 26.45, P value 0.4).
Hylan G-F 20 (Synvisc) + appropriate care versus appropriate care
alone
Two trials includedwere comparisons of the combination ofHylan
G-F20 and appropriate care (AC) to appropriate care alone (Kahan
2003a; Raynauld 2002).
Efficacy
A statistically significant difference in favour of Hylan G-F 20 and
AC compared to AC alone was found in the WOMAC OA In-
dex pain subscale (0 to 20 Likert) at 45 to 52 weeks postinjection
(WMD -3.16; 95% CI -4.17 to -2.15, P < 0.00001) (Raynauld
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2002). The combination group was 22% more effective than AC
alone group. A statistically significant difference in favour of Hy-
lan G-F 20 and AC compared to AC alone was found in the
WOMAC OA Index physical function subscale (0 to 68 Likert)
at 45 to 52 weeks postinjection (WMD -9.61; 95% CI -13.09 to
-6.13, P < 0.00001) (Raynauld 2002). The combination group
was 22% more effective than AC alone group. The patient global
assessment, based on the number of patients improved in the study
knee, was statistically better for the Hylan G-F 20 and AC group
(73%) compared to AC alone (27%) (RR 2.68; 95% CI 1.98 to
3.62, P < 0.00001) (Raynauld 2002). TheNNT for patient global
assessment was 2.
A statistically significant difference in favour of Hylan G-F 20 and
AC compared to AC alone was found in the WOMACOA Index
pain subscale (0 to 100 mm VAS) (WMD -12.70; 95% CI -16.41
to -8.99, P < 0.00001) (Kahan 2003a). The combination group
was 25% more effective than AC alone. A statistically significant
difference in favour of Hylan G-F 20 and AC compared to AC
alone was found in the WOMAC OA Index physical function
subscale (WMD -13.20; 95% CI -17.02 to -9.38, P < 0.00001)
(Kahan 2003a). The combination group was 24% more effective
than AC alone. A statistically significant difference was found in
favour of Hylan G-F 20 and AC compared to AC alone in the
Lequesne Index (0 to 24) (WMD -2.20; 95% CI -2.98 to -1.42,
P < 0.00001) (Kahan 2003a). The combination group was 18%
more effective thanAC alone. The patient global assessment, based
on effectiveness rated as good or satisfactory, was statistically better
for the Hylan G-F 20 and AC group (74%) compared to AC
alone (51%) (RR 1.44; 95% CI 1.25 to 1.66, P < 0.00001) (
Kahan 2003a). The NNT for patient global assessment was 4.
The number of responders, defined as those patients with at least
a 20% decrease in pain on walking, was significantly higher in the
Hylan G-F 20 and AC group (88%) compared to AC alone (68%)
(RR 1.30; 95% CI 1.18 to 1.43, P < 0.00001) (Kahan 2003a).
Safety
There was no statistically significant difference in the total with-
drawals overall (RR 0.30; 95% CI 0.08 to 1.08, P value 0.07)
(Kahan 2003a; Raynauld 2002). There was no statistically signif-
icant difference in the number of patients reporting side effects
from baseline (RR (random-effects model) 0.94; 95% CI 0.44 to
2.02, P value 0.9) (Kahan 2003a; Raynauld 2002). There was no
difference in the number of patients withdrawn due to adverse
events in the Kahan trial (Kahan 2003a) (RR 2.00; 95% CI 0.18
to 21.92, P value 0.6). The number of patients reporting mild,
moderate or severe side effects at the end of the study was signifi-
cantly higher in the AC alone group (68%) compared to theHylan
G-F 20 and AC group (52%) (RR 0.76; 95% CI 0.61 to 0.94, P
value 0.01) (Raynauld 2002). There was a statistically significant
difference in the number of patients with gastrointestinal adverse
events in favour of the Hylan G-F 20 and AC group compared
to AC alone (RR 0.38; 95% CI 0.25 to 0.60, P value 0.00002)
(Kahan 2003a; Raynauld 2002). Significantly fewer patients with-
drew due to lack of effectiveness in the Hylan G-F 20 and AC
group (2%) compared to the AC alone group (7%) (RR 0.35;
95% CI 0.14 to 0.88, P value 0.03) (Kahan 2003a).
Hylan G-F 20 (Synvisc) versus other hyaluronan
Five RCTs have been comparisons of Hylan G-F 20 and hyaluro-
nan: 1) Artzal (Karlsson 2002) - readers are directed to the Artz
product results, 2) Artz (Wobig 1999b (Artz)) andHealon (Wobig
1999a (Healon)), 3) Hyalgan (Brown 2003) - readers are directed
to the Hyalgan product results, 4) Orthovisc (Bayramoglu 2003)
- readers are directed to the Orthovisc product results, and 5)
Arthrease (Thompson 2002) - readers are directed to the BioHy
(Arthrease) product results.
The Wobig 199 trial had two active arms: Artz (Wobig 1999b
(Artz) and Healon (Wobig 1999a (Healon)). Since Healon is not
indicated for the treatment of knee OA we have completed the
analysis both including and excluding this arm.
Efficacy
There was no statistically significant difference in pain on weight
bearing (0 to 100 mm VAS) at 1 to 4 weeks postinjection (WMD
-2.06; 95% CI -7.45 to 3.32, P value 0.41)(Karlsson 2002c (AvS),
Wobig 1999a (Healon),Wobig 1999b (Artz)) or at 14 to 26 weeks
postinjection (WMD -5.00; 95% CI -14.98 to 4.98, P value 0.3)
(Karlsson 2002c (AvS)). There was a statistically significant dif-
ference in favour of Hylan G-F 20 compared to other hyaluro-
nans at 5 to 13 weeks postinjection (WMD -6.59; 95% CI -
12.46 to -0.73, P value 0.03) (Karlsson 2002c (AvS);Wobig 1999a
(Healon); Wobig 1999b (Artz)). There was a statistically signifi-
cant difference in favour of Hylan G-F 20 in pain at night (0-100
mm VAS) at 1 to 4 weeks postinjection (WMD -7.07; 95% CI -
13.41 to -0.73, P value 0.03), but no difference at 5 to 13 weeks
postinjection (WMD -3.50; 95% CI -11.34 to 4.34, P value 0.4)
(Wobig 1999a (Healon); Wobig 1999b (Artz)). There was no sig-
nificant difference in improvement in knee movement (0 to 100
mm VAS) at 1 to 4 weeks postinjection (WMD -0.50; 95% CI -
10.30 to 9.30, P value 0.9), but there was a statistically significant
difference in favour of Hylan G-F 20 at 5 to 13 weeks postinjec-
tion (WMD 12.50; 95% CI 2.70 to 22.30, P value 0.01). There
was no significant difference in the patient global evaluation of
treatment efficacy (0 to 100 mm VAS) at 1 to 4 weeks postinjec-
tion (WMD 2.00; 95% CI -7.80 to 11.80, P value 0.7), or at 5-
13 weeks postinjection (WMD 9.50; 95% CI -0.30 to 19.30, P
value 0.06).
When excluding the Healon arm, there was no statistically signifi-
cant difference in pain on weight bearing at 1 to 4 weeks postinjec-
tion (WMD-0.23; 95%CI -6.39 to 5.92, P value 0.9) or at 5 to 13
weeks postinjection (WMD (random-effects model) -8.11; 95%
CI -22.79 to 6.57, P value 0.3) (Karlsson 2002c (AvS), Wobig
1999b (Artz)). There was no statistically significant difference in
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pain at night at 1 to 4 weeks postinjection (WMD -3.00; 95%
CI -12.80 to 6.80, P value 0.5) or at 5 to 13 weeks postinjection
(WMD -4.00; 95%CI -15.09 to 7.09, P value 0.5) (Wobig 1999b
(Artz)). There was no significant difference in improvement in
knee movement (0-100 mm VAS) at 1 to 4 weeks postinjection
(WMD -1.00; 95% CI -14.86 to 12.86, P value 0.9). There was a
significant difference in improvement in kneemovement in favour
of Hylan G-F 20 at 5 to 13 weeks postinjection (WMD 17.00;
95% CI 3.14 to 30.66, P value 0.02). There was no significant
difference in patient global evaluation of treatment efficacy at 1
to 4 weeks postinjection (WMD 5.00; 95% CI -8.86 to 18.86, P
value 0.5). There was a statistically significant difference in patient
global evaluation of treatment efficacy in favour of Hylan G-F 20
at 5 to 13 weeks postinjection (WMD 16.00; 95% CI 2.14 to
29.86, P value 0.02).
Safety
The safety profile of the three groups (Artz,Healon andHylanG-F
20) was very similar (Wobig 1999). No patients reported systemic
reactions. Two Hylan G-F 20 patients and one Artz patient re-
ported local reactions. OneHylan G-F 20 patient and twoHealon
patients withdrew from the trial.
Product - NRD-101
Description of studies:
Two RCTs have been included (Pham 2003; Tsukamoto 1995
(abstract); Yamamoto 1994).
Pham et al. reported, as an abstract, a one-year, parallel-group,
double-blind, placebo-controlled, multicentre RCT performed in
France comparing three weekly injections of NRD-101 plus oral
placebo to: 1) three weekly injections of saline solution plus Di-
acerein 50 mg twice daily, and 2) three weekly IA injections of
saline solution plus oral placebo (Pham 2003). The objective was
to evaluate long-term structural and symptomatic efficacy of three
courses (every three months) of three weekly IA injections of
NRD-101 over a one-year period. No statistically significant dif-
ferences were found for pain. There was a statistically significant
deterioration in joint space width but no difference between the
three groups. The trial did not find any structural and/or symp-
tomatic effect for NRD-101 and Diacerein.
Yamamoto et al. reported a five-week, parallel-group, double-blind
RCT performed at 31 centres in Japan comparing five weekly in-
jections of NRD-101 (produced by fermentation using Strepto-
coccus equi, a type of lactobacilli, Denki Kagaku Kogyo) to five
weekly injections of Artz in 203 patients with OA of the knee
(Tsukamoto 1995; Yamamoto 1994). Statistically significant dif-
ferences in favour of NRD-101 were reported for ’final global im-
provement’ and ’usefulness’ but not for evaluation of improvement
in clinical symptoms. Adverse events were reported for 2 of 100
NRD-101 patients and 3 of 99 Artz patients.
This comparative HA trial was of short duration with the longest
assessment only one week postinjection. The 31 trial sites were
all Departments of Orthopedic Surgery. Almost all of the clinical
evaluations were based on physician ratings rather than on patient
ratings.
With respect to methodological quality, the average Jadad score
was 4 out of 5; the Pham trial scoring 3 and the Yamamoto
trial scoring 5. Allocation concealment was adequate for the Ya-
mamoto trial but unclear for the Pham trial. One trial was ex-
cluded (Kurokawa 1994).
NRD-101 versus placebo
Efficacy
No efficacy data on the symptomatic outcome measures were ex-
tracted from the Pham trial as means and standard deviations were
not published in the abstract (Pham 2003). Data were reported on
the percentage of progressors (joint space narrowing greater than
0.5 mm). There was no statistically significant difference between
NRD 101 + oral placebo 23 of 131 (17.6%) and saline injection
+ oral placebo 17 out of 85 (20.3%) (RR 0.88; 95% CI 0.50 to
1.54, P value 0.7).
Safety
There was no statistically significant difference in the number of
completers: NRD 101 + oral placebo 123 of 131 (93.9%) and
saline injection + oral placebo 79 of 85 (92.9%) (RR 1.01; 95%
CI 0.94 to 1.09, P value 0.8) (Pham 2003).
NRD-101 versus corticosteroid: no trials included.
NRD-101 versus NSAID
Efficacy
Data were reported on the percentage of progressors (joint space
narrowing greater than 0.5 mm) (Pham 2003). There was no sta-
tistically significant difference between NRD 101 +
oral placebo 23 of 131 (17.6%) and Diacerein + saline injection
16 of 85 (18.9%) (RR 0.93; 95% CI 0.52 to 1.66, P value 0.8).
Safety
There was no statistically significant difference in the number of
completers: NRD 101 + oral placebo 123 of 131 (93.9%) and
Diacerein + saline injection 80 of 85 (94.1%) (RR 1.00; 95% CI
0.93 to 1.07, P value 0.9) (Pham 2003).
NRD-101 versus other hyaluronans
Efficacy
For the NRD-101 comparison against Artz (Tsukamoto 1995;
Yamamoto 1994) there were no statistically significant differences
between the two products in any measure of efficacy at 1 to 4
weeks postinjection: spontaneous pain (RR 1.17; 95% CI 0.92 to
27Viscosupplementation for the treatment of osteoarthritis of the knee (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1.48, P value 0.2), pain on pressure (RR 1.12; 95% CI 0.88 to
1.42, P value 0.4), pain during the night (RR 0.98; 95% CI 0.78
to 1.24, P value 0.9), passive movement pain (RR 0.88; 95% CI
0.67 to 1.16, P value 0.4), passive flexion (WMD 1.00; 95% CI
-2.73 to 4.73, P value 0.6), passive extension (WMD -0.20; 95%
CI -1.79 to 1.39, P value 0.8), and patient global assessment (RR
1.03; 95% CI 0.80 to 1.33, P value 0.8).
Safety
There was no statistically significant difference in the total number
of withdrawals overall in the Artz group (15%) compared to the
NRD-101 group (6%) (RR 0.40; 95% CI 0.16 to 1.00, P value
0.05) (Yamamoto 1994). There were a similar number of adverse
events reported in the two groups: 2 of 100 in NRD-101 and 3
of 99 in the Artz group (RR 0.66; 95% CI 0.11 to 3.87, P value
0.6).
Product -Orthovisc
Description of studies
Seven randomised controlled trials of Orthovisc (Anika Ther-
apeutics, Inc., Woburn, MA) have been included. Four have
been reported as journal articles (Bayramoglu 2003; Brandt 2001;
Tascioglu 2003; Tekeoglu 1998), one was the basis of a specializa-
tion thesis (Kalay 1997), one was presented as a poster at the 10th
National Rheumatology Congress in Turkey (Guler 1996), and
one remains unpublished (Hizmetli 1999). Orthovisc has been
compared against placebo (Brandt 2001; Guler 1996; Hizmetli
1999), betamethasone (Tekeoglu 1998), 6-methylprednisolone
acetate (Tascioglu 2003), IA hylan (Bayramoglu 2003), and phys-
ical therapy (Bayramoglu 2003; Kalay 1997). With the excep-
tion of the Brandt RCT (Brandt 2001), which was conducted in
the United States, the other six RCT were conducted in Turkey.
With respect to methodological quality, the average Jadad score
was 2.7 out of 5, with two trials scoring 4 (Brandt 2001; Hizmetli
1999), one trial scoring 3 (Guler 1996), and four trials scor-
ing 2 (Bayramoglu 2003; Kalay 1997; Tascioglu 2003; Tekeoglu
1998). Allocation concealment was adequately described in one
trial (Brandt 2001) and unclear (not reported) in the remaining
six trials. Seven trials were excluded (Ates 2001; Birbara 2004;
Koyuncu 2002; Olszynski 2002; Oron 2003; Sepici 2002; Toh
2002; Toh 2003). Five trials are awaiting assessment (Gur 2002;
Kilinc 2002; Kotevoglu 2002; Neustadt 2004; Renk[inodot]tepe
20). These trials have only been published as abstracts with no
extractable data, and at the closure of the database for this review
no full length manuscripts have been published.
Bayramoglu et al. reported a three-month, parallel-group RCT
performed at a single centre in Turkey comparing three weekly in-
jections of Orthovisc plus a physical therapy programme to three
weekly injections of Hylan G-F 20 plus a physical therapy pro-
gramme to a physical therapy programme alone (deep tissue heat-
ing with short wave diathermy, transcutaneous electrical neuro-
muscular stimulation and exercises) in 46 patients with OA of
the knee (Bayramoglu 2003). The authors were particularly in-
terested in examining the effect of IA HA injection on muscu-
lar strength; testing the hypothesis that if patients were relieved
of pain and disability then indirectly they would build stronger
quadriceps muscles. They reported within-group improvement in
the Lequesne score for all three groups but no between-group dif-
ference. No within- or between-group difference was detected in
muscular strength. No between-group differences were reported
for range of motion, knee instability, existing deformities and ra-
diographic grade. No adverse events were associated with the IA
hyaluronic acid injections.
The Bayramoglu et al. RCT had a small sample size. However, it
was classified as a pilot study. The presence or absence of effusion,
usage of rescue and concomitant medications, and OA diagnosis
criteria were not reported. There was a difference in the num-
ber of patients with bilateral disease: 100% physical therapy (PT)
group, 75% Orthovisc group and 67% Hylan G-F 20 group. No
difference was found with respect to the MW of the HA prod-
ucts. Since PT is part of the first line nonpharmacologic therapy
in the medical management of patients with OA of the knee, the
designation of PT alone as a treatment group in comparison to
the two combination groups (pharmacologic + nonpharmacologic
groups) was a particular interest in this trial.
Brandt et al. reported a 27-week, placebo-controlled, double-blind
RCTperformed at 10 centres in theUnited States comparing three
weekly injections of Orthovisc to three weekly injections of saline
in 226 patients with OA of the knee (Brandt 2001). The authors
examined the influence of contralateral knee pain in a post hoc
analysis of patients who completed at least 15 weeks of the trial,
had no major protocol violations, and aWOMACOA Index pain
score less than 12 in the contralateral knee. This ’effectiveness’
population controlled for the severity in the contralateral knee.
The authors concluded that, in patients with mild to moderate
OA of the knee, Orthovisc produced statistically and clinically
significant improvement. No side effects were attributed to treat-
ment. The incidence of injection site reaction was similar in both
groups: 2.1% Orthovisc and 1.5% saline.
The Brandt et al. RCT did not report the presence or ab-
sence of effusion or disease duration (Brandt 2001). In this trial,
acetaminophen was permitted at the recommended treatment
dosage of 1 g four times daily, but was restricted 24 h before as-
sessment visits. Patients in this trial had a high percentage of bi-
lateral knee disease, but only the index knee received treatment.
WOMAC OA Index questionnaires were completed by patients
for each knee separately. The severity of pain in the contralateral
knee confounded the outcome measurements in the index knee.
The authors discussed how the pain response may be affected
by severity of contralateral knee pain. They also noted the large
placebo response detected in this trial. Although 78% of the pa-
tients randomised completed the trial, results were based only on
the effectiveness population (i.e. 60%). It is of note that no sig-
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nificant difference was detected in the intent-to-treat population
between Orthovisc and placebo. The authors defined a clinically
meaningful improvement as a decrease of at least three units in
the WOMAC pain subscale score. They utilised a 1 to 5 scoring
system for the Likert version of theWOMACOA Index resulting
in a score range of 5 to 25 for the pain subscale of the Index.
Guler et al. reported a 10-week, placebo-controlled, double-blind
RCT performed at one centre in Turkey comparing three weekly
injections of Orthovisc to three weekly injections of saline in 30
patients with OA of the knee (Guler 1996). Statistically signifi-
cant improvement was reported in the Orthovisc group for the
WOMACpain and physical function subscales, walking time, and
acetaminophen usage compared to the saline group. No adverse
events were reported.
The small trial by Guler et al. demonstrated between-group dif-
ferences (Guler 1996). Of particular note, there was a statistically
significant decrease in the use of acetaminophen in the Orthovisc
group. Although the abstract reported WOMAC OA Index sub-
scale ranges with the minimum set at zero, it appeared that the
score was based on 1 to 5.
Hizmetli et al. completed a one-year, placebo-controlled, dou-
ble-blind RCT in Turkey comparing three weekly injections of
Orthovisc to saline in 50 patients with OA of the knee (Hizmetli
1999). A fourth injection was given at six months. Statistically
significant differences in all subscales of the WOMAC OA Index
in favour of Orthovisc were reported. No local or systemic side ef-
fects were observed. This unpublished report was kindly provided
by Anika Therapeutics Inc.
The Hizmetli et al. trial was one of a few unpublished trials in-
cluded in this review (Hizmetli 1999). The manuscript did not
report presence or absence of effusion, disease duration, or pres-
ence of uni/bilateral disease. The trial addressed repeat treatment
at six months. Analgesics were restricted for the first four weeks of
the trial.
Kalay reported a 56-day, parallel-group, open-label RCT per-
formed at a single centre in Turkey comparing two weekly injec-
tions of Orthovisc plus a physical therapy programme to a physical
therapy programme (paraffin, short wave, quadriceps exercises) in
40 patients with OA of the knee (Kalay 1997). Statistically sig-
nificant improvement was reported in the Orthovisc group com-
pared to the physical therapy alone group for the following clin-
ical outcome measures: pain, paracetamol usage, walk time, and
patient and investigator evaluation of treatment. Two patients in
the Orthovisc group had local pain and swelling which resolved
within 24 hours.
The Kalay trial utilised a two-injection schedule rather than a
three-injection schedule (Kalay 1997). The publication did not
report the presence or absence of effusion or disease duration.
However, supplemental use of paracetamol as rescue medication
was graded and recorded. Statistically significant decreases in con-
sumption were seen in both groups at the end of the study com-
pared to baseline. As well, a statistically significant between-group
difference in favour of Orthovisc was found at the eighth week.
Tascioglu and Oner reported a six-month, parallel-group, open-
label RCT performed at a single centre in Turkey comparing three
weekly injections of Orthovisc to three weekly injections of 6-
methylprednisolone acetate (6-MPA) in 69 female patients with
OA of the knee (Tascioglu 2003). A significant improvement was
reported in both groups at week four in pain and Lequesne out-
come measures. At three months, a significant improvement in
pain and Lequesne was reported in favour of Orthovisc compared
to 6-MPA. By six months, there was no difference between the
two groups. No serious systemic adverse events were reported that
could be related to the treatment. Similar percentages of patients
reported knee pain after injection (Orthovisc 21%, 6-MPA 18%).
There was no significant between-group difference with respect to
adverse events.
In the Tascioglu and Oner trial paracetamol to a maximum of 3 g
was permitted but with restriction 48 hours prior to an assessment
(Tascioglu 2003). The percentage of patients with uni and bilateral
disease was not reported.
Tekeoglu et al. reported a 15-week, parallel-group, open-label
RCT performed in Turkey comparing three weekly injections of
Orthovisc to three weekly injections of betamethasone in 40 fe-
male patients with OA of the knee (Tekeoglu 1998). In the short
term (week 3), betamethasone was more effective than Orthovisc.
In the long term (week 15), Orthovisc was more effective than
betamethasone. No local or systemic reactions were reported.
The Tekeoglu et al. trial allowed patients to take paracetamol as
well (Tekeoglu 1998). Again, the percentage of patients with uni
and bilateral disease was not reported. In this RCT, patients were
advised to rest for one day after injection ’to avoid overcharging
the injected joint’.
Orthovisc versus placebo
Efficacy
Pain, as measured by the WOMAC OA Index (scored 5 to 25),
improved significantly with Orthovisc versus placebo (Hizmetli
1999) (WMD -7.50; 95% CI -10.21 to -4.79, P < 0.00001) at 1
to 4 weeks postinjection; (WMD -5.95; 95% CI -7.87 to -4.03,
P < 0.00001) at 5 to 13 weeks postinjection; (WMD -5.60; 95%
CI -7.43 to -3.77, P < 0.00001) at 14 to 26 weeks postinjection;
and (WMD -5.30; 95% CI -7.02 to -3.58, P < 0.00001) at 45 to
52 weeks postinjection. Orthovisc was between 32 and 45% more
effective than saline in relieving pain asmeasured by theWOMAC
OA Index pain subscale. Physical function, as measured by the
WOMACOAIndex (scored 17 to85), improved significantlywith
Orthovisc versus placebo at three of four follow-up assessments
(WMD -12.25; 95% CI -20.83 to -3.67, P value 0.005) at 1 to 4
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weeks postinjection; (WMD -10.15; 95% CI -17.72 to -2.58, P
value 0.009) at 5 to 13 weeks postinjection; (WMD -9.30; 95%
CI -17.00 to -1.60, P value 0.02) at 14 to 26 weeks postinjection;
and (WMD -7.10; 95% CI -15.42 to -1.22, P value 0.09) at 45 to
52 weeks postinjection. Orthovisc was between 16 and 26% more
effective than saline in improving physical function as measured
by the WOMAC OA Index physical function subscale.
Patient satisfaction with treatment was similar in the Orthovisc
(73%) and saline (33%) groups (Guler 1996); (RR 2.20; 95% CI
1.01 to 4.79, P value 0.05) at 5 to 13 weeks postinjection.
In Brandt’s trial (Brandt 2001), results are presented only for the
effectiveness population which represents approximately a 40%
loss of the initially randomised population. Orthovisc was not sta-
tistically significantly different than saline in the number of pa-
tients who achieved a greater than five-unit improvement in the
WOMAC pain score relative to baseline score by 25 weeks postin-
jection (Orthovisc 58%, saline 40%) (RR 1.42; 95% CI 1.00 to
2.02, P value 0.05). The RevMan analysis (P value 0.05) disagreed
with the publication analysis where a statistically significant dif-
ference was detected in favour of Orthovisc (P value 0.04).
There was no statistically significant difference in the number of
patients who improved in the WOMAC pain subscale score at 14
to 26 weeks postinjection: Orthovisc 92% versus saline 87% (RR
1.06; 95% CI 0.95 to 1.19, P value 0.3).
Safety
No local or systemic adverse events were observed in the Hizmetli
trial (Hizmetli 1999). No complications (e.g. during or after in-
traarticular injection) were reported in the Guler trial (Guler
1996).
The safety data was based on the intention to treat population in
the Brandt trial (Brandt 2001). There were no statistically signifi-
cant differences between Orthovisc and saline in the safety profile.
Orthovisc versus corticosteroid
Efficacy
In the Orthovisc/betamethasone comparison (Tekeoglu 1998), at
1 to 4 weeks postinjection, there were no statistically significant
differences for:WOMAC function (scored 17 to 85) (WMD3.00;
95% CI -2.39 to 8.39, P value 0.3); the number of patients good
or very good (RR 0.83; 95% CI 0.47 to 1.47, P value 0.5); and
maximum flexion (WMD -4.90; 95% CI -14.69 to 4.89, P value
0.3). At 5 to 13 weeks postinjection, Orthovisc was significantly
better than betamethasone for WOMAC function (WMD -9.00;
95% CI -14.15 to -3.85, P value 0.0006). Orthovisc was 20%
more effective than betamethasone in improving physical func-
tion. Orthovisc was significantly better than betamethasone for
patient global assessment (i.e. number of patients good/very good)
(RR 1.88; 95% CI 1.04 to 3.39, P value 0.04). The NNT for
patient global assessment was 3. There was no between-group dif-
ference for maximum flexion at 5 to 13 weeks (WMD -7.05; 95%
CI -15.48 to 1.38, P value 0.10).
In theOrthovisc/6-methylprednisolone acetate (6-MPA) compar-
ison (Tascioglu 2003), there were no statistically significant differ-
ences between the two groups for any of the pain outcome mea-
sures (0 to 100 mmVAS), the Lequesne Index (0 to 24), or flexion
outcome measures at 1 to 4 weeks postinjection. However, at 5
to 13 weeks postinjection, statistically significant differences were
detected in all outcome measures, except flexion, in favour of the
Orthovisc group: pain on weight bearing (WMD -15.64; 95%
CI -24.51 to -6.77, P value 0.0006); pain at rest (WMD -7.70;
95% CI -13.50 to -1.90, P value 0.009); pain on walking (WMD
-18.43; 95% CI -29.19 to -7.67, P value 0.0008); Lequesne In-
dex (WMD -1.40; 95% CI -2.13 to -0.67, P value 0.0002). For
flexion the WMD was 2.36 (95% CI -1.82 to 6.54) P value 0.3.
Orthovisc was between 25 and 32%more effective than 6-MPA in
relieving pain. Orthovisc was 18% more effective than 6-MPA in
improving function (Lequesne). At 14 to 26 weeks postinjection,
statistically significant differences in all outcome measures, except
pain on rest, were detected in favour of the Orthovisc group: pain
on weight bearing (WMD -15.40; 95% CI -25.91 to -4.89, P
value 0.004); pain on walking (WMD -14.90; 95% CI -25.91 to
-3.89, P value 0.008); Lequesne Index (WMD -1.14; 95% CI -
2.16 to -0.12, P value 0.03), and flexion (WMD 5.00; 95% CI
0.19 to 9.81, P value 0.04). For pain at rest the WMD was -2.90
(95%CI -9.47 to 3.67) P value 0.4. Orthovisc was between 20 and
31% more effective than 6-MPA in relieving pain and between 4
and 15% more effective than 6-MPA in improving function.
The RevMan analysis differed from the publication analysis
(Tascioglu 2003). The publication reported no statistically signif-
icant between-group difference at six months in pain on weight
bearing whereas RevMan detected a statistically significant dif-
ference (P value 0.004) in favour of Orthovisc compared to 6-
MPA. The publication reported no statistically significant be-
tween-group difference at six months in pain on walking whereas
RevMan detected a statistically significant difference (P value
0.008) in favour of Orthovisc compared to 6-MPA. The publi-
cation reported no statistically significant between-group differ-
ence at six months in the Lequesne Index whereas RevMan de-
tected a statistically significant difference (P value 0.03) in favour
of Orthovisc compared to 6-MPA. The publication reported no
statistically significant between-group difference at six months in
flexion whereas RevMan detected a statistically significant differ-
ence (P value 0.04) in favour of Orthovisc compared to 6-MPA.
Safety
There were no adverse local (e.g. postinjection synovitis) or sys-
temic reactions reported in either the Orthovisc or betametha-
sone group with all patients completing the trial (Tekeoglu 1998).
There were no statistically significant differences in the safety pro-
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file of Orthovisc compared to 6-MPA (Tascioglu 2003). A similar
number of patients were withdrawn overall: Orthovisc 6.7% and
6-MPA 10% (RR 0.67; 95% CI 0.12 to 3.71, P value 0.6). One
patient in each group withdrew due to increased pain (RR 1.00;
95% CI 0.07 to 15.26; P value 1). A similar number of patients
reported musculoskeletal adverse events: Orthovisc 25% and 6-
MPA 19% (RR 1.35; 95% CI 0.49 to 3.74, P value 0.6). A similar
number of patients reported skin adverse events: Orthovisc 7%
and 6-MPA 4% (RR 1.93; 95% CI 0.19 to 20.05, P value 0.6). A
similar number of patients reported gastrointestinal adverse events:
Orthovisc 11% and 6-MPA 7% (RR 1.45; 95% CI 0.26 to 7.99,
P value 0.7). A similar number of patients reported general adverse
events: Orthovisc 14% and 6-MPA 19% (RR 0.77; 95% CI 0.23
to 2.57, P value 0.7). A similar number of patients reported knee
pain after injection: Orthovisc 21% and 6-MPA 19% (RR 1.16;
95% CI 0.40 to 3.35, P value 0.8).
Orthovisc versus NSAID: no trials included.
Orthovisc versus physiotherapy
Efficacy
In theOrthovisc plus physiotherapy versus physiotherapy compar-
ison (Kalay 1997), there were no statistically significant differences
at 1 to 4 weeks postinjection for: activity pain (VAS) (WMD -
1.70; 95%CI -7.22 to 3.82, P value 0.5); spontaneous pain (VAS)
(WMD 0.40; 95% CI -3.23 to 4.03, P value 0.8); night pain
(VAS) (WMD -0.20; 95% CI -4.35 to 3.95, P value 0.9); 25 m
walk time (sec) (WMD 0.75; 95% CI -1.09 to 2.59, P value 0.4);
and flexion WMD was not estimable as the SD of the treatment
group was zero. At 5 to 13weeks postinjection, the combination of
Orthovisc and physiotherapy was better than physiotherapy alone
for activity pain (WMD -6.50; 95% CI -11.93 to -1.07, P value
0.02) and spontaneous pain (WMD -4.10; 95%CI -7.43 to -0.77,
P value 0.02). Orthovisc plus physiotherapy was between 16 and
44% more effective than physiotherapy alone in relieving pain.
No other significant differences were found: night pain (WMD -
3.30; 95% CI -6.93 to 0.23, P value 0.07); walk time (WMD -
1.15; 95% CI -2.83 to 0.53, P value 0.18); and flexion WMD
was not estimable again due to the SD of the treatment group
being zero. The number of patients rating the treatment as effec-
tive or very effective was significantly higher in the Orthovisc plus
physiotherapy arm (95%) compared to the physiotherapy group
(60%) (RR 1.58; 95% CI 1.09 to 2.30, P value 0.02). The NNT
for patient global assessment was 3.
The RevMan analysis differed from the publication analysis. The
publication reported a statistically significant difference in activity
pain at day 21 (1 to 4 weeks postinjection) in favour of Orthovisc
plus physiotherapy compared to physiotherapy alone (P value
0.03) whereas RevMan detected no difference. The publication
reported a statistically significant difference in night pain at day 56
(5 to 13 weeks postinjection) in favour of Orthovisc plus physio-
therapy compared to physiotherapy alone (P value 0.02) whereas
RevMan detected no difference. The publication reported a statis-
tically significant difference in walk time both at day 21 (P value
0.0049) and day 56 (P value 0.0001) in favour of Orthovisc plus
physiotherapy compared to physiotherapy alone whereas RevMan
detected no difference.
In the Orthovisc plus physical therapy versus physical therapy
comparison (Bayramoglu 2003), there were no statistically signif-
icant differences in the Lequesne Index at the end of treatment
at three weeks (WMD -0.20; 95% CI -2.98 to 2.58, P value 0.9)
or at three months (WMD -1.80; 95% CI -5.14 to 1.54, P value
0.3).
Safety
With respect to safety, two patients in the Orthovisc plus physio-
therapy group (Kalay 1997) experienced local pain and swelling
several hours after the IA injections which resolved in 24 hours
with cold application; however, this difference was not statistically
significant (RR 5.00; 95% CI 0.26 to 98.00, P value 0.3). In this
trial the treatment schedule differed from the other four trials, in
that only two injections were given on days 0 and 7. There were
no adverse events associated with the IA hyaluronic acid injections
in the second trial (Bayramoglu 2003). There was no statistically
detectable difference in the number of withdrawals overall (RR
0.07; 95% CI 0.00 to 1.18, P value 0.07). No patients in either
trial withdrew because of adverse events or experienced any sys-
temic adverse events.
Orthovisc versus other hyaluronan
Efficacy
In the one trial included (Bayramoglu 2003), there were no sta-
tistically significant differences between Orthovisc plus a physical
therapy programme versus Hylan G-F 20 plus a physical therapy
programme in the Lequesne Index either at the end of the treat-
ment schedule (WMD 0.50; 95% CI -1.58 to 2.58, P value 0.6)
or at three months (WMD -1.00; 95% CI -3.30 to 1.30, P value
0.4).
Safety
There were no adverse events associated with either of the IA
hyaluronic acid injections (Bayramoglu 2003).
Product - Ostenil
Description of studies
One RCT was excluded: Uebelhart 2003.
Product - Replasyn
Description of studies
One RCT has been reported.
Cohen et al. reported an eight-week, placebo-controlled, double-
blind RCT performed at four centres in Canada and the United
31Viscosupplementation for the treatment of osteoarthritis of the knee (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
States comparing three weekly injections of Replasyn to placebo
(not specified) in 39 patients with OA of the knee (Cohen 1994).
A significant within group difference was found for pain on walk-
ing by week 8 in the Replasyn group. However, no between-group
differences were found in pain on walking, range of motion, the
WOMAC functional index, or patient and physician global as-
sessments. Transient joint pain or swelling was reported in 3 of 19
Replasyn and 6 of 20 placebo patients.
An abstract is the only publication of this trial.
Replasyn versus placebo
Efficacy
Since nomeasure of dispersionwas reported in the abstract (Cohen
1994) this review does not report efficacy data.
Safety
There was no statistically significant difference in the number of
patients with local adverse reactions: Replasyn 16% versus placebo
30% (RR 0.53; 95% CI 0.15 to 1.81, P value 0.3).
Replasyn versus corticosteroid: no trials included.
Replasyn versus NSAID: no trials included.
Replasyn versus other hyaluronan: no trials included.
Product - SLM-10
Description of studies
One RCT has been included.
Kawabata et al. reported a five-week, parallel-group, single-blind
RCT performed at 23 centres in Japan comparing five weekly
injections of SLM-10 (developed and produced by fermentation
with Streptococcus zooepidemicus of Lancefield’s group C, Shi-
seido Co., Ltd.) to five-weekly injections of Artz in 172 patients
with OA of the knee (Kawabata 1993). No statistically significant
between-group differences were reported for patients’ impression,
final global improvement and utility, leading the authors to con-
clude that SLM-10 was as useful as Artz. Adverse events were re-
ported in one SLM-10 patient and two Artz patients. The Jadad
score for this trial was 2 out of 5; single-blind and no specific details
regarding randomisation were reported. Allocation concealment
was adequate.
This comparative HA trial was of short duration with the longest
assessment only one week postinjection. In addition, it was single-
blind because of differences in the HA; SLM-10 was provided in a
syringe while Artz was provided in an ampoule. The 23 trial sites
were all Departments of Orthopedic Surgery. Almost all of the
clinical evaluations were based on attending physician or commit-
tee ratings rather than on patient ratings. The case study commit-
tee, as well as the attending physician, assessed overall severity, final
global improvement, overall safety and usefulness. Differences in
results were noted in assessments made by the attending physician
compared to those made by the committee. In the analysis method
section of the publication, it reports that ”cases which deviated
from the protocol or those judged to be inappropriate as the sub-
jects of assessment were excluded from the analysis of correspond-
ing assessment item“. However, no definition of appropriateness
was reported.
Five trials were excluded (Minami 1993; Ono 1993; Ono 1993a;
Suzu 1993; Taneda 1993).
SLM-10 versus placebo: no trials included.
SLM-10 versus corticosteroid: no trials included.
SLM-10 versus NSAID: no trials included.
SLM-10 versus other hyaluronan
Efficacy
Regarding the SLM-10 comparison against Artz (Kawabata 1993),
significantly more patients improved on pain on pressure in the
Artz group (82%) compared to the SLM-10 group (64%) (RR
0.78; 95% CI 0.64 to 0.96, P value 0.02). The NNT for pain on
pressure was 2. No statistically significant between-group differ-
ences were found for pain in movement (RR 0.89; 95%CI 0.75 to
1.06, P value 0.18), pain when resting (RR 1.05; 95% CI 0.86 to
1.29, P value 0.6), and patient global assessment (RR 0.95; 95%
CI 0.78 to 1.17, P value 0.7).
Safety
There was no statistically significant difference in the total number
of withdrawals overall in the Artz group (12%) compared to SLM-
10 group (3%) (RR 0.29; 95%CI 0.08 to 1.03, P value 0.06). The
incidence of local adverse events related to study drug, resulting in
withdrawal, was similar in the Artz (3%) and the SLM-10 (1%)
groups (RR 0.46; 95% CI 0.04 to 5.03, P value 0.5). One patient
in each group had a local adverse event with no specific causal
relationship to the study drug and continued in the trial (RR 0.93;
95% CI 0.06 to 14.61, P value 1).
Product - Suplasyn
Description of studies
One RCT has been included.
Petrella et al. reported a 12-week, placebo-controlled, double-
blind RCT performed at a single centre in Canada comparing
Suplasyn (a bacterial source HA) plus placebo (lactose), placebo
(lactose plus saline), NSAID (Arthrotec plus saline), and Suplasyn
plus NSAID in 120 patients with OA of the knee (Petrella 2002).
The authors reported that Suplasyn was superior to placebo alone
or NSAIDs alone for pain with physical activity and functional
performance. Suplasyn was as effective as NSAID for resting pain
relief.With respect to safety, Petrella reported that two patients had
moderate gastrointestinal irritation resulting in their withdrawal,
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and that most adverse events occurred in the NSAID plus saline
group. No
serious adverse events occurred.
The efficacy outcome measures extracted from this trial were pain
after walking (0 to 100 mm VAS), WOMAC pain (0 to 10 cm)
and WOMAC function (0 to 10 cm), pain at rest (0 to 100 mm
VAS), and walk time (seconds). Of the four groups, three com-
parisons are reported: (Suplasyn plus lactose) versus (saline plus
lactose), (Suplasyn plus lactose) versus (NSAID plus saline), and
(Suplasyn plus NSAID) versus (NSAIDplus saline); not reporting
the combination of (NSAID plus saline) versus placebo (lactose
plus saline). With respect to methodological quality, it scored 5
out of 5 on the Jadad scale achieving bonus points for providing
details of appropriate randomisation and blinding. Allocation con-
cealment was adequate. An editorial reported the results obtained
from this trial using a factorial design analysis (Felson 2002). Two
trials were excluded (Olszynski 2002; Payne 2000).
Some design points were noted: 1) a medial approach was utilised
for injections; 2) rescue medication with 2600 mg (650 g x 4)
of acetaminophen was permitted; 3) a 10-minute home-based re-
sistance exercise programme was part of the treatment and was
monitored by a patient diary; 4) patients were recruited from a
primary care referral centre; 5) no details were published regard-
ing the presence or absence of effusion, disease duration, and OA
diagnosis criteria. The only significant results reported were based
on within-group comparisons. No information on rescue medica-
tion usage was reported.
A randomised, double-blind trial comparing three and six in-
jections of Suplasyn is awaiting assessment (Petrella 2002). This
trial has only been published as an abstract with no extractable
data and at the closure of the database for this review no full
length manuscript had been published. Three trials were excluded
(Mazieres 2004; Petrella 2003a; Petrella 2003b).
Suplasyn versus placebo
Efficacy
No statistically significant differences were found between Su-
plasyn and placebo for the following outcome measures: pain after
walking (WMD -0.67; 95% CI -1.61 to 0.27, P value
0.2); WOMAC pain (WMD -0.77; 95% CI -2.16 to 0.62, P
value 0.3); WOMAC function (WMD -1.28; 95% CI -2.69 to
0.13, P value 0.08); and walk time (WMD 3.14; 95% CI -6.02 to
12.30, P value 0.5). A statistically significant difference, in favour
of the placebo group (saline + lactose) compared to the treatment
group (Suplasyn plus lactose), was found for the primary outcome
measure, pain at rest (WMD 0.83; 95% CI 0.03 to 1.63, P value
0.04). Suplasyn plus lactose was 25% less effective than saline plus
lactose in relieving pain at rest.
The RevMan analysis differed from the publication analysis. The
publication reported that Suplasyn may be superior to placebo for
pain with physical activity and functional performance whereas
the RevMan analysis detected no difference.
Safety
There was no statistically significant difference in the number of
withdrawals overall: Suplasyn 17% versus placebo 7% (RR 2.50;
95% CI 0.53 to 11.89, P value 0.2).
Suplasyn versus corticosteroid: no trials included.
Suplasyn versus NSAID
Efficacy
No statistically significant differences were found between Su-
plasyn and NSAID for: WOMAC pain (WMD -0.44; 95% CI -
1.80 to 0.92, P value 0.5);WOMAC function (WMD -0.31; 95%
CI -1.60 to 0.98, P value 0.6); walk time (WMD -1.49; 95% CI
-10.38 to 7.40, P value 0.7); pain at rest (WMD 1.02; 95% CI -
0.32 to 2.36, P value 0.14); and pain after walking (WMD 1.08;
95% CI -0.37 to 2.53, P value 0.15).
The RevMan analysis differed from the publication analysis. The
publication reported that Suplasyn may be superior to NSAID
alone for pain relief, pain with physical activity, and functional
performance whereas the RevMan analysis detected no difference.
Safety
There was no statistically significant difference in the number of
withdrawals overall: Suplasyn 17% versus NSAID 3% (RR 5.00;
95% CI 0.62 to 40.29, P value 0.13).
Suplasyn + NSAID versus NSAID alone
Efficacy
No statistically significant differences were found between Su-
plasyn plus NSAID versus NSAID alone for: pain after walking
(WMD 0.24; 95% CI -1.09 to 1.57, P value 0.7); WOMAC pain
(WMD -0.27; 95% CI -1.68 to 1.14, P value 0.7); WOMAC
function (WMD -0.03; 95% CI -1.42 to 1.36, P value 1); pain
at rest (WMD -0.02; 95% CI -1.26 to 1.22, P value 1); and walk
time (WMD -3.48; 95% CI -12.14 to 5.18, P value 0.4).
Safety
There was no statistically significant difference in the number of
withdrawals overall: Suplasyn plus NSAID 13% versus NSAID
alone 3% (RR 4.00; 95% CI 0.47 to 33.73, P value 0.2).
Suplasyn versus other hyaluronan: no trials included.
Product - Synject
Description of studies
One trial was excluded: Alonge 2004.
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Product - Zeel compositum
Description of studies
One RCT included was a comparison of Zeel compositum and
Hyalart (Nahler 1996 [article published in German with English
abstract]; Nahler 1998). With respect to methodological quality,
the Jadad score was 4 out of 5. Allocation concealment was unclear.
Nahler et al. reported a five-week, parallel-group, single-blind
RCT performed at twelve centres in Germany and Austria com-
paring 10 injections (two injections a week for five weeks) of Zeel
compositum to five weekly injections of Hyalart in 121 patients
with OA of the knee (Nahler 1998). Both treatments were equally
effective in treating patients. Undesirable side effects were reported
by 11% of Zeel patients and 23% of Hyalart patients; the most
frequent being local inflammation or irritation following the in-
jection. One patient withdrew from the study early due to sus-
pected allergic reaction after injection with Hyalart. For this trial,
Zeel was the treatment group and Hyalart was the control group.
This is the only RCT in the review comparing homeopathy drug
therapy to HA. It was designed as a clinical equivalence study. The
follow-up assessment was short, one week following the treatment.
As the authors noted, the design was single-blind due to the im-
balance in number of injections (Hyalart n = 5 versus Zeel n = 10).
It was deemed ’unethical’ to equalise the frequency of injections
with additional injections of a placebo.
Zeel versus placebo: no trials included.
Zeel versus corticosteroid: no trials included.
Zeel versus NSAID: no trials included.
Zeel versus other hyaluronans
Efficacy
At the end of treatment (i.e. last injection), there were no statis-
tically significant between-group differences in any of the efficacy
outcome measures: pain during movement (0 to 100
mmVAS) (WMD5.00; 95%CI -3.14 to 13.14, P value 0.2); pain
during the night (0 to 100 mm VAS) (WMD 2.00; 95% CI -6.15
to 10.15, P value 0.6); assessment of improvement (0 to 100 mm
VAS) (WMD -4.00; 95% CI -13.12 to 5.12, P value 0.4); and
assessment of tolerance (0 to 100 mm VAS) (WMD -3.00; 95%
CI -10.09 to 4.09, P value 0.4). There was no statistically signifi-
cant difference in the number of patients who reported noticeable
improvement in symptoms: Zeel 87% versus Hyalart 93% (RR
0.94; 95% CI 0.83 to 1.06, P value 0.3).
Safety
There was no statistically significant difference in the number of
patients with side effects: Zeel 11% versus Hyalart 23% (RR 0.48;
95% CI 0.20 to 1.17, P value 0.11); or in the number of patients
withdrawn due to lack of efficacy: Zeel 4% versus Hyalart 2% (RR
2.00; 95% CI 0.19 to 21.44, P value 0.6).
By-class (pooled) analysis
Thirty-seven trials included comparisons of hyaluronan/hylan and
placebo (Altman 1998; Ardic 2001; Bragantini 1987; Brandt
2001; Bunyaratavej 2001; Carrabba 1995; Cohen 1994; Corrado
1995; Creamer 1994; Day 2004; Dickson 2001; Dougados 1993;
Formiguera Sala 1995; Forster 2003; Grecomoro 1987; Groppa
2001; Guler 1996; Henderson 1994; Hizmetli 1999; Huskisson
1999; Jubb 2003; Karlsson 2002; Lohmander 1996; Moreland
1993; Petrella 2002; Pham 2003; Puhl 1993; Scale 1994a (2 inj);
Scale 1994b (3 inj); Shichikawa 1983a; Shichikawa 1983b; St. J.
Dixon 1988; Tamir 2001; Tsai 2003; Wobig 1998; Wobig 1999c
(NEhyl); Wu 1997).
In this section, we report only analyses based on multiple studies.
Analyses based on single products and/or studies can be found in
the relevant by-product results section. This section is most infor-
mative when read in combination with the relevant by-product
section(s).
There was a statistically significant difference in favour of HA
compared to placebo for pain on weight bearing (0 to100 mm
VAS) at three assessments: at 1 to 4 weeks postinjection, based on
21 trials (WMD (random-effects model) -7.92; 95% CI -11.70 to
-4.14, P value 0.00004); at 5 to 13 weeks postinjection, based on
16 trials (WMD (random-effects model) -12.97; 95% CI -18.00
to -7.93, P < 0.00001); at 14 to 26 weeks postinjection, based on
9 trials (WMD (random-effects model) -9.04; 95% CI -14.83 to
-3.24, P value 0.002); but not at 45 to 52 weeks postinjection,
based on 3 trials (WMD (fixed-effect model) (-2.60; 95% CI -
7.40 to 2.19, P value 0.3).
There was no statistically significant difference in pain at rest (0
to 100 mm VAS) at 1 to 4 weeks postinjection, based on 7 tri-
als (WMD (random-effects model) -3.54; 95% CI -9.21 to 2.13,
P value 0.2). There was no statistically significant difference in
WOMAC pain at 1 to 4 weeks postinjection (WMD -3.07; 95%
CI -7.07 to 0.92, P value 0.13) (Petrella 2002; Tsai 2003). How-
ever, there were statistically significant differences in favour of HA
versus placebo at 5 to 13 weeks (SMD -0.33; 95% CI -0.55 to -
0.10, P value 0.004) (Dickson 2001; Hizmetli 1999; Tsai 2003);
and at 14 to 26 weeks postinjection (WMD -5.66; 95%CI -10.06
to -1.26, P value 0.01) (Tsai 2003).
There was no statistically significant difference inWOMAC func-
tion at 1 to 4 weeks postinjection (WMD -2.24; 95% CI -6.29
to 1.80, P value 0.3) (Petrella 2002; Tsai 2003). However, at 5
to 13 weeks postinjection, there was a statistically significant dif-
ference in favour of HA versus placebo (SMD -0.56; 95% CI -
0.89 to -0.24, P value 0.0007) (Dickson 2001; Hizmetli 1999).
There was no statistically significant difference at 14 to 26 weeks
postinjection (WMD -4.05; 95% CI -8.38 to 0.28, P value 0.07)
(Tsai 2003).
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There was a statistically significant difference in the Lequesne In-
dex both at 1 to 4 weeks postinjection (WMD (random-effects
model) -1.21; 95% CI -2.19 to -0.22, P value 0.02) (Carrabba
1995; Dougados 1993; Huskisson 1999; Puhl 1993); and at 5 to
13 weeks postinjection (WMD -1.30; 95% CI -1.93 to -0.67, P
value 0.00005) (Carrabba 1995; Dickson 2001; Huskisson 1999;
Puhl 1993). There was no statistically significant difference either
at 14 to 26 or 45 to 52 weeks postinjection, (WMD 0.06; 95%
CI -0.75 to 0.87, P value 0.9) (Huskisson 1999; Karlsson 2002;
Lohmander 1996); and (WMD -1.11; 95% CI -2.70 to 0.48), P
value 0.17) (Dougados 1993), respectively.
With respect to patient global assessment (expressed as the num-
ber of patients improved), there were no statistically significant
differences between HA and placebo at any of the four assessment
times: at 1 to 4 weeks post injection (RR (random-effects model)
1.07; 95% CI 0.84 to 1.35, P value 0.6) (Corrado 1995; Creamer
1994; Lohmander 1996; Shichikawa 1983a; Shichikawa 1983b);
at 5 to 13 weeks postinjection (RR (random-effects model) 1.03;
95% CI 0.82 to 1.29, P value 0.8) (Corrado 1995; Dickson 2001;
Guler 1996; Lohmander 1996; Puhl 1993); at 14 to 26 weeks
postinjection (RR (random-effects model) 0.92; 95% CI 0.52 to
1.63, P value 0.8); and at 45 to 52 weeks postinjection (RR 1.17;
95% CI 0.85 to 1.62, P value 0.3).
There was no statistically significant difference in flexion (degrees)
at 1 to 4 weeks postinjection (WMD 3.21; 95% CI -1.27 to
7.68, P value 0.16) (Corrado 1995; Shichikawa 1983a; Shichikawa
1983b). However, at 5 to 13 weeks postinjection there was a statis-
tically significant difference in favour ofHAversus placebo (WMD
7.60; 95% CI 0.46 to 14.74, P value 0.04) (Corrado 1995).
In safety analyses in HA versus placebo comparisons, no statis-
tically significant differences were detected in the following: to-
tal withdrawals overall (1 to 4 weeks, 5 to 13 weeks, 14 to 26
weeks, 45 to 52 weeks postinjection), patients with local adverse
reaction and study drug discontinued, number of patients with
local adverse reaction but study drug continued, number of pa-
tients discontinued due to adverse events, withdrawals due to lack
of efficacy, number of adverse events due to local skin reaction,
number of patients with gastro-intestinal complaints, number of
patients with treatment related adverse events, number of patients
with possible study medication related events, number of serious
adverse events, number of adverse events probably/possibly related
to treatment, and number of patients reporting adverse events. A
statistically significant event favouring placebo was noted in the
number of adverse events for injection site pain (RR 1.70; 95%CI
1.19 to 2.44, P value 0.004).
In comparative studies ofHA versusNSAID, no statistically signif-
icant differences were detected in pain on walking at 1 to 4 weeks
post-injection (WMD 1.56; 95% CI -3.97 to 7.10, P value 0.6)
or total withdrawals overall at 14 to 26 weeks (RR 1.19; 95%CI
0.88 to 1.61, P value 0.3).
In comparative studies of HA versus methylprednisolone acetate,
statistically significant differences in favour of IA steroid were de-
tected in range of motion (degrees of flexion) at 1 to 4 weeks
postinjection (WMD 3.87; 95%CI 0.36 to 7.37, P value 0.03)
and 5 to 13 weeks postinjection (WMD 3.66; 95%CI 0.48 to
6.83, P value 0.02).
In six comparative studies of selected HA products, no statisti-
cally significant differences were detected between the products
concerned in: pain on movement (number of patients improved)
(1 to 4 weeks postinjection), pressure pain (number of patients
improved) (1 to 4 weeks postinjection), Lequesne Index (1 to 4
weeks and 5 to 13 weeks postinjection), or patient global assess-
ment (1 to 4 weeks, 5 to 13 weeks, 14 to 26 weeks and 45 to 52
weeks postinjection).
D I S C U S S I O N
This review is current as of the second quarter of 2004, and con-
tains both by-product and by-class analyses. It is comprehensive
and more current than preceding systematic reviews and avoids
limiting the review to a single product, variable or timepoint,
or forcing different variables assessed using different instruments
through a hierarchical algorithm in a reductionist manner, that
attempts to obtain a single value capturing complex, dynamic, and
heterogeneous phenomena. In developing a strategy for conduct-
ing this review, we have considered the complexity of the HA class
of interventions, issues relating to the design, execution, analysis
and interpretation of clinical trials, and the nuances of systematic
reviews and meta-analytic techniques. It is recognized in combin-
ing studies using different designs that any resulting heterogeneity
may be in part or in whole attributable to design elements, or char-
acteristics of the patient population, rather than to variability in
the efficacy of the HA product. This heterogeneity can in part be
addressed by recognizing the presence and potential determinants
of the heterogeneity and conducting the review in a manner that
attempts to minimize the influence of any existent heterogeneity.
Previous systematic reviews by Lo et al. (Lo 2003) and Wang et
al. (Wang 2004) have reached similar conclusions regarding the
efficacy of HA products, although the magnitude of effect has
differed. Lo et al. (Lo 2003), in particular, concluded that the
effect size may be small at the class level. Bernstein (Bernstein
2004) has drawn attention to the discrepancy between the Lo et
al. (Lo 2003) and Wang et al. (Wang 2004) commentaries on
effect size. Hou andWang (Hou 2004) have correctly asserted that
the reviews differ in the approach to effect size estimation, search
date and searching source, and in their interpretation of funnel
plot distortion. Brandt (Brandt 2004) reported that Dieppe et
al. (Dieppe (in press)) found a pooled effect size of -0.48 with a
confidence interval of -0.72 to -0.23 in an analysis of 11 clinical
trials. It appears, therefore, that the results of the meta-analyses
may be, in part, method dependent and reviewers should be aware
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of the nuances associated with the method used in this and other
meta-analyses.
HA products differ in their origin, method of production, molec-
ular weights (MW), biologic characteristics, rheologic properties,
residence time in the joint and pharmacodynamic properties. As
a consequence, any by-class analysis needs to be approached with
due recognition that the productsmay differ in important respects,
and that this may restrict the valuation of individual products,
particularly where patients have not been randomised to receive
the competing alternatives. The by-class analysis is also less infor-
mative to clinicians, since they generally seek to make evidence-
based decisions in treating individual patients with specific prod-
ucts. In this review, we have presented both by-product
analyses and by-class analyses in order that readers can make their
own judgement regarding individual products as well as the class
as a whole.
The clinical epidemiology toolbox contains numerous alternative
approaches to the design, execution and analysis of clinical trials.
It is our understanding that traditionally, this class of interven-
tion was considered as a device class and originally was not gen-
erally subject to the same evaluation guidelines that then existed
for pharmacologic agents. This may explain, in part, the hetero-
geneity in research designs and outcome measurement techniques
used, a phenomenon, however, not peculiar to this class of in-
terventions. Our review detected differences in a least nineteen
areas of trial design including: clinical environment, sample size,
number of study arms, number of centres, nature of the placebo
comparator, inclusion and exclusion criteria, washout period, re-
treatment opportunity, concomitant therapy, follow-up schedule,
duration of follow-up, outcome measures, age, gender balance,
disease duration, baseline pain severity, radiographic grade, treat-
ment schedule, rescue medication. These differences were some-
times evident, even when comparing different trials involving the
same HA product.
The nuances of systematic reviews and meta-analysis require due
consideration of any assumptions, implicit or explicit that are
made to combine information and data from diverse sources into
valid and meaningful summary statistics. In particular, it is nec-
essary to be familiar with a number of factors including, but not
limited to the following: RevMan 4.1 software and its operations;
assumptions, if any, regarding the value of ρ in imputations which
require converting between change scores and post-test scores; the
significance of the test for heterogeneity and its implications both
on the appropriateness of combining studies and the use of fixed-
effect versus random-effects models of analysis; the consequence
of basing analyses on transformed data, for example where differ-
ent outcomes (pain walking, pain at night, global pain) measured
on different instruments, have been filtered through a hierarchical
algorithm to obtain a single measure of pain suitable for meta-
analysis. This latter issue is particularly concerning given the dif-
ferential impact of interventions on different components of the
symptom complex and between-instrument differences in respon-
siveness (synonym: sensitivity to change). Other methodologic is-
sues include the potential for publication bias, and the interpreta-
tion of the clinical importance of the observed treatment effects.
This review highlights the challenge of interpreting the results
of clinical trials of intra-articular (IA) injections of hyaluronan
and hylan in knee OA. Greater standardisation in methodology
would facilitate assessment of these trials. Complete descriptions
of blinding, randomisation, withdrawals and dropout would im-
prove reporting quality. There was wide variation in the method
of assessment of outcome. The distinction between primary and
secondary outcome measures was infrequently reported. The util-
isation of local anaesthetic also varied as well as description of the
injection technique employed. The inclusion/exclusion criterion
of presence of effusion at study entry was variable with some trials
limiting the entry of subjects with a predefined volume of effu-
sion. Different osteoarthritic populations were included in the tri-
als; some subjects had unilateral disease while others had bilateral
disease. Variability was noted in both timing and method (e.g.
office versus telephone) of assessments, and in the opportunity for
retreatment. In some trials, a per protocol rather than intent-to-
treat statistical analysis was reported.
Safety was reported in variable formats, e.g. number of adverse
events per number of injections, number of ’related’ adverse events,
number of subjects reporting adverse events, number of serious
adverse events, number of local (injection site) reactions, number
of systemic reactions, number of patients withdrawing due to ad-
verse events. The denominator for safety analyses was frequently
based on the intent-to-treat population. However, in some trials
it was difficult to ascertain the denominator (patients versus injec-
tions). Ideally, the following should be reported: 1) withdrawals
overall, 2) withdrawals due to all adverse events, 3) withdrawals
due to system specific adverse events (e.g. gastrointestinal related
grouped, cardiovascular grouped, etc.), and 4) withdrawals due to
lack of efficacy.
Safety of hyaluronan and hylan in the general population for ap-
proved products in the U.S.A. can be examined by review of the
U.S.A. Food and Drug Administration Manufacturers and User
Device Experience (MAUDE) database available online at http:
//www.fda.gov/cdrh/maude.html. Large pharmacoepidemiologic
databases are generally better sources of safety data than small in-
dividual clinical trials. An article by Hammesfahr, Knopf and Sti-
tik reviews the safety data for the three products marketed in the
United States, e.g. Hyalgan, Supartz and Synvisc (Hammesfahr
2003). They concluded that HA therapy is a safe treatment for
OA of the knee. In addition, Hamburger et al. also concluded that
HA therapy is a safe treatment for knee OA, but that there may
be interproduct variability in safety profiles (Hamburger 2003).
The possibility of publication bias exists if reviewers choose to
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exclude unpublished studies. McAuley et al. recommend the in-
clusion of all reports, grey and published, that meet predefined
inclusion criteria in meta-analyses (McAuley 2000). In this review,
nine included studies (Ardic 2001; Brown 2003; Cohen 1994;
Groppa 2001; Guler 1996; Karras 2001; Moreland 1993; Pham
2003; Tsai 2003) were published only as abstracts. However, an in-
house manuscript by Moreland (Moreland 1993) was provided.
The articles by Hizmetli (Hizmetli 1999) and Lin (Lin 2004) were
in-house publications. Two specialization thesis (Auerbach 2002a;
Kalay 1997) were included. Published articles have the advantage
of having undergone the peer review process. Frequently, abstracts
do not provide enough information to be included in reviews, and,
consequently, are excluded.
The method of statistical analysis can affect the result. The util-
isation of follow-up (difference) scores, change (improvement)
scores, or unadjusted post-test (synonym: final value) scores for
continuous outcome measures can influence the result. Vick-
ers and Altman (Vickers 2001), Norman (Norman 1989), Lund
(Lund 1988) and Stucki et al. (Stucki 1996) have discussed this
issue.
A high placebo effect has been noted in HA clinical trials (Bhogal
2000). This response may be attributed to a number of factors
including: 1) removal of excess synovial fluid, 2) patient expecta-
tion, 3) Hawthorne effect of participating in a clinical trial, or 4)
active treatment effect of saline and/or arthrocentesis (Kaptchuk
2000). The modulating effects of rescue analgesia and co-therapy
with other OA treatments on outcome variables also should be
considered.
The effect of treating both unilateral and bilateral disease in the
same trial is problematic. Generally, efficacy results were based on
analyses of the worse joint, while safety results were based on anal-
yses of both joints. In some patients both knees received the same
intervention, while for other patients they received one interven-
tion in one knee and the comparative intervention in the other
knee. The time between treatment of the knees varied consider-
ably with some knees both being treated the same day, while other
knees had a 210-day difference between initiation of treatment.
The selection of a target joint (e.g. study knee) is one method of
resolving this controversy. The problem of analysing the person
versus the joint(s) has been reported in the literature (Sutton 1997;
Zhang 1996).
Some trials used the Ahlback classification of knee OA. A recent
publication, suggested that this classification had some ’major lim-
itations’ (Galli 2004). Even low grade Ahlback grades reflect sub-
stantial structural damage. Patients with higher grade structural
damage may be generally less responsive to treatment (Barrett
2002; Evanich 2001; Lussier 1996; Magilavy 2003; Toh 2002;
Vad 2003).
Limitations of this review are the omission of open trials and case
series, the omission of studies that failed to meet inclusion crite-
ria, the lack of standard outcome measures restricting pooling op-
portunities, and restricted access to source data. Strengths of the
review are the inclusion of only randomised controlled trials, the
focus on four core OARSI and OMERACT outcome measures,
and adherence to the principles of Cochrane systematic reviews.
A product-based discussion is followed by a class-based discus-
sion. All comments are based on the trials that could be included
in this review, the data that could be extracted and the analyses
that could be performed, and should be interpreted and utilized
by readers with the understanding that the review was conducted
using the methodology described in the earlier part of this doc-
ument, a methodology anchored to the Cochrane review process
using RevMan 4.1 software, and limited potentially by restricted
access to both unpublished studies and primary data. It should
be recalled that HA products are not generally immediate in their
onset, and that the 5 to 13 week time period may be one of the
more relevant for single course studies, while later periods may be
particularly relevant for studies allowingmore than a single course.
Statistically detectable differences seen in the 1 to 4 week postin-
jection period represent a relatively early onset of action and are
not necessarily expected in all responding patients or all studies.
It should also be noted that statistically detectable improvement
may not necessarily be detected on all variables or at the same
point in time. Function may improve more slowly than pain, and
it may be more difficult to detect an effect on night pain than on
walking pain. Finally, comparisons against other efficacious forms
of treatment are likely to result in either no statistically detectable
difference in efficacy or in relatively small differences (cf studies
of HA products against placebo). The inability to show a statisti-
cally detectable difference between an HA product and placebo,
in at least one key variable such as pain, function or patient global
assessment from about 5 to 13 weeks onwards might be regarded
with some degree of concern.
RevMan output for continuous data can be in the form of the
WMD or SMD. The WMD provides a summary statistic whose
magnitude is related to a number of factors including the treat-
ment effect and the scale length of the instrument on which the
underlying data were collected.What constitutes aminimum clin-
ically important difference (MCID) is subject to ongoing debate
(Bellamy 1993). The value for the minimum perceptible clinical
improvement (MPCI) for theWOMAC Index is approximately10
normalised units (0 to 100). This may serve as one indicator of
the clinical importance of the WMD for pain, stiffness and func-
tion measured on 0 to 100 normalised unit scales. In contrast, the
SMD provides a summary statistic adjusted by the variance, is of a
different order of magnitude to theWMD and expresses the effect
size as a unitless measure. What constitutes a small, medium, or
large effect size is a matter for debate. We have used the proposals
advanced by Cohen (Cohen 1977), and operationalised in a recent
publications by Jordan et al. (Jordan 2003), and Mazieres et al.
(Mazieres 2001) i.e. small effect size = 0.2, moderate effect size,
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i.e. clinically recognisable = 0.5, large effect size = 0.8. Other mea-
sures of clinical value are the percentage superiority in response
and the NNT. We are not aware of published critical values for
these parameters in OA management. Nevertheless, tables have
been provided for all the aforementioned parameters, in order that
readers can make informed decisions. It should be noted that the
magnitude of these parameters differs with product, comparison,
variable and time period.
We have observed that in some analyses, the RevMan 4.1 output
differs from the original publication (Table 36). Repeat analyses
based on RevMan 4.2 produced comparable results, also disparate
with the original publication. The discrepancies are likely due to
the use of secondary data and the statistical methods available
within the software programme. Reviewers are advised to consider
these disparities when making product-based evaluations.
Product - Adant
No placebo-controlled trials were included in this review. The
only data that could be included in the review suggested that
Adant is not different to Hyalgan with respect to patient global
assessment at 1 to 4 weeks, 5 to 13 weeks, and 14 to 26 weeks,
or with respect to the risk of experiencing injection-related pain.
This review provides some supportive evidence for the efficacy and
safety of Adant, but is based on limited data, and does not include
placebo-controlled trials.
Product - Artz (Artzal)
In comparative studies of Artz and placebo included in this re-
view, several outcomemeasures (Lequesne Index, range of motion,
WOMACOA Index), failed to detect a statistically significant dif-
ference at 1 to 4 weeks, 5 to 13 weeks, 14 to 26 weeks and 45 to
52 weeks, with the exception of patient global assessment at 1 to 4
weeks and 5 to 13 weeks and pain and the number of clinical fail-
ures at 5 to 13 weeks postinjection. Given the inclusion of single
course studies, and the time-dependent dynamics of HA therapy,
the positive effects of Artz on pain and patient global assessment
seen at 5 to 13 weeks postinjection are expected. It is of note that
statistically significant differences were detected on one pain mea-
sure but not another at 5 to 13 weeks. Significant effects on phys-
ical function cannot be confirmed from these analyses. It should
be noted that the original analyses give a more positive result than
the RevMan analyses we have performed. Taken collectively, the
data generally support the efficacy of Artz (Artzal).
Analyses supported the safety of Artz, with no statistically signif-
icant differences from placebo being detected for the majority of
safety variables.
No trials of Artzal against either corticosteroid or NSAID therapy
were reported and no comment can be made on the relative effec-
tiveness or safety against these two classes of
interventions.
In comparative analyses of Artz and Hylan G-F 20, there were no
statistically significant differences at any of the four time periods
in any of the four efficacy or three safety variables. This analysis
derives from an ostensibly negative study. The two products could
not be differentiated based on this single study.
Product - BioHy (Arthrease)
The placebo-controlled study is inconclusive for efficacy, likely as
a result of previously described methodologic issues. There was
no statistically significant between-group difference in the pro-
portion of patients experiencing postinjection pain, or in overall
withdrawals and there were no systemic reactions in either group,
providing some support for the safety of
BioHy within the limits of the available data.
No trials of BioHy against either corticosteroid or NSAID ther-
apy were reported and no comment can be made on the relative
effectiveness or safety against these two classes of interventions.
In comparative analyses of BioHy and Hylan G-F 20, there were
no statistically significant differences at either of the time periods
in either efficacy variable, or one of the two safety variables. Joint
effusion was significantly less likely in the BioHy group. The two
products could not be differentiated based on this single study.
Product - Fermathron
No trials of Fermathron against placebo were reported and effi-
cacy against placebo cannot, therefore, be assessed. No trials of
Fermathron against either corticosteroid or NSAID therapy were
reported and no comment can be made on the relative effective-
ness or safety against these two classes of interventions.
In comparative analyses of Fermathron and Hyalart, there were no
statistically significant differences at either of the time periods in
any of the three efficacy variables, or in the safety variable. The two
products could not be differentiated based on this single study.
Product - Hyalgan
In comparative studies of Hyalgan and placebo included in this
review, statistically significant differences were detected at 1 to 4
weeks (pain on weight-bearing, spontaneous pain, pain at rest,
Lequesne Index, number of joints improved for walking pain,
number of joints improved for weight under load), 5 to 13 weeks
(pain on weight-bearing, spontaneous pain, pain at rest, Lequesne
Index, number of joints improved for walking pain, number of
joints improved for weight under load, flexion, patient global as-
sessment), 14 to 26 weeks (pain on weight-bearing, WOMAC
pain). Statistically significant differenceswere not detected for pain
at rest at 14 to 26 weeks, pain on weight bearing at 45 to 52
weeks, night pain,WOMACpain at 1 to 4 weeks or 5 to 13 weeks,
WOMAC function, Lequesne Index at 14 to 26 weeks, flexion at
1 to 4 weeks, or patient global assessment at 1 to 4 weeks, 14 to
26 weeks and 45 to 52 weeks. Many of the aforementioned sta-
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tistically significant differences were highly significant, and clin-
ically important (WMD (disregarding sign) for pain (0 to 100
mm) varying from 3.93 to 33.50). Overall, these analyses strongly
support the evidence for efficacy of Hyalgan. No statistically sig-
nificant differences from placebo were detected in the majority
of safety variables although number of patients with local adverse
events, number of patients with local adverse events that caused
discontinuation, and number of patients with treatment-related
adverse events was significantly greater with Hyalgan. Analyses of
safety data also support the safety of Hyalgan.
Comparative studies of Hyalgan against IA methylprednisolone
suggest that Hyalgan is superior to methylprednisolone at 5 to
13 weeks postinjection on spontaneous pain intensity, number of
patients with moderate to severe pain under load, number of pa-
tients with moderate or greater rest pain, flexion, patient global
assessment, but with the exception of flexion was not different at 1
to 4 weeks. No statistically significant differences were detected at
14 to 26 weeks or 45 to 52 weeks postinjection. These differences
are probably due to the quick onset but often relatively short dura-
tion of the response to IA corticosteroid treatment. Overall, these
analyses suggest that Hyalgan is comparable, or superior in effi-
cacy to methylprednisolone, notwithstanding that the latter has
a faster onset of action but the former a longer duration of ac-
tion. Analyses of safety data also supported the safety of Hyalgan,
with no statistically significant differences from IA methylpred-
nisolone being detected in safety variables. The comparative study
of Hyalgan against IA triamcinolone hexacetonide suggests that
Hyalgan is not different in efficacy to triamcinolone hexacetonide,
except in pain at night at 14 to 26 weeks. Analyses of safety data
supported the safety of Hyalgan, with no statistically significant
differences from IA triamcinolone hexacetonide being detected in
safety variables. Collectively these data support the efficacy and
safety of Hyalgan, and show some 5 to 13 week postinjection ad-
vantages in favour of Hyalgan over methylprednisolone.
The comparative study of Hyalgan against NSAID suggests that
Hyalgan is comparable in efficacy to NSAID therapy at 1 to 4
weeks, 5 to 13 weeks, and 14 to 26 weeks postinjection, based on
pain after a 50-feet walk and number of patients with moderate
to marked pain. There were significantly fewer patients with gas-
trointestinal complaints, but more injection-site pain on Hyalgan;
otherwise there were no statistically detectable differences in sa-
fety. Overall, these analyses suggest that Hyalgan is comparable in
efficacy to NSAID therapy and similar in safety, with the excep-
tion of more injection-site pain events but fewer gastrointestinal
adverse events than NSAID.
The comparative study of Hyalgan against mucopolysaccharide
polysulfuric acid ester detected statistically significant differences
in pain, Larson rating and patient global assessment, but no dif-
ference in function or range of motion. There was no difference
in safety profile. The data are limited and no conclusion can be
reached from this review regarding relative efficacy and safety.
The comparative study of Hyalgan versus conventional therapy
detected statistically significant differences in arthroscopy score
but not in clinical outcomes at 45 to 52 weeks. The data are lim-
ited, but are of interest in terms of potential structure modification
effects.
Product - Hylan G-F 20 (Synvisc)
In comparative studies of Hylan G-F 20 and placebo included
in this review, statistically significant differences were detected
at 1 to 4 weeks (pain on weight-bearing, night pain, improve-
ment inmost painful kneemovement, patient global assessment of
treatment efficacy), 5 to 13 weeks (pain on weight-bearing, night
pain, WOMAC function, Lequesne Index, improvement in most
painful knee movement, patient global assessment of treatment
efficacy), 14 to 26 weeks (pain on weight-bearing, night pain). Sta-
tistically significant differences were not detected for pain walking,
pain at rest, pain overall orWOMACpain. Many of the aforemen-
tioned statistically significant differences were highly significant,
and clinically important (WMD (disregarding sign) for pain (0
to 100 mm) varying from 7.22 to 34.66). Overall, these analyses
strongly support the evidence for efficacy of Hylan G-F 20. Anal-
yses of safety data also support the safety of Hylan G-F 20, with
no statistically significant differences from placebo being detected
in the majority of safety variables.
Comparative studies of Hylan G-F 20 against corticosteroid sug-
gest that Hylan G-F 20 is superior to triamcinolone hexace-
tonide at 5 to 13 weeks, and 14 to 26 weeks post injection on
WOMAC pain walking on a flat surface, WOMAC function and
total WOMAC score, but not at 1 to 4 weeks. This difference is
probably due to the quick onset but often relatively short dura-
tion of the response to IA corticosteroid treatment. Overall, these
analyses suggest that Hylan G-F 20 is comparable in efficacy to
IA corticosteroid, notwithstanding that the latter has a faster on-
set of action but the former a longer duration of action. Analyses
of safety data also supported the safety of Hylan G-F 20, with
no statistically significant differences from IA corticosteroid being
detected in the majority of safety variables.
Comparative studies of Hylan G-F20 against NSAID suggest that
Hylan G-F 20 is comparable in efficacy to NSAID therapy at 5 to
13 weeks, and 14 to 26 weeks postinjection, based on the majority
of variables. There were significantly fewer patients with possible
or probable related systemic adverse events on Hylan G-F 20 but
otherwise there were no statistically detectable differences in safety.
Overall, these analyses suggest that Hylan G-F 20 is comparable
in efficacy to NSAID therapy and similar or slightly superior in
safety.
The comparative study of Hylan G-F 20 plus physiotherapy
against physiotherapy alone detected no difference in Lequesne
score or withdrawals but is limited in its scope and generalisability.
The comparative study of Hylan G-F 20 and intra-articular
gaseous oxygen, detected no statistically significant differences on
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the majority of variables. Indeed the only variable on which a dif-
ference was detected was pain under load at 5 to 13 weeks and was
in favour of intra-articular gaseous oxygen. The two treatments
could not be differentiated based on this single study.
Two comparative studies of Hylan G-F 20 plus appropriate care
versus appropriate care alone both confirm the superiority of
adding Hylan G-F 20 to appropriate care as assessed by the
WOMAC OA Index, Lequesne Index and patient global assess-
ment. Safety variables either detected no statistically significant
difference or were in favour of Hylan G-F 20 plus appropriate
care. These studies provide strong support for the incorporation
of Hylan G-F 20 into routine clinical care treatment paradigms.
Product - NRD-101
In the comparative analyses against Artz, no statistically signifi-
cant differences were detected between the products in efficacy
or safety. The two products could not be differentiated based on
this single study. No comment can be made regarding the rela-
tive efficacy of NRD-101 and placebo, since efficacy data relevant
to performing RevMan analysis, could not be extracted from the
original publication.
Product - Orthovisc
In comparative studies of Orthovisc and placebo included in this
review, statistically significant differences in WOMAC pain and
WOMAC function were detected at 1 to 4 weeks, 5 to 13 weeks,
and 14 to 26 weeks postinjection. These analyses support the
evidence for efficacy of Orthovisc. Analyses of safety data also
supported the safety of Orthovisc, with no statistically significant
differences from placebo being detected in the safety profile.
Comparative studies of Orthovisc against corticosteroid suggest
that Orthovisc is superior to 6-MPA at 5 to 13 weeks and 14 to
26 weeks postinjection and superior to betamethasone at 5 to 13
weeks postinjection. No statistically significant differences were
detected at 1 to 4 weeks against either corticosteroid. This time-
dependent difference is probably due to the quick onset but often
relatively short duration of the response to IA corticosteroid treat-
ment. Overall, these analyses suggest that Orthovisc is comparable
in efficacy to IA corticosteroids at 1 to 4 weeks and superior at 5 to
13 weeks and 14 to 26 weeks, notwithstanding that the latter have
a faster onset of action but the former a longer duration of action.
Analyses of safety data also support the safety of Orthovisc, with
no statistically significant differences from either IA corticosteroid
preparation being detected in the safety profile.
No trials ofOrthovisc against eitherNSAID therapywere reported
and no comment can bemade on the relative effectiveness or safety
against this class of intervention.
In the comparative study of Orthovisc plus physiotherapy against
physiotherapy alone, no statistically significant differences in effi-
cacy variables were detected at 1 to 4 weeks postinjection. Statis-
tically significant differences in favour of Orthovisc were noted in
some, but not all, variables at 5 to 13 weeks postinjection. There
were no statistically significant differences in safety profile. These
analyses suggest that adding Orthovisc to physiotherapy may be
beneficial with respect to activity pain and spontaneous pain, at 5
to 13 weeks postinjection.
In a comparative analysis of Orthovisc plus physical therapy versus
Hylan G-F 20 plus physical therapy there were no statistically
significant differences in efficacy or safety. The two products could
not be differentiated based on this single study.
Product - Replasyn
It was not possible to conduct informative analysis of Replasyn
as part of this review, and therefore no conclusion can be reached
regarding efficacy or safety, based on our review. The original pub-
lication, referred to previously, noted a significant difference in
only one of six variables.
Product - SLM-10
SLM-10 was comparable in efficacy to Artz on three outcome
measures and statistically significantly inferior on pain on pressure.
Therewas nodifference in safety profile. This reviewprovides some
supportive evidence for the efficacy and safety of SLM-10, but is
based on limited data, and does not include placebo-controlled
trials or studies against NSAID, IA corticosteroid or appropriate
care.
Product - Suplasyn
No statistically significant differences were detected in our analy-
ses between Suplasyn and placebo for four of the five efficacy mea-
sures and for the fifth favoured the control group. No statistically
detectable differences were noted in the safety profile. The review
does not incontrovertibly support the efficacy of Suplasyn, given
negative outcomes for the majority of variables in our RevMan
analyses, which are somewhat at variance with the original pub-
lication. However, Felson and Anderson (Felson 2002) published
an editorial on HA injections for OA in the same issue of Archives
of Internal Medicine in which the Petrella trial (Petrella 2002) was
published. They re-evaluated the data of Petrella analysing it as a
factorial experiment, and noted that Suplasyn had no ”significant
or important clinical effect on pain“ and ”there [were] null results
for disability and other outcomes“.
No statistically significant differences in efficacy or safety variables
were detected between Suplasyn and NSAID. The two treatment
strategies could not be differentiated based on this single study.
Product - Zeel compositum
No statistically significant differences in efficacy or safety variables
were detected between Zeel compositum and Hyalart. The two
products could not be differentiated based on this study.
By-class analyses
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The pooled analyses address issues relating to class characteris-
tics and may not be shared to the same extent by each individual
HA product. Readers including practitioners, regulators and third
party payers should be cautious in extrapolating from the class to
an individual product or vice versa, as the class-based analysis may
either under-estimate or over-estimate the performance of individ-
ual component products. For product-based information, read-
ers are referred to the relevant preceding sections. Only compar-
isons against placebo are discussed, because of the relatively large
number of studies available for some of these analyses. The other
comparisons were limited, in some cases, by a relative paucity of
studies.
Statistically significant differences were detected between HA and
placebo at 1 to 4 weeks (pain on weight bearing, Lequesne Index),
5 to 13 weeks (pain on weight bearing, WOMAC pain, WOMAC
function, Lequesne Index, flexion), and 14 to 26 weeks (pain
on weight bearing, WOMAC pain) postinjection. Apart from a
higher incidence of injection site pain, no statistically significant
differences versus placebo were noted in the safety profile vari-
ables. These data generally support the evidence for the efficacy
and safety (versus placebo) of the HA class of intervention.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The review presented is comprehensive and permits practitioners
to more fully consider the therapeutic profile of HA products.
Each analysis addresses a different issue, and practitioners are rec-
ommended to review those analyses specifically relating to their
questions. This should involve examining the original publica-
tion, the methodology employed in conducting the review, the
results for the product(s) of interest, with attention to the relevant
variables and timepoints. Readers should consider the clinical im-
portance as well as the statistical significance of any differences
detected. Readers should be aware that the results of our review
derive from a defined approach to the analysis of selected stud-
ies, that selected studies vary in quality and that the analyses do
not consider studies excluded from consideration. Nevertheless,
the approach is traditional, follows Cochrane guidelines and uses
RevMan 4.1 software.
Controversy in the existing literature is part due to a combination
of the heterogeneous time-dependant nature of the response to the
HA class of products, diversity in protocol design in the contribut-
ing studies, and the different approaches taken to the conduct of
systematic reviews. We have attempted to dissect out the effect of
these issues by performing multiple analyses on a by-product, by-
comparison, by-variable, by-timepoint basis. While this does not
provide a single answer to questions of efficacy, effectiveness and
safety, the analyses permit the complexity of the HA effect to be
appreciated.
The analyses suggest that there is considerable heterogeneity in
the clinical response, such that there are differential therapeutic
effects by different HA products, on different variables and that
the response is time dependent. For example, when pain on weight
bearing at 5 to 13 weeks postinjection is considered the evidence is
very supportive of therapeutic benefit over placebo, and the effect
size (SRM) may be as high as 0.94 depending on the product and
is 0.58 for the HA class in general. Given that effect sizes can be
classified as small (0.2), medium (0.5) or large (0.8), these analyses
suggest a range of effect sizes up to large product-based effect on
pain on weight bearing, and a moderate class-based effect on pain
on weight bearing.
The dynamics of the response are such that a statistically signifi-
cant, clinically important, effect 1 to 4 weeks postinjection versus
placebo is not necessarily achievable. Nevertheless, early responses
are observed in some comparisons. In contrast, in comparisons
against placebo theremay be amore durable, albeit slower response
compared to IA corticosteroids. In long-term studies, the effects of
combining single course with repeat treatment studies in our anal-
yses deserve due consideration, particularly when reviewing the
late stage endpoints, for example 45 to 52 weeks. In single course
studies the last course may have been almost one year prior when
a persisting effect might not be expected, while in repeat-course
studies the last course may have been recent, or even 5 to 13 weeks
prior, when a clinical benefit might well be anticipated. These nu-
ances deserve due recognition since they account for some of the
diversity in the responses reported in the literature.
These issues notwithstanding, HA products generally appear su-
perior to placebo on multiple efficacy variables, providing support
for the use of those HA products for which the effect is not only
statistically significant but also clinically important. These bene-
fits appear to be achievable without attributable systemic adverse
events but with occasional local reactions which tend, for themost
part, to be relatively transient, resolving without sequelae either
spontaneously or with simple intervention. It should be noted that
this review is not the premier source of safety data, since sample
sizes are relatively small in the trials reported, particularly for de-
tecting less frequent or even rare adverse events. Readers are re-
ferred to the general literature and the surveillance literature for
a more comprehensive appreciation of safety issues. Nevertheless,
based on the evidence reviewed, HA products appear in general to
be safe.
Implications for research
The following types of studies would be informative: long-term
trials (up to one year) including repeat course studies, head-to-
head comparisons of different HA products, effectiveness, cost-
effectiveness and cost-utility studies, studies of different OA sub-
groups, dissection of the determinants of the response toHAprod-
ucts, exploration of the apparently differential effect of HA prod-
ucts on different variables. The aforementioned studies should
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follow OARSI and other similar guidelines for the conduct and
design of OA studies. The use of standardized outcome measures
is encouraged to facilitate meta-analyses and between trial com-
parisons.
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